data_1qp3_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1qp3 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CE ' HG12 ' A' ' 21' ' ' VAL . 2.1 mmmm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.052 0.454 . . . . 0.0 110.166 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.643 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.851 ' HG3' HG13 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.495 HD12 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.407 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.773 HG21 ' HG2' ' A' ' 9' ' ' ARG . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t . . . . . 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.415 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 120.848 0.356 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.415 ' CE2' ' HD2' ' A' ' 33' ' ' LYS . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.852 HG11 ' CZ ' ' A' ' 40' ' ' PHE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.852 ' CZ ' HG11 ' A' ' 38' ' ' VAL . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.728 HD22 HD13 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.728 HD13 HD22 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.813 ' O ' HG22 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.813 HG22 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.51 ' HB2' HG21 ' A' ' 38' ' ' VAL . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.643 HD23 HG21 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.851 HG13 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.419 HG23 ' HB3' ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.481 ' HG3' HG13 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.504 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.459 HD22 HG23 ' A' ' 66' ' ' VAL . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.414 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.414 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.563 HG13 ' CG2' ' A' ' 68' ' ' VAL . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.485 HG13 HG13 ' A' ' 36' ' ' VAL . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.499 1.979 0 CA-C-O 120.879 0.371 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.414 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.485 HG13 HG13 ' A' ' 24' ' ' VAL . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.504 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.537 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.583 HG22 ' N ' ' A' ' 56' ' ' ASN . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.657 ' O ' HG21 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.657 HG21 ' O ' ' A' ' 56' ' ' ASN . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.419 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.456 ' C ' HG21 ' A' ' 66' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.459 HG23 HD22 ' A' ' 11' ' ' LEU . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.563 ' CG2' HG13 ' A' ' 21' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.046 0.451 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.436 HG23 ' HB3' ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.746 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.466 HD11 ' CZ ' ' A' ' 40' ' ' PHE . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.428 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.571 ' HB3' ' HG ' ' A' ' 15' ' ' SER . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.408 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.571 ' HG ' ' HB3' ' A' ' 12' ' ' ARG . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.408 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.409 ' O ' HG21 ' A' ' 21' ' ' VAL . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.409 HG21 ' O ' ' A' ' 20' ' ' ASP . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt . . . . . 0 N--CA 1.497 1.898 0 CA-C-O 120.988 0.423 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.478 ' HH ' ' HE ' ' A' ' 12' ' ' ARG . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.587 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.41 ' HG3' HH11 ' A' ' 39' ' ' ARG . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.4 HD22 ' HB ' ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.579 HG22 ' H ' ' A' ' 56' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.646 HD22 HG21 ' A' ' 57' ' ' THR . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.646 HG21 HD22 ' A' ' 56' ' ' ASN . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.408 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.81 ' HB2' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.587 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.81 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.452 HD22 ' O ' ' A' ' 9' ' ' ARG . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.579 ' O ' HG12 ' A' ' 68' ' ' VAL . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.746 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.07 0.462 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.437 HG21 ' CD2' ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.648 ' HG3' HG13 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.448 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.893 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.41 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.412 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.412 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.514 ' C ' HG23 ' A' ' 27' ' ' VAL . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.514 HG23 ' C ' ' A' ' 26' ' ' SER . 58.6 t . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.424 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.847 0 CA-C-O 120.985 0.422 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.424 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.523 HG21 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.55 HG13 ' N ' ' A' ' 39' ' ' ARG . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.55 ' N ' HG13 ' A' ' 38' ' ' VAL . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.448 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 1.029 HD22 HG21 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 1.029 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.496 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.437 ' CD2' HG21 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.893 HG21 HD22 ' A' ' 11' ' ' LEU . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.648 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.137 0.494 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.574 HG21 HD23 ' A' ' 65' ' ' LEU . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.576 ' HG3' HG13 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.795 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.774 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.717 ' CZ ' ' HH ' ' A' ' 34' ' ' TYR . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.678 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.421 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 120.946 0.403 . . . . 0.0 110.256 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.717 ' HH ' ' CZ ' ' A' ' 12' ' ' ARG . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.552 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.678 HD12 ' O ' ' A' ' 26' ' ' SER . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.795 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.532 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.433 HD22 ' HB ' ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.422 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.568 HG22 ' H ' ' A' ' 56' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.807 HD22 HG21 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.807 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 38' ' ' VAL . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.574 HD23 HG21 ' A' ' 8' ' ' VAL . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.462 HG21 HD23 ' A' ' 11' ' ' LEU . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.576 HG13 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.083 0.468 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.568 ' N ' HD23 ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.422 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.42 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.422 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.419 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.423 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.006 0.431 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.423 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.416 HG12 HD22 ' A' ' 59' ' ' ASN . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.625 HG13 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.625 ' N ' HG13 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.58 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.617 HD22 HG21 ' A' ' 57' ' ' THR . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.617 HG21 HD22 ' A' ' 56' ' ' ASN . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.416 HD22 HG12 ' A' ' 37' ' ' ILE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.866 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.848 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.866 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.462 ' O ' HG12 ' A' ' 68' ' ' VAL . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 67' ' ' GLU . 34.9 m . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HG2' ' HG1' ' A' ' 23' ' ' THR . 38.4 mtmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.098 0.475 . . . . 0.0 110.175 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.651 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.567 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 HG13 HG21 ' A' ' 68' ' ' VAL . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.437 ' HG1' ' HG2' ' A' ' 7' ' ' LYS . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.42 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 120.953 0.406 . . . . 0.0 110.363 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.42 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.593 HG23 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.603 HG22 ' N ' ' A' ' 38' ' ' VAL . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.603 ' N ' HG22 ' A' ' 37' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.42 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.651 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.668 HG22 ' N ' ' A' ' 56' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.691 ' ND2' HG21 ' A' ' 57' ' ' THR . 9.9 p-10 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.691 HG21 ' ND2' ' A' ' 56' ' ' ASN . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.411 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.525 ' HD2' HG21 ' A' ' 38' ' ' VAL . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.593 ' HB3' HG23 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.52 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.492 ' O ' HG12 ' A' ' 68' ' ' VAL . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.492 HG12 ' O ' ' A' ' 67' ' ' GLU . 36.0 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 121.088 0.47 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.515 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.625 ' HG3' HG13 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.962 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.609 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.614 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.419 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.419 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.538 HG12 HG21 ' A' ' 68' ' ' VAL . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.413 ' HB1' HG22 ' A' ' 37' ' ' ILE . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.634 ' O ' HG21 ' A' ' 27' ' ' VAL . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.634 HG21 ' O ' ' A' ' 26' ' ' SER . 58.1 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.025 0.44 . . . . 0.0 110.294 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.446 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.68 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.637 HG12 HD22 ' A' ' 59' ' ' ASN . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.962 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.405 ' CZ ' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ASN . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.821 ' O ' HG22 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.637 HD22 HG12 ' A' ' 37' ' ' ILE . 27.7 m120 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.614 ' HE2' ' HG ' ' A' ' 15' ' ' SER . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.656 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.68 ' HB3' HG23 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.656 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.557 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.601 ' CD2' HD12 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.609 HG21 HD22 ' A' ' 11' ' ' LEU . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.625 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.098 0.475 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.546 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.65 ' HG2' HG21 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.564 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.564 HD21 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.83 ' HH ' ' HE3' ' A' ' 42' ' ' LYS . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.437 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.078 0.466 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.547 HG21 ' O ' ' A' ' 58' ' ' ASN . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.426 HG21 ' C ' ' A' ' 37' ' ' ILE . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.545 ' HG3' HG21 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.83 ' HE3' ' HH ' ' A' ' 16' ' ' TYR . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.714 HG23 ' ND2' ' A' ' 58' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.696 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.545 HG21 ' HG3' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.714 ' ND2' HG23 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.404 ' N ' ' CD1' ' A' ' 34' ' ' TYR . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HB3' HG23 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.595 HD22 ' O ' ' A' ' 9' ' ' ARG . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.519 ' O ' HG12 ' A' ' 68' ' ' VAL . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.65 HG21 ' HG2' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.098 0.475 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.848 HG21 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.539 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.79 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.79 HD21 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.4 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.651 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t . . . . . 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.999 0.428 . . . . 0.0 110.426 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.416 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 58' ' ' ASN . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.59 HG13 ' N ' ' A' ' 39' ' ' ARG . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.59 ' N ' HG13 ' A' ' 38' ' ' VAL . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 58' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.802 HD22 HG21 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.802 HG21 HD22 ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.561 ' O ' HG22 ' A' ' 37' ' ' ILE . 1.5 m-80 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.848 HD22 HG21 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.464 ' C ' HG12 ' A' ' 68' ' ' VAL . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.651 HG21 HG22 ' A' ' 21' ' ' VAL . 34.9 m . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.081 0.467 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.509 HG23 HD23 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.803 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.412 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.515 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.458 HH22 ' HH ' ' A' ' 34' ' ' TYR . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.663 ' HH ' ' NZ ' ' A' ' 42' ' ' LYS . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.415 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.411 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt . . . . . 0 N--CA 1.498 1.93 0 CA-C-O 120.898 0.38 . . . . 0.0 110.379 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.458 ' HH ' HH22 ' A' ' 12' ' ' ARG . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.612 HG23 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.648 HG21 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.663 ' NZ ' ' HH ' ' A' ' 16' ' ' TYR . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.535 HG22 ' N ' ' A' ' 56' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.599 ' OD1' HG21 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.599 HG21 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.648 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.6 m-80 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.408 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.612 ' HB3' HG23 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.509 HD23 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.803 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.623 ' CE ' ' HG1' ' A' ' 23' ' ' THR . 17.6 mmtt . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 121.092 0.472 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.602 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.543 ' CD2' HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.415 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.415 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.448 HG11 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.623 ' HG1' ' CE ' ' A' ' 7' ' ' LYS . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.008 0.432 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.416 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG11 ' CE1' ' A' ' 40' ' ' PHE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.665 ' HG3' HG23 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.552 ' CE1' HG11 ' A' ' 38' ' ' VAL . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.472 HD22 ' HB ' ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.637 HG23 ' OD1' ' A' ' 58' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.429 ' N ' HG22 ' A' ' 55' ' ' ILE . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.665 HG23 ' HG3' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.637 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.807 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.477 ' HB3' HG23 ' A' ' 36' ' ' VAL . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.741 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.807 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.602 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.543 HG21 ' CD2' ' A' ' 11' ' ' LEU . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.581 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.517 ' O ' HG23 ' A' ' 68' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.088 0.471 . . . . 0.0 110.096 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.477 HG23 HD12 ' A' ' 65' ' ' LEU . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.539 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.642 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.544 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.502 ' HG2' ' HG ' ' A' ' 15' ' ' SER . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.502 ' HG ' ' HG2' ' A' ' 12' ' ' ARG . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 68' ' ' VAL . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.409 HG21 HG22 ' A' ' 36' ' ' VAL . 57.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 120.985 0.421 . . . . 0.0 110.459 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.418 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.499 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.52 HD21 ' H ' ' A' ' 55' ' ' ILE . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 55' ' ' ILE . 11.5 p-10 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.594 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.4 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.788 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.499 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.742 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.788 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.642 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.539 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.827 ' CD ' ' HG1' ' A' ' 23' ' ' THR . 10.9 mmmt . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.036 0.446 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.629 HG21 HD23 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.506 ' HG2' HG21 ' A' ' 21' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.453 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.753 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.827 ' HG1' ' CD ' ' A' ' 7' ' ' LYS . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.491 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? . . . . . 0 N--CA 1.497 1.914 0 CA-C-O 120.966 0.412 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.474 HG23 ' HB3' ' A' ' 62' ' ' GLU . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.529 HD22 HD13 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.596 HG22 ' N ' ' A' ' 56' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.634 ' O ' HG21 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.634 HG21 ' O ' ' A' ' 56' ' ' ASN . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.409 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.858 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG23 ' A' ' 36' ' ' VAL . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.772 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.858 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.629 HD23 HG21 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.753 HG21 HD22 ' A' ' 11' ' ' LEU . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.527 ' O ' HG12 ' A' ' 68' ' ' VAL . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 67' ' ' GLU . 35.8 m . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.058 0.456 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.579 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.487 ' C ' HD21 ' A' ' 11' ' ' LEU . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.797 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.429 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.843 ' HH ' ' HE3' ' A' ' 42' ' ' LYS . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 37' ' ' ILE . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.417 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.995 0.426 . . . . 0.0 110.41 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.429 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.47 HD12 ' O ' ' A' ' 26' ' ' SER . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.427 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.843 ' HE3' ' HH ' ' A' ' 16' ' ' TYR . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.446 ' CB ' HD13 ' A' ' 55' ' ' ILE . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.572 HG22 ' N ' ' A' ' 56' ' ' ASN . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.653 HD21 HG21 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.653 HG21 HD21 ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.878 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.878 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.424 HG12 ' N ' ' A' ' 67' ' ' GLU . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.424 ' N ' HG12 ' A' ' 66' ' ' VAL . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.579 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.522 ' HD2' HG11 ' A' ' 21' ' ' VAL . 10.7 mtmt . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.062 0.458 . . . . 0.0 110.245 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.453 HG23 ' HB3' ' A' ' 65' ' ' LEU . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.64 ' HG3' HG13 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.65 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.807 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.414 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.544 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.413 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.414 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.412 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' HD2' ' A' ' 7' ' ' LYS . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.496 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.8 t . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.934 0 CA-C-O 121.056 0.455 . . . . 0.0 110.409 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.403 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.62 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.496 HD12 ' O ' ' A' ' 26' ' ' SER . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' N ' HG22 ' A' ' 37' ' ' ILE . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.41 HD21 ' H ' ' A' ' 55' ' ' ILE . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.805 ' O ' HG22 ' A' ' 57' ' ' THR . 2.5 p30 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.805 HG22 ' O ' ' A' ' 56' ' ' ASN . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.544 ' HE2' ' HG ' ' A' ' 15' ' ' SER . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.62 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.453 ' HB3' HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.558 HG21 HD23 ' A' ' 11' ' ' LEU . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.64 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.127 0.489 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.453 HG21 ' CD2' ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.488 ' O ' HD22 ' A' ' 65' ' ' LEU . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.552 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.567 ' CD2' HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.416 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.42 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 120.98 0.419 . . . . 0.0 110.394 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.42 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.438 HG12 HD22 ' A' ' 59' ' ' ASN . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.538 ' N ' HG13 ' A' ' 38' ' ' VAL . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.552 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.451 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.656 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.656 ' N ' HG22 ' A' ' 55' ' ' ILE . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.6 ' CG2' HD22 ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.411 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . 0.438 HD22 HG12 ' A' ' 37' ' ' ILE . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.417 ' CD2' ' HB ' ' A' ' 38' ' ' VAL . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.488 HD22 ' O ' ' A' ' 9' ' ' ARG . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.567 HG21 ' CD2' ' A' ' 11' ' ' LEU . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . 0.424 ' C ' HG11 ' A' ' 68' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.456 HG13 ' HG3' ' A' ' 9' ' ' ARG . 35.7 m . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 121.071 0.463 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.611 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.677 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.413 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.431 ' CZ ' ' HH ' ' A' ' 34' ' ' TYR . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.417 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.417 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.615 ' O ' HG21 ' A' ' 27' ' ' VAL . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.615 HG21 ' O ' ' A' ' 26' ' ' SER . 58.3 t . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.3 ptpt . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.027 0.441 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.431 ' HH ' ' CZ ' ' A' ' 12' ' ' ARG . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.614 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.505 HG11 ' CE1' ' A' ' 40' ' ' PHE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.45 ' N ' HG13 ' A' ' 38' ' ' VAL . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.505 ' CE1' HG11 ' A' ' 38' ' ' VAL . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.467 HD21 ' H ' ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.589 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.589 ' N ' HG22 ' A' ' 55' ' ' ILE . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.592 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.614 ' HB3' HG23 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.592 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 8' ' ' VAL . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.611 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.7 mtmt . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.055 0.455 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.753 HG21 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.513 ' HG2' HG21 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.478 ' HA ' HD13 ' A' ' 10' ' ' ILE . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.669 HD22 HG23 ' A' ' 66' ' ' VAL . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HD3' ' CE2' ' A' ' 60' ' ' PHE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.513 HG21 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 38' ' ' VAL . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.497 ' C ' HG23 ' A' ' 27' ' ' VAL . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.497 HG23 ' C ' ' A' ' 26' ' ' SER . 58.2 t . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.421 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 121.057 0.456 . . . . 0.0 110.267 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.421 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.432 HG11 ' N ' ' A' ' 37' ' ' ILE . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.786 HG21 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 23' ' ' THR . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.587 HD22 HD13 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.587 HD13 HD22 ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.76 ' O ' HG22 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.76 HG22 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.786 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.753 HD22 HG21 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.669 HG23 HD22 ' A' ' 11' ' ' LEU . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.49 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.541 ' HD3' ' HG1' ' A' ' 23' ' ' THR . 26.7 mmtm . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.093 0.473 . . . . 0.0 110.209 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.851 HG21 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.725 ' CG ' HG13 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.474 HD12 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.481 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.541 ' HG1' ' HD3' ' A' ' 7' ' ' LYS . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.488 ' HG ' ' N ' ' A' ' 27' ' ' VAL . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.488 ' N ' ' HG ' ' A' ' 26' ' ' SER . 68.5 t . . . . . 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 120.893 0.378 . . . . 0.0 110.537 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.474 HG23 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 39' ' ' ARG . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.419 ' CG ' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.613 HG23 ' ND2' ' A' ' 58' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.565 ' N ' HG22 ' A' ' 55' ' ' ILE . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.559 ' CG2' HD22 ' A' ' 56' ' ' ASN . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.613 ' ND2' HG23 ' A' ' 55' ' ' ILE . 1.6 m-80 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.406 ' N ' ' CD1' ' A' ' 34' ' ' TYR . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG23 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.851 HD22 HG21 ' A' ' 8' ' ' VAL . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.725 HG13 ' CG ' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.515 ' HB2' ' HE3' ' A' ' 1' ' ' MET . 39.5 mtm . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 121.029 0.443 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.955 HG11 HG22 ' A' ' 24' ' ' VAL . 61.6 t -90.02 167.0 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.602 -0.686 . . . . 0.0 110.033 178.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.711 ' H ' HG13 ' A' ' 2' ' ' VAL . 3.2 mp0 -107.3 165.96 11.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.561 -0.712 . . . . 0.0 110.19 -177.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -70.79 94.06 1.01 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.547 -0.721 . . . . 0.0 110.167 177.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.13 30.19 3.24 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.443 ' HB2' HG13 ' A' ' 2' ' ' VAL . 0.4 OUTLIER -92.99 -177.6 4.54 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.577 -0.955 . . . . 0.0 110.177 178.115 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.489 ' CE ' HG12 ' A' ' 21' ' ' VAL . 2.1 mmmm -125.33 99.14 5.93 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.616 -0.678 . . . . 0.0 110.166 178.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.643 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.851 ' HG3' HG13 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.495 HD12 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.407 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.773 HG21 ' HG2' ' A' ' 9' ' ' ARG . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.955 HG22 HG11 ' A' ' 2' ' ' VAL . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t -117.73 142.04 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -108.49 98.88 8.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.55 -0.719 . . . . 0.0 110.224 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -85.35 94.76 9.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.175 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 9.1 m -156.19 -51.91 0.08 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 110.218 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.65 76.63 0.02 OUTLIER Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.751 HD12 ' O ' ' A' ' 34' ' ' TYR . 40.9 pt -127.54 -164.62 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.996 . . . . 0.0 110.245 178.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.415 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt -89.92 -24.1 21.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.559 -0.713 . . . . 0.0 110.586 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.751 ' O ' HD12 ' A' ' 32' ' ' ILE . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.852 HG11 ' CZ ' ' A' ' 40' ' ' PHE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.852 ' CZ ' HG11 ' A' ' 38' ' ' VAL . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.728 HD22 HD13 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.728 HD13 HD22 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.813 ' O ' HG22 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.813 HG22 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.51 ' HB2' HG21 ' A' ' 38' ' ' VAL . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.643 HD23 HG21 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.851 HG13 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -114.88 50.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -80.85 164.95 22.29 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.665 -0.647 . . . . 0.0 110.213 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.574 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . . . -82.41 176.56 3.71 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.548 -0.72 . . . . 0.0 110.228 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.574 ' HD2' ' HB2' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.93 146.58 36.15 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.323 1.17 . . . . 0.0 110.991 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -141.5 146.38 36.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.562 -0.711 . . . . 0.0 110.144 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.46 130.69 35.03 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.545 -0.722 . . . . 0.0 110.209 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.1 mttt -108.05 164.6 14.41 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.532 -0.73 . . . . 0.0 110.157 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 177.78 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.362 0 O-C-N 123.345 1.182 . . . . 0.0 110.973 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 52.93 -178.29 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.388 -0.82 . . . . 0.0 110.768 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 3.7 tttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.917 -1.039 . . . . 0.0 110.305 178.687 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.042 0.449 . . . . 0.0 110.174 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.1 t -81.65 79.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.636 -0.665 . . . . 0.0 109.938 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -116.55 168.22 10.37 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.608 -0.682 . . . . 0.0 110.203 177.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 ptt-85 -61.09 147.61 43.28 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.64 -0.662 . . . . 0.0 110.254 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.58 -30.65 9.25 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.47 169.41 12.87 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.594 -0.945 . . . . 0.0 110.224 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt -121.82 122.26 39.06 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.599 -0.688 . . . . 0.0 110.179 177.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.419 HG23 ' HB3' ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.481 ' HG3' HG13 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.504 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.459 HD22 HG23 ' A' ' 66' ' ' VAL . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.414 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.414 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.563 HG13 ' CG2' ' A' ' 68' ' ' VAL . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.485 HG13 HG13 ' A' ' 36' ' ' VAL . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -93.02 119.54 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -108.01 114.57 28.58 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.656 -0.653 . . . . 0.0 110.172 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -106.17 49.05 0.81 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.566 -0.709 . . . . 0.0 110.198 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.3 t -97.57 29.03 3.46 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.56 -0.713 . . . . 0.0 110.242 178.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.68 62.41 2.85 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.631 HD11 ' O ' ' A' ' 34' ' ' TYR . 45.1 pt -122.31 158.57 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.618 -0.931 . . . . 0.0 110.299 178.229 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -60.04 -26.45 66.12 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.537 -0.727 . . . . 0.0 110.403 -178.228 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.631 ' O ' HD11 ' A' ' 32' ' ' ILE . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.485 HG13 HG13 ' A' ' 24' ' ' VAL . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.504 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.537 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.583 HG22 ' N ' ' A' ' 56' ' ' ASN . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.657 ' O ' HG21 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.657 HG21 ' O ' ' A' ' 56' ' ' ASN . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.419 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.456 ' C ' HG21 ' A' ' 66' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.459 HG23 HD22 ' A' ' 11' ' ' LEU . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.563 ' CG2' HG13 ' A' ' 21' ' ' VAL . 35.0 m -123.93 54.33 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -77.06 166.47 23.25 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.551 -0.718 . . . . 0.0 110.106 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.45 163.82 8.08 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.687 . . . . 0.0 110.236 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.81 156.9 8.54 Favored 'Trans proline' 0 N--CA 1.491 1.348 0 O-C-N 123.43 1.226 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 32.7 mttt -98.05 164.19 12.45 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.525 -0.734 . . . . 0.0 110.203 178.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.07 166.64 14.86 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.611 -0.681 . . . . 0.0 110.234 178.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mtpt -82.99 150.54 61.82 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.689 -0.632 . . . . 0.0 110.188 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 172.69 0.17 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.405 1.213 . . . . 0.0 110.998 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.7 tptt -97.29 34.12 1.84 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.549 -0.719 . . . . 0.0 110.151 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.322 178.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.055 0.455 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.849 HG11 HG22 ' A' ' 24' ' ' VAL . 61.6 t -85.56 167.06 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.622 -0.674 . . . . 0.0 109.942 178.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.688 ' H ' HG13 ' A' ' 2' ' ' VAL . 3.2 mp0 -118.62 156.69 28.76 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.606 -0.684 . . . . 0.0 110.209 -177.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.8 mtt180 -74.99 110.28 9.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.516 -0.74 . . . . 0.0 110.135 176.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 127.62 -29.61 4.19 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -178.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.98 144.13 45.34 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.527 -0.984 . . . . 0.0 110.18 179.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -97.98 127.31 43.85 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.591 -0.693 . . . . 0.0 110.155 179.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.436 HG23 ' HB3' ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.746 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.466 HD11 ' CZ ' ' A' ' 40' ' ' PHE . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.428 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.571 ' HB3' ' HG ' ' A' ' 15' ' ' SER . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.408 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.571 ' HG ' ' HB3' ' A' ' 12' ' ' ARG . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.408 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.409 ' O ' HG21 ' A' ' 21' ' ' VAL . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.409 HG21 ' O ' ' A' ' 20' ' ' ASP . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.849 HG22 HG11 ' A' ' 2' ' ' VAL . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.4 119.67 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.729 ' HB3' HD13 ' A' ' 32' ' ' ILE . 25.9 t70 -106.55 143.37 34.76 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.563 -0.711 . . . . 0.0 110.199 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -131.96 79.96 1.89 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.652 -0.655 . . . . 0.0 110.16 177.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.5 m -133.64 -69.86 0.54 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.558 -0.714 . . . . 0.0 110.22 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.67 49.63 0.52 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.729 HD13 ' HB3' ' A' ' 28' ' ' ASP . 44.6 pt -120.72 140.08 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.542 -0.975 . . . . 0.0 110.234 177.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.414 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt -65.96 -27.84 68.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.577 -0.702 . . . . 0.0 110.346 -178.082 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.478 ' HH ' ' HE ' ' A' ' 12' ' ' ARG . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.587 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.41 ' HG3' HH11 ' A' ' 39' ' ' ARG . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.4 HD22 ' HB ' ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.579 HG22 ' H ' ' A' ' 56' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.646 HD22 HG21 ' A' ' 57' ' ' THR . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.646 HG21 HD22 ' A' ' 56' ' ' ASN . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.408 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.81 ' HB2' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.587 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.81 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.452 HD22 ' O ' ' A' ' 9' ' ' ARG . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.579 ' O ' HG12 ' A' ' 68' ' ' VAL . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.746 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -143.18 58.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -77.86 -176.24 4.35 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.622 -0.674 . . . . 0.0 110.17 177.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.37 149.25 57.65 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.522 -0.736 . . . . 0.0 110.261 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 157.08 8.55 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 O-C-N 123.407 1.214 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -167.67 47.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.578 -0.701 . . . . 0.0 110.207 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.98 148.86 25.98 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.518 -0.739 . . . . 0.0 110.198 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -156.3 62.98 3.17 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.553 -0.717 . . . . 0.0 110.271 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.93 -26.9 33.19 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.365 1.192 . . . . 0.0 110.975 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.2 pttt -155.34 154.8 32.6 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.546 -0.721 . . . . 0.0 110.348 178.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.9 tptt . . . . . 0 N--CA 1.494 1.752 0 CA-C-O 117.961 -1.018 . . . . 0.0 110.198 178.721 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.6 mtm . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.04 0.448 . . . . 0.0 110.193 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.4 m -69.96 71.06 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.585 -0.697 . . . . 0.0 110.25 -178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.63 -167.23 1.83 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.712 . . . . 0.0 110.149 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.91 127.17 31.5 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.538 -0.726 . . . . 0.0 110.14 178.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.74 -30.28 9.68 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -79.69 137.41 37.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.617 -0.931 . . . . 0.0 110.289 178.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp -97.83 133.88 41.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.549 -0.72 . . . . 0.0 110.205 179.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.437 HG21 ' CD2' ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.648 ' HG3' HG13 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.448 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.893 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.41 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.412 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.412 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.514 ' C ' HG23 ' A' ' 27' ' ' VAL . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.514 HG23 ' C ' ' A' ' 26' ' ' SER . 58.6 t -138.1 119.66 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.79 ' HB3' HD13 ' A' ' 32' ' ' ILE . 0.6 OUTLIER -98.24 138.93 34.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.567 -0.708 . . . . 0.0 110.198 179.298 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -125.22 32.06 5.46 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.579 -0.7 . . . . 0.0 110.259 178.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.0 m -85.31 -64.64 1.12 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.527 -0.733 . . . . 0.0 110.252 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 178.03 67.36 0.06 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.827 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.5 pt -123.36 149.37 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.539 -0.977 . . . . 0.0 110.281 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.424 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -60.73 -32.34 71.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.559 -0.713 . . . . 0.0 110.33 -177.563 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.827 ' O ' HD12 ' A' ' 32' ' ' ILE . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.496 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.523 HG21 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.55 HG13 ' N ' ' A' ' 39' ' ' ARG . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.55 ' N ' HG13 ' A' ' 38' ' ' VAL . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.448 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 1.029 HD22 HG21 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 1.029 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.496 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.437 ' CD2' HG21 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.893 HG21 HD22 ' A' ' 11' ' ' LEU . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.648 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -114.51 46.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.69 -154.78 0.14 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.606 -0.683 . . . . 0.0 109.688 177.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.52 163.43 61.45 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.206 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.9 146.5 36.25 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.452 1.238 . . . . 0.0 110.948 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.4 tttm -167.74 90.24 0.32 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.25 178.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.54 139.78 32.67 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.562 -0.711 . . . . 0.0 110.191 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.4 mmtt -143.64 170.28 8.83 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.548 -0.72 . . . . 0.0 110.222 178.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 150.28 23.77 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.35 1.184 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.28 47.78 1.35 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.602 -0.686 . . . . 0.0 110.15 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.282 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.638 ' HE3' ' HG2' ' A' ' 3' ' ' GLN . 23.5 ptm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.079 0.466 . . . . 0.0 110.33 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.03 71.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.525 -0.734 . . . . 0.0 110.167 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.638 ' HG2' ' HE3' ' A' ' 1' ' ' MET . 27.4 mm-40 -128.07 -169.28 2.03 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.606 -0.684 . . . . 0.0 110.237 177.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.7 ttt180 -61.32 131.83 51.59 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.537 -0.727 . . . . 0.0 110.195 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.49 29.86 67.46 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 177.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 t -100.03 136.31 40.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.933 . . . . 0.0 110.189 177.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -82.71 99.57 9.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.542 -0.724 . . . . 0.0 110.204 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.574 HG21 HD23 ' A' ' 65' ' ' LEU . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.576 ' HG3' HG13 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.795 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.774 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.717 ' CZ ' ' HH ' ' A' ' 34' ' ' TYR . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.678 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -118.37 123.45 71.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.481 ' HB3' HD13 ' A' ' 32' ' ' ILE . 2.0 t0 -120.73 149.14 42.99 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.514 -0.741 . . . . 0.0 110.225 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.0 tp60 -134.64 48.01 2.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.552 -0.718 . . . . 0.0 110.21 178.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.415 ' H ' ' HG ' ' A' ' 30' ' ' SER . 11.3 p -98.47 29.07 3.8 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.26 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.33 57.12 1.7 Allowed Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 178.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.481 HD13 ' HB3' ' A' ' 28' ' ' ASP . 44.9 pt -121.98 144.72 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.499 -1.001 . . . . 0.0 110.24 177.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.421 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER -62.61 -28.58 69.99 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.534 -0.729 . . . . 0.0 110.256 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.717 ' HH ' ' CZ ' ' A' ' 12' ' ' ARG . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.552 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.678 HD12 ' O ' ' A' ' 26' ' ' SER . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.795 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.532 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.433 HD22 ' HB ' ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.422 ' HB2' HD13 ' A' ' 55' ' ' ILE . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.568 HG22 ' H ' ' A' ' 56' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.807 HD22 HG21 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.807 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 38' ' ' VAL . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.574 HD23 HG21 ' A' ' 8' ' ' VAL . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.462 HG21 HD23 ' A' ' 11' ' ' LEU . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.576 HG13 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -141.44 51.52 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -124.99 131.97 53.33 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.499 -0.75 . . . . 0.0 110.192 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.41 156.47 65.77 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 178.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.83 -177.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.429 1.226 . . . . 0.0 110.978 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -87.26 160.11 18.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.592 -0.693 . . . . 0.0 110.272 178.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.32 116.8 23.2 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.543 -0.723 . . . . 0.0 110.189 178.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.8 mtpp -142.19 157.77 62.75 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.566 -0.709 . . . . 0.0 110.173 178.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.91 -27.76 36.51 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.461 1.242 . . . . 0.0 111.011 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -111.08 131.56 54.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.505 -0.747 . . . . 0.0 110.229 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.7 mttp . . . . . 0 N--CA 1.494 1.744 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.183 178.74 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.3 ptt? . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.087 0.47 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.646 HG11 HG22 ' A' ' 24' ' ' VAL . 67.7 t -80.41 162.66 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.607 -0.683 . . . . 0.0 109.913 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.6 ' N ' HG13 ' A' ' 2' ' ' VAL . 1.2 mp0 -97.39 156.82 16.29 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.645 -0.66 . . . . 0.0 110.25 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -68.58 109.43 3.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.13 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.01 8.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -99.97 161.28 13.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.525 -0.985 . . . . 0.0 110.254 177.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -105.01 102.45 11.95 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.481 -0.762 . . . . 0.0 110.194 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.434 HG11 HG12 ' A' ' 2' ' ' VAL . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.568 HD23 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.422 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.42 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.422 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.419 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.646 HG22 HG11 ' A' ' 2' ' ' VAL . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -102.47 119.65 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -121.49 145.89 47.47 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -145.47 79.33 1.57 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.57 -0.706 . . . . 0.0 110.198 178.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -133.15 28.96 4.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.601 -0.687 . . . . 0.0 110.262 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.28 36.29 1.03 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.4 pt -120.62 139.05 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.58 -0.953 . . . . 0.0 110.246 177.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.423 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -67.86 -27.53 66.77 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.582 -0.699 . . . . 0.0 110.33 -177.205 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.423 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.416 HG12 HD22 ' A' ' 59' ' ' ASN . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.625 HG13 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.625 ' N ' HG13 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.58 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.617 HD22 HG21 ' A' ' 57' ' ' THR . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.617 HG21 HD22 ' A' ' 56' ' ' ASN . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.416 HD22 HG12 ' A' ' 37' ' ' ILE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.866 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.848 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.866 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.462 ' O ' HG12 ' A' ' 68' ' ' VAL . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 67' ' ' GLU . 34.9 m -140.93 52.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -151.4 80.48 1.3 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.63 -0.669 . . . . 0.0 110.239 178.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -89.99 161.16 38.96 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.597 -0.689 . . . . 0.0 110.281 178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.92 151.07 21.33 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 O-C-N 123.471 1.248 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.1 tttp -166.37 47.75 0.07 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.163 178.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.99 133.17 34.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.585 -0.697 . . . . 0.0 110.191 178.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.414 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.8 OUTLIER -82.71 -50.3 0.76 Allowed Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.538 -0.726 . . . . 0.0 110.548 178.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.43 159.76 2.89 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 O-C-N 123.11 1.058 . . . . 0.0 111.091 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 10.9 ptpt -59.91 -26.47 65.94 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.454 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.19 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.142 0.496 . . . . 0.0 110.204 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.2 t -80.89 79.56 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.498 -0.751 . . . . 0.0 109.918 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -123.06 177.28 5.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.568 -0.707 . . . . 0.0 110.226 177.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -61.06 149.06 38.22 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.59 9.43 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.8 156.51 18.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.58 -0.953 . . . . 0.0 110.23 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HG2' ' HG1' ' A' ' 23' ' ' THR . 38.4 mtmt -108.26 118.53 37.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.558 -0.714 . . . . 0.0 110.175 178.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.651 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.567 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 HG13 HG21 ' A' ' 68' ' ' VAL . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.437 ' HG1' ' HG2' ' A' ' 7' ' ' LYS . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.12 119.71 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.611 ' HB3' HD13 ' A' ' 32' ' ' ILE . 13.4 t0 -99.64 97.24 8.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.648 -0.658 . . . . 0.0 110.175 179.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -84.08 81.38 8.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.576 -0.703 . . . . 0.0 110.207 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.788 ' HG ' ' H ' ' A' ' 31' ' ' GLY . 17.5 p -135.11 -71.74 0.48 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.575 -0.703 . . . . 0.0 110.156 179.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.788 ' H ' ' HG ' ' A' ' 30' ' ' SER . . . -174.77 60.88 0.12 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 178.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.611 HD13 ' HB3' ' A' ' 28' ' ' ASP . 47.1 pt -120.1 145.71 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.553 -0.969 . . . . 0.0 110.294 177.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.42 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER -64.15 -27.58 69.17 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.536 -0.727 . . . . 0.0 110.363 -179.602 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.604 ' O ' HD12 ' A' ' 32' ' ' ILE . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.593 HG23 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.603 HG22 ' N ' ' A' ' 38' ' ' VAL . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.603 ' N ' HG22 ' A' ' 37' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.42 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.651 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.668 HG22 ' N ' ' A' ' 56' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.691 ' ND2' HG21 ' A' ' 57' ' ' THR . 9.9 p-10 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.691 HG21 ' ND2' ' A' ' 56' ' ' ASN . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.411 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.525 ' HD2' HG21 ' A' ' 38' ' ' VAL . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.593 ' HB3' HG23 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.52 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.492 ' O ' HG12 ' A' ' 68' ' ' VAL . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.492 HG12 ' O ' ' A' ' 67' ' ' GLU . 36.0 m -144.62 28.77 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -85.09 -28.89 25.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.553 -0.717 . . . . 0.0 110.201 179.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -81.03 179.41 1.93 Allowed Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.57 -0.706 . . . . 0.0 110.239 178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.01 -175.89 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.382 1.201 . . . . 0.0 110.984 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 53.3 mttt -80.7 -168.06 1.61 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.54 -0.725 . . . . 0.0 110.221 178.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -79.91 144.43 33.4 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt 52.58 81.38 0.26 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.429 -0.794 . . . . 0.0 110.766 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.97 -59.55 1.0 Allowed 'Trans proline' 0 N--CA 1.491 1.363 0 O-C-N 123.476 1.251 . . . . 0.0 111.005 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -83.05 139.11 33.44 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.601 -0.687 . . . . 0.0 110.188 178.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.4 ptmm? . . . . . 0 N--CA 1.495 1.778 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.284 178.761 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.079 0.466 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.599 HG12 ' H ' ' A' ' 3' ' ' GLN . 68.5 t -90.02 166.97 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.588 -0.695 . . . . 0.0 109.898 178.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.599 ' H ' HG12 ' A' ' 2' ' ' VAL . 13.0 mp0 -121.45 163.24 19.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.606 -0.684 . . . . 0.0 110.261 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.16 107.32 7.17 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.492 -0.755 . . . . 0.0 110.218 176.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 123.01 -30.2 5.12 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.21 162.18 7.86 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.525 -0.985 . . . . 0.0 110.188 179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt -112.84 129.1 56.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.554 -0.716 . . . . 0.0 110.143 177.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.515 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.625 ' HG3' HG13 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.962 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.609 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.614 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.419 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.419 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.538 HG12 HG21 ' A' ' 68' ' ' VAL . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.406 HG22 HG13 ' A' ' 2' ' ' VAL . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.413 ' HB1' HG22 ' A' ' 37' ' ' ILE . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.634 ' O ' HG21 ' A' ' 27' ' ' VAL . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.634 HG21 ' O ' ' A' ' 26' ' ' SER . 58.1 t -145.05 119.61 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -93.79 124.58 37.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.592 -0.693 . . . . 0.0 110.211 178.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -98.41 103.12 15.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 178.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 t -165.65 -45.13 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.504 -0.748 . . . . 0.0 110.192 178.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.7 75.75 0.2 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.728 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.8 pt -118.38 177.63 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.931 . . . . 0.0 110.296 178.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt -61.14 -29.03 69.53 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.582 -0.699 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.728 ' O ' HD12 ' A' ' 32' ' ' ILE . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.68 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.637 HG12 HD22 ' A' ' 59' ' ' ASN . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.962 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.405 ' CZ ' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.573 HG22 ' N ' ' A' ' 56' ' ' ASN . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.821 ' O ' HG22 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.637 HD22 HG12 ' A' ' 37' ' ' ILE . 27.7 m120 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.614 ' HE2' ' HG ' ' A' ' 15' ' ' SER . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.656 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.68 ' HB3' HG23 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.656 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.557 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.601 ' CD2' HD12 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.609 HG21 HD22 ' A' ' 11' ' ' LEU . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.625 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m -145.43 71.35 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -61.2 158.26 14.42 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.207 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.88 111.47 3.94 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.523 -0.735 . . . . 0.0 110.204 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.15 -175.63 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.428 0 O-C-N 123.185 1.097 . . . . 0.0 111.043 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.2 mttp -78.96 -168.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.589 -0.694 . . . . 0.0 110.205 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.54 156.5 19.46 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.614 -0.679 . . . . 0.0 110.164 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -112.01 95.44 29.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.569 -0.707 . . . . 0.0 110.208 178.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.86 113.71 1.38 Allowed 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.332 1.174 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -91.11 49.14 1.59 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.663 -0.648 . . . . 0.0 110.152 178.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.223 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 ttt . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.081 0.467 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.458 ' O ' HG22 ' A' ' 2' ' ' VAL . 34.4 m -62.68 116.9 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.325 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -136.39 -175.2 3.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.561 -0.712 . . . . 0.0 110.211 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.0 mmm-85 -72.92 110.55 7.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 177.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.03 -30.27 8.16 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' HG22 ' A' ' 24' ' ' VAL . 0.3 OUTLIER -61.91 130.57 46.27 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.605 -0.938 . . . . 0.0 110.154 179.122 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.4 127.95 38.08 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 178.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.546 HG21 HD23 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.65 ' HG2' HG21 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.564 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.564 HD21 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.83 ' HH ' ' HE3' ' A' ' 42' ' ' LYS . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.511 HG22 ' O ' ' A' ' 6' ' ' SER . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.437 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.49 119.79 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -125.12 84.46 2.28 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.0 110.257 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -83.96 80.51 9.14 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 178.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 18.2 t -122.84 -50.74 1.94 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.606 -0.684 . . . . 0.0 110.238 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 174.64 54.67 0.05 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 178.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.632 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.7 pt -121.24 163.07 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.605 -0.938 . . . . 0.0 110.245 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt -59.95 -26.95 66.39 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.632 ' O ' HD12 ' A' ' 32' ' ' ILE . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.547 HG21 ' O ' ' A' ' 58' ' ' ASN . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.426 HG21 ' C ' ' A' ' 37' ' ' ILE . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.545 ' HG3' HG21 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.83 ' HE3' ' HH ' ' A' ' 16' ' ' TYR . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.714 HG23 ' ND2' ' A' ' 58' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.696 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.545 HG21 ' HG3' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.714 ' ND2' HG23 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.404 ' N ' ' CD1' ' A' ' 34' ' ' TYR . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.525 ' HB3' HG23 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.595 HD22 ' O ' ' A' ' 9' ' ' ARG . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.519 ' O ' HG12 ' A' ' 68' ' ' VAL . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.65 HG21 ' HG2' ' A' ' 9' ' ' ARG . 34.9 m -140.76 49.5 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -108.96 -28.97 8.83 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.251 178.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.476 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . . . -62.36 173.23 1.0 Allowed Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.61 -0.681 . . . . 0.0 110.197 178.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.476 ' HD2' ' HB2' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.91 178.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.353 1.186 . . . . 0.0 110.91 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.38 45.94 2.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.549 -0.719 . . . . 0.0 110.251 178.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.56 165.24 15.62 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.644 -0.66 . . . . 0.0 110.241 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.8 tttt -105.4 149.57 37.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.574 -0.704 . . . . 0.0 110.216 178.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.89 150.21 23.76 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.445 1.234 . . . . 0.0 111.001 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 15.3 tttt 52.85 92.83 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.467 -0.771 . . . . 0.0 110.787 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.3 tttt . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.257 178.672 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.8 mtt . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.112 0.482 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.478 ' CG1' HG22 ' A' ' 24' ' ' VAL . 57.9 t -89.97 167.01 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.479 -0.763 . . . . 0.0 110.02 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.0 mp0 -118.09 162.89 17.46 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.508 -0.745 . . . . 0.0 110.229 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.0 ttm180 -68.77 109.98 4.11 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.541 -0.724 . . . . 0.0 110.137 176.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.12 29.74 8.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.79 -159.26 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.515 -0.991 . . . . 0.0 110.116 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -148.39 104.72 3.54 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.578 -0.701 . . . . 0.0 110.133 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.848 HG21 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.539 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.79 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.79 HD21 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.4 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.651 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.478 HG22 ' CG1' ' A' ' 2' ' ' VAL . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t -122.0 119.82 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.676 ' HB3' HD13 ' A' ' 32' ' ' ILE . 9.0 t70 -84.01 125.14 31.78 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.201 178.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -104.94 33.59 3.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.563 -0.711 . . . . 0.0 110.162 178.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.4 m -101.32 -52.99 3.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.614 -0.679 . . . . 0.0 110.231 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.34 83.96 0.04 OUTLIER Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.676 HD13 ' HB3' ' A' ' 28' ' ' ASP . 44.9 pt -127.3 159.75 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.579 -0.954 . . . . 0.0 110.252 178.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -59.97 -26.51 66.08 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.593 -0.692 . . . . 0.0 110.426 -178.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.536 ' O ' HD12 ' A' ' 32' ' ' ILE . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.561 HG22 ' O ' ' A' ' 58' ' ' ASN . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.59 HG13 ' N ' ' A' ' 39' ' ' ARG . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.59 ' N ' HG13 ' A' ' 38' ' ' VAL . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.547 HG23 HD21 ' A' ' 58' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.802 HD22 HG21 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.802 HG21 HD22 ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.561 ' O ' HG22 ' A' ' 37' ' ' ILE . 1.5 m-80 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.848 HD22 HG21 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.464 ' C ' HG12 ' A' ' 68' ' ' VAL . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.651 HG21 HG22 ' A' ' 21' ' ' VAL . 34.9 m -136.99 28.79 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -129.22 48.6 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.653 -0.655 . . . . 0.0 110.17 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.622 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . . . -83.23 -177.04 0.88 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.231 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.622 ' HD2' ' HB2' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -53.07 -174.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.434 1.228 . . . . 0.0 111.024 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 23.8 mmtt -74.49 167.62 21.34 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.169 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.67 -158.88 0.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.547 -0.72 . . . . 0.0 110.238 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 15.5 mttt 52.67 85.33 0.19 Allowed Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.419 -0.8 . . . . 0.0 110.802 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.85 177.16 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.416 0 O-C-N 123.408 1.215 . . . . 0.0 111.038 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 mttt 52.91 -165.85 0.07 Allowed 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.481 -0.762 . . . . 0.0 110.814 178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 33.0 tttt . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.209 178.6 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.4 ptp . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.122 0.487 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.576 HG11 ' O ' ' A' ' 2' ' ' VAL . 8.7 p -69.55 72.68 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.57 -0.706 . . . . 0.0 110.216 -178.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -133.86 -165.89 1.71 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.547 -0.721 . . . . 0.0 110.046 177.132 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.459 ' HA ' HG12 ' A' ' 24' ' ' VAL . 5.5 tmm_? -62.53 124.73 21.73 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.195 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.38 -30.31 8.67 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.8 155.71 29.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.587 -0.949 . . . . 0.0 110.225 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -110.1 125.82 53.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.509 HG23 HD23 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.803 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.412 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.515 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.458 HH22 ' HH ' ' A' ' 34' ' ' TYR . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.663 ' HH ' ' NZ ' ' A' ' 42' ' ' LYS . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.415 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.411 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.459 HG12 ' HA ' ' A' ' 4' ' ' ARG . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t -131.27 144.29 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.474 ' HB3' HD13 ' A' ' 32' ' ' ILE . 4.5 t70 -120.94 101.54 7.76 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.526 -0.733 . . . . 0.0 110.273 178.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.8 mt-30 -90.09 81.8 6.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.582 -0.699 . . . . 0.0 110.152 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.6 p -143.85 -70.32 0.31 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.457 -0.777 . . . . 0.0 110.191 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 167.26 64.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.825 HD12 ' O ' ' A' ' 34' ' ' TYR . 40.2 pt -116.17 172.01 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.567 -0.96 . . . . 0.0 110.281 178.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt -60.12 -26.56 66.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.526 -0.734 . . . . 0.0 110.379 -178.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.825 ' O ' HD12 ' A' ' 32' ' ' ILE . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.612 HG23 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.648 HG21 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.663 ' NZ ' ' HH ' ' A' ' 16' ' ' TYR . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.535 HG22 ' N ' ' A' ' 56' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.599 ' OD1' HG21 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.599 HG21 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.648 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.6 m-80 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.408 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.612 ' HB3' HG23 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.509 HD23 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.803 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m -110.78 38.82 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -92.85 92.55 7.96 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.152 175.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.17 111.13 3.3 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.648 -0.657 . . . . 0.0 110.239 -178.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.32 -175.14 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.472 0 O-C-N 123.105 1.055 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.7 mttm -108.63 48.57 0.85 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.577 -0.702 . . . . 0.0 110.299 177.389 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.64 -161.19 0.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.707 . . . . 0.0 110.257 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -115.28 165.65 13.75 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.584 -0.697 . . . . 0.0 110.219 178.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.94 153.12 16.04 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 O-C-N 123.435 1.229 . . . . 0.0 110.968 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -168.25 148.69 4.84 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.53 -0.731 . . . . 0.0 110.296 178.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.2 pttt . . . . . 0 N--CA 1.495 1.805 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.269 178.613 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.088 0.47 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.8 p -70.58 69.52 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.57 -0.706 . . . . 0.0 110.173 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -130.1 -173.86 3.16 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.553 -0.717 . . . . 0.0 110.245 178.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.483 ' HA ' HG12 ' A' ' 24' ' ' VAL . 2.7 ptt180 -61.2 126.42 27.29 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.631 -0.668 . . . . 0.0 110.281 178.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 -30.58 7.03 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 153.02 26.02 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.585 -0.95 . . . . 0.0 110.177 178.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.623 ' CE ' ' HG1' ' A' ' 23' ' ' THR . 17.6 mmtt -102.9 127.66 50.01 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.565 -0.71 . . . . 0.0 110.172 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.602 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.543 ' CD2' HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.415 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.415 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.448 HG11 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.623 ' HG1' ' CE ' ' A' ' 7' ' ' LYS . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 4' ' ' ARG . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t -117.6 135.11 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.835 ' CB ' HD13 ' A' ' 32' ' ' ILE . 3.8 t0 -84.06 110.08 18.18 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.579 -0.7 . . . . 0.0 110.177 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . 0.42 ' C ' ' HG ' ' A' ' 30' ' ' SER . 17.6 tt0 -93.71 82.32 4.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.505 -0.747 . . . . 0.0 110.252 178.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.42 ' HG ' ' C ' ' A' ' 29' ' ' GLN . 15.1 m -164.35 -58.98 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.243 178.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.61 82.46 0.04 OUTLIER Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.835 HD13 ' CB ' ' A' ' 28' ' ' ASP . 44.8 pt -123.88 165.66 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.605 -0.938 . . . . 0.0 110.246 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt -60.06 -26.5 66.2 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.557 -0.714 . . . . 0.0 110.46 -178.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.729 ' O ' HD12 ' A' ' 32' ' ' ILE . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG11 ' CE1' ' A' ' 40' ' ' PHE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.665 ' HG3' HG23 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.552 ' CE1' HG11 ' A' ' 38' ' ' VAL . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.472 HD22 ' HB ' ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.637 HG23 ' OD1' ' A' ' 58' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.429 ' N ' HG22 ' A' ' 55' ' ' ILE . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.665 HG23 ' HG3' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.637 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.413 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.807 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.477 ' HB3' HG23 ' A' ' 36' ' ' VAL . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.741 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.807 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.602 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.543 HG21 ' CD2' ' A' ' 11' ' ' LEU . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.59 ' OE1' ' HB1' ' A' ' 70' ' ' ALA . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.581 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -129.12 40.85 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -162.17 33.78 0.12 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.528 -0.733 . . . . 0.0 110.242 178.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.59 ' HB1' ' OE1' ' A' ' 67' ' ' GLU . . . -83.34 167.99 25.34 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.583 -0.698 . . . . 0.0 110.199 178.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 173.52 0.14 Allowed 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.436 1.229 . . . . 0.0 110.965 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 pttt -166.37 52.57 0.09 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.631 -0.668 . . . . 0.0 110.28 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -81.86 -176.0 5.88 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 110.186 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -113.75 91.68 22.26 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.654 . . . . 0.0 110.238 178.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.9 149.78 25.11 Favored 'Trans proline' 0 N--CA 1.491 1.338 0 O-C-N 123.404 1.212 . . . . 0.0 110.971 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? 52.83 -169.69 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.357 -0.839 . . . . 0.0 110.775 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.233 178.679 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.129 0.49 . . . . 0.0 110.195 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 57.7 t -90.08 79.15 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.558 -0.714 . . . . 0.0 109.998 178.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -116.26 -173.3 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.621 -0.675 . . . . 0.0 110.196 178.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.408 ' HA ' HG12 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -61.34 134.57 57.09 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 178.689 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.93 -29.71 9.47 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.635 ' OG ' HG22 ' A' ' 24' ' ' VAL . 12.5 p -60.57 125.09 22.4 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.491 -1.005 . . . . 0.0 110.286 -177.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.517 ' O ' HG23 ' A' ' 68' ' ' VAL . 0.7 OUTLIER -75.85 68.34 2.37 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.45 -0.781 . . . . 0.0 110.096 172.531 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.477 HG23 HD12 ' A' ' 65' ' ' LEU . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.539 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.642 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.544 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.502 ' HG2' ' HG ' ' A' ' 15' ' ' SER . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.502 ' HG ' ' HG2' ' A' ' 12' ' ' ARG . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.413 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 68' ' ' VAL . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.635 HG22 ' OG ' ' A' ' 6' ' ' SER . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.409 HG21 HG22 ' A' ' 36' ' ' VAL . 57.5 t -108.78 125.79 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -106.63 117.98 35.46 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 110.188 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -82.03 79.85 8.44 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.567 -0.708 . . . . 0.0 110.184 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.836 ' HG ' ' H ' ' A' ' 31' ' ' GLY . 33.1 t -133.28 -159.15 0.94 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.609 -0.682 . . . . 0.0 110.199 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.836 ' H ' ' HG ' ' A' ' 30' ' ' SER . . . -91.87 50.1 2.83 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 37.0 pt -110.29 142.59 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.48 -1.012 . . . . 0.0 110.267 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.418 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -70.59 -26.39 63.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.611 -0.681 . . . . 0.0 110.459 -175.971 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.418 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.499 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.52 HD21 ' H ' ' A' ' 55' ' ' ILE . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.678 HG22 ' H ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.678 ' H ' HG22 ' A' ' 55' ' ' ILE . 11.5 p-10 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.594 HG21 HD22 ' A' ' 56' ' ' ASN . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.4 ' OD1' HG23 ' A' ' 55' ' ' ILE . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.423 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.788 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.499 ' HB3' HG23 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.742 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.788 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.642 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.539 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -132.99 43.86 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.3 tt0 -87.0 160.28 18.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.546 -0.722 . . . . 0.0 110.155 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.27 161.0 55.99 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.631 -0.668 . . . . 0.0 110.164 178.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.97 174.6 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.371 0 O-C-N 123.411 1.216 . . . . 0.0 110.938 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -82.85 -159.16 0.31 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.574 -0.704 . . . . 0.0 110.206 178.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.07 150.76 37.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.193 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 62.6 mttm 52.65 82.13 0.25 Allowed Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.383 -0.823 . . . . 0.0 110.719 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.92 -32.89 59.3 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 O-C-N 123.411 1.216 . . . . 0.0 111.036 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 61.7 mttt -83.2 161.39 21.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.523 -0.736 . . . . 0.0 110.23 178.631 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 pttt . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.229 178.898 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.5 mtt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.105 0.478 . . . . 0.0 110.265 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.3 t -83.85 79.0 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.615 -0.678 . . . . 0.0 109.941 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.3 mp0 -133.78 177.53 7.65 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 110.211 178.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.627 HH21 ' HB ' ' A' ' 27' ' ' VAL . 5.7 ptp180 -61.3 127.31 30.89 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.515 -0.741 . . . . 0.0 110.252 178.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.49 -31.5 5.95 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.46 155.86 20.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.649 -0.913 . . . . 0.0 110.215 178.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.827 ' CD ' ' HG1' ' A' ' 23' ' ' THR . 10.9 mmmt -108.42 126.1 52.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.592 -0.693 . . . . 0.0 110.199 178.548 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.629 HG21 HD23 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.506 ' HG2' HG21 ' A' ' 21' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.453 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.753 HD22 HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.413 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.827 ' HG1' ' CD ' ' A' ' 7' ' ' LYS . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.491 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.627 ' HB ' HH21 ' A' ' 4' ' ' ARG . 57.3 t -107.96 119.72 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -113.87 118.03 33.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.565 -0.709 . . . . 0.0 110.21 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -102.83 48.51 0.86 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.519 -0.738 . . . . 0.0 110.203 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.5 t -98.99 28.99 4.03 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.568 -0.707 . . . . 0.0 110.247 178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.82 80.69 0.3 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 178.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.751 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.8 pt -139.42 166.97 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.497 -1.002 . . . . 0.0 110.345 178.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? -59.96 -27.07 66.5 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.607 -0.683 . . . . 0.0 110.388 -178.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.751 ' O ' HD12 ' A' ' 32' ' ' ILE . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.474 HG23 ' HB3' ' A' ' 62' ' ' GLU . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.491 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.529 HD22 HD13 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.596 HG22 ' N ' ' A' ' 56' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.634 ' O ' HG21 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.634 HG21 ' O ' ' A' ' 56' ' ' ASN . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.409 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.858 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG23 ' A' ' 36' ' ' VAL . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.772 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.858 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.629 HD23 HG21 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.753 HG21 HD22 ' A' ' 11' ' ' LEU . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.527 ' O ' HG12 ' A' ' 68' ' ' VAL . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 67' ' ' GLU . 35.8 m -141.35 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -79.94 164.97 23.09 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.461 -0.774 . . . . 0.0 110.231 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.49 149.04 60.25 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 179.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.98 169.12 0.4 Allowed 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.414 1.218 . . . . 0.0 111.006 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt 52.9 82.56 0.07 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.455 -0.778 . . . . 0.0 110.825 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 177.75 6.39 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.623 -0.673 . . . . 0.0 110.209 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt 52.62 94.97 0.05 OUTLIER Pre-proline 0 N--CA 1.501 2.092 0 O-C-N 121.458 -0.776 . . . . 0.0 110.782 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.9 173.66 0.13 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.37 1.195 . . . . 0.0 110.974 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -83.22 -41.01 18.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.516 -0.74 . . . . 0.0 110.202 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.495 1.781 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.132 178.784 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 tpt . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 120.993 0.425 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.46 ' CG1' HG13 ' A' ' 8' ' ' VAL . 34.2 m -61.13 -165.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.675 -0.641 . . . . 0.0 110.297 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -140.19 165.56 27.04 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.573 -0.704 . . . . 0.0 110.182 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.2 mtm180 -71.96 93.6 1.38 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.543 -0.723 . . . . 0.0 110.105 176.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.11 30.2 3.49 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.06 -167.8 1.57 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.456 -1.026 . . . . 0.0 110.18 178.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -136.04 113.77 11.06 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.581 -0.699 . . . . 0.0 110.253 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.46 HG13 ' CG1' ' A' ' 2' ' ' VAL . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.579 ' HG3' HG13 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.487 ' C ' HD21 ' A' ' 11' ' ' LEU . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.797 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.429 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.409 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.843 ' HH ' ' HE3' ' A' ' 42' ' ' LYS . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 37' ' ' ILE . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -120.83 128.41 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -106.5 126.28 52.06 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.528 -0.733 . . . . 0.0 110.169 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -90.52 50.05 1.77 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.54 -0.725 . . . . 0.0 110.205 178.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.4 m -105.74 -159.32 0.7 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.576 -0.702 . . . . 0.0 110.222 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.22 62.52 0.43 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 178.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.455 HD12 ' O ' ' A' ' 34' ' ' TYR . 30.8 pt -108.34 169.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.603 -0.94 . . . . 0.0 110.242 178.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.417 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -60.16 -26.6 66.43 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.548 -0.72 . . . . 0.0 110.41 -177.394 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.455 ' O ' HD12 ' A' ' 32' ' ' ILE . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.47 HD12 ' O ' ' A' ' 26' ' ' SER . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.427 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.843 ' HE3' ' HH ' ' A' ' 16' ' ' TYR . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.446 ' CB ' HD13 ' A' ' 55' ' ' ILE . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.572 HG22 ' N ' ' A' ' 56' ' ' ASN . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.653 HD21 HG21 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.653 HG21 HD21 ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.878 ' HB2' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.878 ' OD1' ' HB2' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.424 HG12 ' N ' ' A' ' 67' ' ' GLU . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.424 ' N ' HG12 ' A' ' 66' ' ' VAL . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.579 HG13 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -134.97 53.29 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -112.01 119.94 40.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.563 -0.71 . . . . 0.0 110.175 177.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -90.05 112.31 51.63 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.552 -0.717 . . . . 0.0 110.187 179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.06 -176.34 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.105 1.055 . . . . 0.0 111.03 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.4 tptt -82.19 160.72 22.97 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.539 -0.725 . . . . 0.0 110.21 178.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.73 84.33 7.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.541 -0.725 . . . . 0.0 110.165 178.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.5 mtmm 52.62 88.69 0.11 Allowed Pre-proline 0 N--CA 1.502 2.151 0 O-C-N 121.456 -0.777 . . . . 0.0 110.71 178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.01 -30.78 50.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.498 1.262 . . . . 0.0 110.974 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 6.3 ttmm -139.13 131.11 27.84 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.58 -0.7 . . . . 0.0 110.151 178.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.287 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.402 ' H1 ' ' HB2' ' A' ' 62' ' ' GLU . 19.1 ttp . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.122 0.487 . . . . 0.0 110.18 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.886 HG22 HG22 ' A' ' 24' ' ' VAL . 35.3 m -69.4 -165.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.573 -0.704 . . . . 0.0 110.232 178.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.3 mp0 -118.14 157.35 27.07 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.6 -0.687 . . . . 0.0 110.175 -179.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 29.8 mtp180 -75.44 110.15 9.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.524 -0.735 . . . . 0.0 110.152 176.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 119.39 -29.81 6.01 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.08 152.86 42.08 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.572 -0.958 . . . . 0.0 110.241 178.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.522 ' HD2' HG11 ' A' ' 21' ' ' VAL . 10.7 mtmt -104.36 127.08 51.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.591 -0.693 . . . . 0.0 110.245 179.132 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.478 ' CG1' HG13 ' A' ' 2' ' ' VAL . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.64 ' HG3' HG13 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.65 ' C ' HD21 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.807 ' N ' HD21 ' A' ' 11' ' ' LEU . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.414 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.544 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.413 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.414 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.412 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' HD2' ' A' ' 7' ' ' LYS . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.886 HG22 HG22 ' A' ' 2' ' ' VAL . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.496 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.8 t -125.07 119.65 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -116.22 113.74 23.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.496 -0.753 . . . . 0.0 110.248 178.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -100.78 81.54 2.3 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.575 -0.703 . . . . 0.0 110.196 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.8 m -128.88 29.01 5.28 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.589 -0.695 . . . . 0.0 110.232 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.12 53.52 7.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 178.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.849 HD12 ' O ' ' A' ' 34' ' ' TYR . 40.6 pt -114.15 166.19 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.635 -0.921 . . . . 0.0 110.23 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -59.88 -27.13 66.44 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.524 -0.735 . . . . 0.0 110.409 -177.989 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.849 ' O ' HD12 ' A' ' 32' ' ' ILE . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.62 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.496 HD12 ' O ' ' A' ' 26' ' ' SER . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' N ' HG22 ' A' ' 37' ' ' ILE . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.41 HD21 ' H ' ' A' ' 55' ' ' ILE . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.805 ' O ' HG22 ' A' ' 57' ' ' THR . 2.5 p30 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.805 HG22 ' O ' ' A' ' 56' ' ' ASN . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.544 ' HE2' ' HG ' ' A' ' 15' ' ' SER . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.62 ' HB3' HG23 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.453 ' HB3' HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.558 HG21 HD23 ' A' ' 11' ' ' LEU . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.705 HG22 ' H ' ' A' ' 69' ' ' GLU . 34.5 m -134.03 -40.67 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.705 ' H ' HG22 ' A' ' 68' ' ' VAL . 0.3 OUTLIER 53.13 -171.37 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.306 -0.871 . . . . 0.0 110.547 179.092 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.58 151.49 94.43 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.46 -0.775 . . . . 0.0 110.128 178.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 146.55 36.23 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.427 1.225 . . . . 0.0 111.011 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -167.53 32.44 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.616 -0.677 . . . . 0.0 110.308 178.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.85 87.67 7.04 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.603 -0.685 . . . . 0.0 110.248 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.417 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.2 OUTLIER -84.12 -50.22 0.63 Allowed Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.655 -0.653 . . . . 0.0 110.593 178.497 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.5 179.58 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.486 0 O-C-N 123.15 1.079 . . . . 0.0 111.085 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 13.3 tptp -83.21 82.09 8.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.71 . . . . 0.0 110.269 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.202 178.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.404 ' H3 ' ' HG2' ' A' ' 1' ' ' MET . 3.3 ptt? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.082 0.468 . . . . 0.0 110.26 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.46 117.46 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.601 -0.687 . . . . 0.0 110.084 178.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -168.05 165.36 13.52 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 110.082 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.685 ' HA ' HG12 ' A' ' 24' ' ' VAL . 13.2 ttp180 -60.84 113.57 2.57 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.518 -0.739 . . . . 0.0 110.208 178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.21 -30.13 6.68 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -178.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.72 151.18 34.28 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.532 -0.981 . . . . 0.0 110.143 178.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -106.75 125.26 50.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.552 -0.717 . . . . 0.0 110.196 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.453 HG21 ' CD2' ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.488 ' O ' HD22 ' A' ' 65' ' ' LEU . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.552 HD11 ' HZ ' ' A' ' 40' ' ' PHE . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.567 ' CD2' HG21 ' A' ' 66' ' ' VAL . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.416 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.685 HG12 ' HA ' ' A' ' 4' ' ' ARG . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -107.36 119.83 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -130.22 148.22 52.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.58 -0.7 . . . . 0.0 110.284 178.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 23.1 tt0 -152.56 98.51 2.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.152 178.139 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -156.1 28.89 0.36 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.546 -0.721 . . . . 0.0 110.206 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.54 -30.51 2.77 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.9 pt -60.41 142.32 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.601 -0.941 . . . . 0.0 110.304 -177.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.42 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt -70.46 -26.75 63.78 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.516 -0.74 . . . . 0.0 110.394 -176.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.42 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.438 HG12 HD22 ' A' ' 59' ' ' ASN . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.538 ' N ' HG13 ' A' ' 38' ' ' VAL . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.552 ' HZ ' HD11 ' A' ' 10' ' ' ILE . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.451 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.656 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.656 ' N ' HG22 ' A' ' 55' ' ' ILE . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.6 ' CG2' HD22 ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.411 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . 0.438 HD22 HG12 ' A' ' 37' ' ' ILE . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.417 ' CD2' ' HB ' ' A' ' 38' ' ' VAL . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.488 HD22 ' O ' ' A' ' 9' ' ' ARG . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.567 HG21 ' CD2' ' A' ' 11' ' ' LEU . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . 0.424 ' C ' HG11 ' A' ' 68' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.456 HG13 ' HG3' ' A' ' 9' ' ' ARG . 35.7 m -138.5 61.7 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -61.7 165.32 5.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.583 -0.698 . . . . 0.0 110.193 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.35 159.72 63.96 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 178.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.02 154.93 12.24 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.437 1.23 . . . . 0.0 110.95 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -104.21 149.87 24.9 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.501 -0.75 . . . . 0.0 110.21 178.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.44 -174.32 5.22 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.569 -0.707 . . . . 0.0 110.22 178.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.2 mptt 52.6 94.54 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 O-C-N 121.43 -0.794 . . . . 0.0 110.775 179.005 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 -177.01 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.424 1.223 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.3 ttmt -99.42 130.12 45.66 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.569 -0.707 . . . . 0.0 110.194 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.3 pttt . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.325 -178.81 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.106 0.479 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.872 HG22 HG21 ' A' ' 24' ' ' VAL . 34.4 m -61.06 -165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.538 -0.726 . . . . 0.0 110.228 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -122.43 149.06 44.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.599 -0.688 . . . . 0.0 110.168 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt-85 -61.4 117.54 5.81 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.56 -0.712 . . . . 0.0 110.286 178.221 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 119.32 -30.64 5.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.48 168.51 2.76 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.523 -0.987 . . . . 0.0 110.203 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -122.06 126.51 48.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.601 -0.687 . . . . 0.0 110.242 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.611 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.677 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.413 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.431 ' CZ ' ' HH ' ' A' ' 34' ' ' TYR . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.417 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.417 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.872 HG21 HG22 ' A' ' 2' ' ' VAL . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.615 ' O ' HG21 ' A' ' 27' ' ' VAL . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.615 HG21 ' O ' ' A' ' 26' ' ' SER . 58.3 t -144.58 121.78 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -99.84 106.21 18.04 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.532 -0.73 . . . . 0.0 110.24 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.3 tp60 -83.44 90.05 7.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.6 -0.687 . . . . 0.0 110.182 178.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -146.71 -67.97 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.557 -0.714 . . . . 0.0 110.279 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.27 72.08 0.02 OUTLIER Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.749 HD12 ' O ' ' A' ' 34' ' ' TYR . 43.7 pt -121.46 169.05 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.596 -0.943 . . . . 0.0 110.263 178.471 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.3 ptpt -59.82 -26.65 65.96 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.555 -0.715 . . . . 0.0 110.458 -178.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.749 ' O ' HD12 ' A' ' 32' ' ' ILE . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.614 HG23 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.505 HG11 ' CE1' ' A' ' 40' ' ' PHE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.45 ' N ' HG13 ' A' ' 38' ' ' VAL . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.505 ' CE1' HG11 ' A' ' 38' ' ' VAL . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.467 HD21 ' H ' ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.589 HG22 ' N ' ' A' ' 56' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.589 ' N ' HG22 ' A' ' 55' ' ' ILE . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.592 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.614 ' HB3' HG23 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.523 ' OD2' ' HB2' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.592 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 8' ' ' VAL . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.611 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m -111.84 -26.16 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 52.93 -178.09 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.222 -0.924 . . . . 0.0 110.75 178.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.75 ' HB2' ' HD2' ' A' ' 71' ' ' PRO . . . -85.47 -177.11 0.87 Allowed Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.63 -0.669 . . . . 0.0 110.265 178.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.75 ' HD2' ' HB2' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -52.86 176.6 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.382 1.201 . . . . 0.0 111.038 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -84.09 108.88 17.28 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.598 -0.689 . . . . 0.0 110.159 178.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 -159.5 0.6 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.656 . . . . 0.0 110.19 178.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 6.1 ttmt -139.76 84.68 15.29 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 110.196 178.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.01 -176.69 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.404 1.213 . . . . 0.0 110.953 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.0 ptmt -111.88 166.36 11.27 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.605 -0.684 . . . . 0.0 110.275 178.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.221 178.691 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttm . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.094 0.473 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.6 t -80.83 167.02 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.541 -0.724 . . . . 0.0 109.964 178.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -115.33 166.36 11.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.58 -0.7 . . . . 0.0 110.246 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -67.33 113.54 5.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.497 -0.752 . . . . 0.0 110.219 177.433 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.67 30.01 11.18 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.64 156.45 16.41 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.967 . . . . 0.0 110.187 177.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.7 mtmt -106.8 106.01 16.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.584 -0.698 . . . . 0.0 110.204 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.753 HG21 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.513 ' HG2' HG21 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.478 ' HA ' HD13 ' A' ' 10' ' ' ILE . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.669 HD22 HG23 ' A' ' 66' ' ' VAL . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.409 ' HD3' ' CE2' ' A' ' 60' ' ' PHE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.513 HG21 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 38' ' ' VAL . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.497 ' C ' HG23 ' A' ' 27' ' ' VAL . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.497 HG23 ' C ' ' A' ' 26' ' ' SER . 58.2 t -136.05 166.97 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.37 160.16 22.16 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.559 -0.713 . . . . 0.0 110.221 178.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -108.59 34.37 3.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 178.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.641 ' OG ' HG22 ' A' ' 32' ' ' ILE . 83.4 p -131.83 -163.61 1.35 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 110.253 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -114.0 45.15 1.36 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 178.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.641 HG22 ' OG ' ' A' ' 30' ' ' SER . 27.6 pt -61.03 178.98 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.561 -0.964 . . . . 0.0 110.334 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.421 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -61.31 -29.32 69.81 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 110.267 -179.736 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.421 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.432 HG11 ' N ' ' A' ' 37' ' ' ILE . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.786 HG21 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 23' ' ' THR . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.587 HD22 HD13 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.587 HD13 HD22 ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.76 ' O ' HG22 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.76 HG22 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.786 ' O ' HG21 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.409 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.753 HD22 HG21 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.669 HG23 HD22 ' A' ' 11' ' ' LEU . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.685 HG22 ' N ' ' A' ' 69' ' ' GLU . 34.5 m -133.98 -40.7 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.685 ' N ' HG22 ' A' ' 68' ' ' VAL . 0.7 OUTLIER 57.31 162.3 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.307 -0.871 . . . . 0.0 110.374 178.524 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -89.11 173.13 6.39 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.344 -0.847 . . . . 0.0 110.199 -174.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.9 151.16 21.02 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.435 1.229 . . . . 0.0 111.025 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.0 mtmt -127.27 48.59 2.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.563 -0.711 . . . . 0.0 110.2 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.68 110.96 18.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.561 -0.712 . . . . 0.0 110.207 178.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 15.9 mtpt -83.44 -50.41 0.68 Allowed Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 121.559 -0.713 . . . . 0.0 110.447 178.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.411 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.38 103.55 0.07 OUTLIER 'Trans proline' 0 N--CA 1.493 1.488 0 O-C-N 123.104 1.055 . . . . 0.0 111.078 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -124.94 29.03 6.26 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.518 -0.739 . . . . 0.0 110.273 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 tttp . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.136 178.786 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 34.0 mtm . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.065 0.46 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.961 HG11 HG22 ' A' ' 24' ' ' VAL . 57.8 t -83.15 166.87 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.546 -0.721 . . . . 0.0 110.042 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.691 ' N ' HG13 ' A' ' 2' ' ' VAL . 0.8 OUTLIER -93.73 149.02 21.58 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.522 -0.736 . . . . 0.0 110.195 178.898 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.0 ttt-85 -70.93 93.23 0.97 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.199 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.44 30.3 3.14 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.38 156.52 16.42 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.554 -0.968 . . . . 0.0 110.167 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.541 ' HD3' ' HG1' ' A' ' 23' ' ' THR . 26.7 mmtm -100.31 109.76 21.98 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.579 -0.701 . . . . 0.0 110.209 178.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.851 HG21 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.725 ' CG ' HG13 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.474 HD12 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.481 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.541 ' HG1' ' HD3' ' A' ' 7' ' ' LYS . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.961 HG22 HG11 ' A' ' 2' ' ' VAL . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.488 ' HG ' ' N ' ' A' ' 27' ' ' VAL . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.488 ' N ' ' HG ' ' A' ' 26' ' ' SER . 68.5 t -117.94 154.29 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.796 ' HB3' HD11 ' A' ' 32' ' ' ILE . 0.6 OUTLIER -94.79 -159.02 0.68 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.73 . . . . 0.0 110.218 177.605 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -126.8 -72.45 0.65 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.537 -0.727 . . . . 0.0 110.265 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.3 t -132.58 166.61 21.71 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.582 -0.699 . . . . 0.0 110.228 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.525 ' C ' HG23 ' A' ' 32' ' ' ILE . . . 65.48 54.46 26.17 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.796 HD11 ' HB3' ' A' ' 28' ' ' ASP . 43.3 pt -148.11 146.26 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.554 -0.968 . . . . 0.0 110.258 -178.155 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.09 -24.14 21.21 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.542 -0.724 . . . . 0.0 110.537 175.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.751 ' HA ' HD12 ' A' ' 32' ' ' ILE . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.474 HG23 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 39' ' ' ARG . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.419 ' CG ' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.613 HG23 ' ND2' ' A' ' 58' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.565 ' N ' HG22 ' A' ' 55' ' ' ILE . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.559 ' CG2' HD22 ' A' ' 56' ' ' ASN . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.613 ' ND2' HG23 ' A' ' 55' ' ' ILE . 1.6 m-80 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.406 ' N ' ' CD1' ' A' ' 34' ' ' TYR . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG23 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.851 HD22 HG21 ' A' ' 8' ' ' VAL . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.725 HG13 ' CG ' ' A' ' 9' ' ' ARG . 34.9 m -113.3 36.3 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -116.39 135.52 53.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.534 -0.729 . . . . 0.0 110.214 178.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.97 111.44 3.93 Favored Pre-proline 0 N--CA 1.497 1.903 0 O-C-N 121.694 -0.629 . . . . 0.0 110.231 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.08 178.74 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.161 1.085 . . . . 0.0 110.999 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.0 155.46 19.36 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.24 178.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.1 82.85 8.07 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.582 -0.699 . . . . 0.0 110.229 178.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.423 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 3.1 mmtt -81.82 -50.42 0.87 Allowed Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.6 -0.687 . . . . 0.0 110.523 178.64 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.43 179.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.148 1.078 . . . . 0.0 111.089 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 11.1 tptm 52.88 45.64 28.36 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.383 -0.823 . . . . 0.0 110.859 178.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.222 178.721 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.052 0.454 . . . . 0.0 110.166 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.711 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.761 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.591 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.511 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.427 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.555 HG22 HG21 ' A' ' 68' ' ' VAL . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t . . . . . 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 120.848 0.356 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CE2' ' HD2' ' A' ' 33' ' ' LYS . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' A' ' 17' ' ' TRP . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.635 HD21 HD12 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.635 HD12 HD21 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.533 ' O ' HG23 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.533 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.711 HD22 HG23 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.761 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.78 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.808 ' HG3' HG11 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.8 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.462 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.499 1.979 0 CA-C-O 120.879 0.371 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.409 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.462 HD12 ' O ' ' A' ' 26' ' ' SER . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.8 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 57' ' ' THR . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.458 ' C ' HG23 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HG3' ' A' ' 39' ' ' ARG . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.444 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.78 HD22 HG23 ' A' ' 8' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 68' ' ' VAL . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 8' ' ' VAL . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.808 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.046 0.451 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.709 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.56 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.442 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.473 ' H ' HG22 ' A' ' 10' ' ' ILE . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.434 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt . . . . . 0 N--CA 1.497 1.898 0 CA-C-O 120.988 0.423 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.434 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.539 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.56 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.562 ' HA ' HG22 ' A' ' 57' ' ' THR . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.573 HD21 HD12 ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 44' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' ILE . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 39' ' ' ARG . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.693 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.693 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.574 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.709 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.07 0.462 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.557 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.758 ' HG3' HG11 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.67 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.463 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.434 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.536 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.847 0 CA-C-O 120.985 0.422 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.5 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.67 HG11 HD11 ' A' ' 10' ' ' ILE . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.433 ' HG3' HG22 ' A' ' 57' ' ' THR . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 55' ' ' ILE . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.579 ' ND2' HG23 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.579 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.5 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.622 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.508 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.622 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.758 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.137 0.494 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.716 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.687 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.414 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 120.946 0.403 . . . . 0.0 110.256 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.441 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.521 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' N ' HD12 ' A' ' 37' ' ' ILE . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.687 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.488 HD21 HD12 ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.488 HD12 HD21 ' A' ' 44' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.667 ' ND2' HG23 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.734 HG22 ' HG2' ' A' ' 39' ' ' ARG . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.521 ' HB3' HG21 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.716 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.083 0.468 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.512 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.69 ' HG3' HG11 ' A' ' 68' ' ' VAL . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.435 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.409 ' O ' HD12 ' A' ' 37' ' ' ILE . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.006 0.431 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.443 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 26' ' ' SER . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.438 HG12 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.435 ' CE1' ' HB3' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.627 HD21 HD12 ' A' ' 55' ' ' ILE . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.627 HD12 HD21 ' A' ' 44' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.413 ' N ' HG22 ' A' ' 55' ' ' ILE . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASN . . . . . 0.402 ' O ' ' CD1' ' A' ' 60' ' ' PHE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.657 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.657 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.646 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.512 HD22 HG23 ' A' ' 8' ' ' VAL . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.69 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.467 ' HB3' HG12 ' A' ' 21' ' ' VAL . 38.4 mtmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.098 0.475 . . . . 0.0 110.175 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.708 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.471 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.447 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.467 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.467 HG12 ' HB3' ' A' ' 7' ' ' LYS . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 120.953 0.406 . . . . 0.0 110.363 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.471 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.553 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.553 HD12 HD21 ' A' ' 44' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.475 ' N ' HG22 ' A' ' 55' ' ' ILE . 1.9 p30 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HA ' ' A' ' 39' ' ' ARG . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.687 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.463 ' HB3' HG21 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.687 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.421 ' CD ' ' HB3' ' A' ' 61' ' ' ALA . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.651 HD22 HG23 ' A' ' 8' ' ' VAL . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.708 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 121.088 0.47 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.52 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 1.026 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.483 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.025 0.44 . . . . 0.0 110.294 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.446 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 1.026 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CE1' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.469 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.516 HG22 ' H ' ' A' ' 57' ' ' THR . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.567 ' HB2' HD11 ' A' ' 65' ' ' LEU . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.564 ' HB3' HG21 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.597 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.098 0.475 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.654 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.726 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.703 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.703 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.466 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.078 0.466 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.538 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.524 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.531 ' HA ' HG22 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.467 HG22 ' N ' ' A' ' 56' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.467 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.467 ' O ' HG23 ' A' ' 37' ' ' ILE . 1.3 m120 -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.67 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.538 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.67 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.654 HD22 HG23 ' A' ' 8' ' ' VAL . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.726 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.098 0.475 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.765 HG23 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.47 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.673 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.543 ' H ' HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.415 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t . . . . . 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.408 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.999 0.428 . . . . 0.0 110.426 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.43 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 65' ' ' LEU . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.681 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.547 ' HG3' HG22 ' A' ' 57' ' ' THR . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.528 HD21 HD13 ' A' ' 55' ' ' ILE . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HD11 ' A' ' 55' ' ' ILE . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.526 ' N ' HD12 ' A' ' 55' ' ' ILE . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 44' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.71 ' ND2' HG23 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.71 HG23 ' ND2' ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.403 ' CE1' ' HD3' ' A' ' 12' ' ' ARG . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.43 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.765 HD22 HG23 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.47 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.081 0.467 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.504 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.769 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.474 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.428 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.428 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.46 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt . . . . . 0 N--CA 1.498 1.93 0 CA-C-O 120.898 0.38 . . . . 0.0 110.379 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.433 HG21 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 10' ' ' ILE . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.535 ' HG3' HG22 ' A' ' 57' ' ' THR . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.535 HD21 HD12 ' A' ' 55' ' ' ILE . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.535 HD12 HD21 ' A' ' 44' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.804 ' OD1' HG23 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.804 HG23 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.4 m120 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.433 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.415 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.504 HD22 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.408 ' HA ' HG12 ' A' ' 8' ' ' VAL . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.769 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.519 ' HD2' HG12 ' A' ' 21' ' ' VAL . 17.6 mmtt . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 121.092 0.472 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.608 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.679 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.662 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.476 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.519 HG12 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.008 0.432 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.658 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.449 ' HA ' HG22 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.517 HD21 HD12 ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 44' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.449 HG22 ' HA ' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.701 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.615 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.701 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.662 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.679 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.088 0.471 . . . . 0.0 110.096 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.601 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.723 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.403 ' H ' HG22 ' A' ' 10' ' ' ILE . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 120.985 0.421 . . . . 0.0 110.459 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.44 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . 1.4 p30 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.698 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.466 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.698 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.723 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.9 mmmt . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.036 0.446 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.653 HG23 HD22 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.691 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.572 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.427 ' H ' HG22 ' A' ' 10' ' ' ILE . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.421 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.516 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.667 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? . . . . . 0 N--CA 1.497 1.914 0 CA-C-O 120.966 0.412 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.667 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.572 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.567 HD21 HD12 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.567 HD12 HD21 ' A' ' 44' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.449 ' C ' HG23 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.502 ' H ' HG22 ' A' ' 55' ' ' ILE . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.433 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.695 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.585 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.695 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.653 HD22 HG23 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.691 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.8 m . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.058 0.456 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.563 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.63 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 38' ' ' VAL . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.436 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.438 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.405 HG22 HG21 ' A' ' 68' ' ' VAL . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.407 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.995 0.426 . . . . 0.0 110.41 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.438 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.529 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.527 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.492 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.532 HG22 ' H ' ' A' ' 57' ' ' THR . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.41 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.417 ' HB3' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.563 HD22 HG23 ' A' ' 8' ' ' VAL . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.63 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 mtmt . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.062 0.458 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.617 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.552 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.552 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.421 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.432 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 HG22 ' A' ' 36' ' ' VAL . 57.8 t . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.934 0 CA-C-O 121.056 0.455 . . . . 0.0 110.409 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.403 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.501 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 57' ' ' THR . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.547 ' H ' HG22 ' A' ' 55' ' ' ILE . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.508 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.4 m120 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.582 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.501 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.582 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.617 HD22 HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.127 0.489 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.591 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 21' ' ' VAL . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.428 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.45 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 120.98 0.419 . . . . 0.0 110.394 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.469 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.709 ' HG3' HG22 ' A' ' 57' ' ' THR . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.639 HD21 HD12 ' A' ' 55' ' ' ILE . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.639 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.794 ' ND2' HG23 ' A' ' 57' ' ' THR . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.794 HG23 ' ND2' ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.469 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.591 HD22 HG23 ' A' ' 8' ' ' VAL . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.48 ' HA ' HG12 ' A' ' 8' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.429 ' O ' HG23 ' A' ' 68' ' ' VAL . 35.7 m . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 121.071 0.463 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.688 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.724 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.694 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.567 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.42 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 5.3 ptpt . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.027 0.441 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.401 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.505 HD21 HD12 ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.505 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HB3' HG21 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.558 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.729 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.694 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLU . . . . . 0.445 ' HA ' HG12 ' A' ' 8' ' ' VAL . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.724 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.7 mtmt . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.055 0.455 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.641 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.551 ' HG2' HG22 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.445 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.445 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.41 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.551 HG22 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.43 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 121.057 0.456 . . . . 0.0 110.267 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.43 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.471 ' ND2' HD12 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.471 HD12 ' ND2' ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.608 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.629 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.629 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.641 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.529 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.093 0.473 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.588 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.635 ' HG3' HG11 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.696 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.606 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.664 ' O ' HD12 ' A' ' 37' ' ' ILE . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.5 t . . . . . 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 120.893 0.378 . . . . 0.0 110.537 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.664 HD12 ' O ' ' A' ' 26' ' ' SER . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.543 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.72 ' HG2' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.563 HD21 HD12 ' A' ' 55' ' ' ILE . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.563 HD12 HD21 ' A' ' 44' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.68 ' ND2' HG23 ' A' ' 57' ' ' THR . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.72 HG22 ' HG2' ' A' ' 39' ' ' ARG . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.653 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLU . . . . . 0.653 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.696 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.635 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.5 mtm . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 121.029 0.443 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.961 HG11 HG21 ' A' ' 24' ' ' VAL . 61.6 t -90.02 167.0 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.602 -0.686 . . . . 0.0 110.033 178.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.48 ' N ' HG12 ' A' ' 2' ' ' VAL . 18.5 mp0 -107.3 165.96 11.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.561 -0.712 . . . . 0.0 110.19 -177.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -70.79 94.06 1.01 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.547 -0.721 . . . . 0.0 110.167 177.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.13 30.19 3.24 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.99 -177.6 4.54 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.577 -0.955 . . . . 0.0 110.177 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -125.33 99.14 5.93 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.616 -0.678 . . . . 0.0 110.166 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.711 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.761 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.591 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.511 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.427 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.555 HG22 HG21 ' A' ' 68' ' ' VAL . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.961 HG21 HG11 ' A' ' 2' ' ' VAL . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t -117.73 142.04 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -108.49 98.88 8.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.55 -0.719 . . . . 0.0 110.224 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -85.35 94.76 9.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.175 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 9.1 m -156.19 -51.91 0.08 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 110.218 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.65 76.63 0.02 OUTLIER Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.448 HD11 ' O ' ' A' ' 34' ' ' TYR . 40.9 pt -127.54 -164.62 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.996 . . . . 0.0 110.245 178.54 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt -89.92 -24.1 21.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.559 -0.713 . . . . 0.0 110.586 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.448 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' A' ' 17' ' ' TRP . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.635 HD21 HD12 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.635 HD12 HD21 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.533 ' O ' HG23 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.533 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.711 HD22 HG23 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.761 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -114.88 50.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -80.85 164.95 22.29 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.665 -0.647 . . . . 0.0 110.213 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.595 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -82.41 176.56 3.71 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.548 -0.72 . . . . 0.0 110.228 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.93 146.58 36.15 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.323 1.17 . . . . 0.0 110.991 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -141.5 146.38 36.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.562 -0.711 . . . . 0.0 110.144 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.46 130.69 35.03 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.545 -0.722 . . . . 0.0 110.209 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.1 mttt -108.05 164.6 14.41 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.532 -0.73 . . . . 0.0 110.157 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 177.78 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.362 0 O-C-N 123.345 1.182 . . . . 0.0 110.973 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 52.93 -178.29 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.388 -0.82 . . . . 0.0 110.768 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 3.7 tttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.917 -1.039 . . . . 0.0 110.305 178.687 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.042 0.449 . . . . 0.0 110.174 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.1 t -81.65 79.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.636 -0.665 . . . . 0.0 109.938 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -116.55 168.22 10.37 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.608 -0.682 . . . . 0.0 110.203 177.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 ptt-85 -61.09 147.61 43.28 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.64 -0.662 . . . . 0.0 110.254 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.58 -30.65 9.25 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.47 169.41 12.87 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.594 -0.945 . . . . 0.0 110.224 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt -121.82 122.26 39.06 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.599 -0.688 . . . . 0.0 110.179 177.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.78 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.808 ' HG3' HG11 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.8 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.462 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -93.02 119.54 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -108.01 114.57 28.58 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.656 -0.653 . . . . 0.0 110.172 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -106.17 49.05 0.81 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.566 -0.709 . . . . 0.0 110.198 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.3 t -97.57 29.03 3.46 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.56 -0.713 . . . . 0.0 110.242 178.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.68 62.41 2.85 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.41 HD11 ' HA ' ' A' ' 35' ' ' PRO . 45.1 pt -122.31 158.57 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.618 -0.931 . . . . 0.0 110.299 178.229 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -60.04 -26.45 66.12 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.537 -0.727 . . . . 0.0 110.403 -178.228 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.409 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.41 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.462 HD12 ' O ' ' A' ' 26' ' ' SER . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.8 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 57' ' ' THR . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.458 ' C ' HG23 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HG3' ' A' ' 39' ' ' ARG . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.444 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.78 HD22 HG23 ' A' ' 8' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 68' ' ' VAL . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 8' ' ' VAL . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.808 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m -123.93 54.33 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -77.06 166.47 23.25 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.551 -0.718 . . . . 0.0 110.106 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.45 163.82 8.08 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.687 . . . . 0.0 110.236 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.81 156.9 8.54 Favored 'Trans proline' 0 N--CA 1.491 1.348 0 O-C-N 123.43 1.226 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 32.7 mttt -98.05 164.19 12.45 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.525 -0.734 . . . . 0.0 110.203 178.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.07 166.64 14.86 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.611 -0.681 . . . . 0.0 110.234 178.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mtpt -82.99 150.54 61.82 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.689 -0.632 . . . . 0.0 110.188 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 172.69 0.17 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.405 1.213 . . . . 0.0 110.998 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.7 tptt -97.29 34.12 1.84 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.549 -0.719 . . . . 0.0 110.151 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.322 178.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.055 0.455 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.49 ' CG1' HG21 ' A' ' 24' ' ' VAL . 61.6 t -85.56 167.06 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.622 -0.674 . . . . 0.0 109.942 178.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 2' ' ' VAL . 18.4 mp0 -118.62 156.69 28.76 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.606 -0.684 . . . . 0.0 110.209 -177.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.8 mtt180 -74.99 110.28 9.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.516 -0.74 . . . . 0.0 110.135 176.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 127.62 -29.61 4.19 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -178.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.98 144.13 45.34 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.527 -0.984 . . . . 0.0 110.18 179.062 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -97.98 127.31 43.85 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.591 -0.693 . . . . 0.0 110.155 179.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.709 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.56 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.442 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.473 ' H ' HG22 ' A' ' 10' ' ' ILE . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.49 HG21 ' CG1' ' A' ' 2' ' ' VAL . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.4 119.67 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -106.55 143.37 34.76 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.563 -0.711 . . . . 0.0 110.199 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -131.96 79.96 1.89 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.652 -0.655 . . . . 0.0 110.16 177.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.5 m -133.64 -69.86 0.54 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.558 -0.714 . . . . 0.0 110.22 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.67 49.63 0.52 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.6 pt -120.72 140.08 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.542 -0.975 . . . . 0.0 110.234 177.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.434 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt -65.96 -27.84 68.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.577 -0.702 . . . . 0.0 110.346 -178.082 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.434 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.539 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.56 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.562 ' HA ' HG22 ' A' ' 57' ' ' THR . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.573 HD21 HD12 ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 44' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' ILE . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 39' ' ' ARG . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.693 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.693 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.574 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.709 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -143.18 58.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -77.86 -176.24 4.35 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.622 -0.674 . . . . 0.0 110.17 177.243 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.37 149.25 57.65 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.522 -0.736 . . . . 0.0 110.261 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 157.08 8.55 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 O-C-N 123.407 1.214 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -167.67 47.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.578 -0.701 . . . . 0.0 110.207 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.98 148.86 25.98 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.518 -0.739 . . . . 0.0 110.198 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -156.3 62.98 3.17 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.553 -0.717 . . . . 0.0 110.271 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.93 -26.9 33.19 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.365 1.192 . . . . 0.0 110.975 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.2 pttt -155.34 154.8 32.6 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.546 -0.721 . . . . 0.0 110.348 178.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.9 tptt . . . . . 0 N--CA 1.494 1.752 0 CA-C-O 117.961 -1.018 . . . . 0.0 110.198 178.721 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.6 mtm . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.04 0.448 . . . . 0.0 110.193 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 2' ' ' VAL . 34.4 m -69.96 71.06 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.585 -0.697 . . . . 0.0 110.25 -178.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 8.3 mp0 -131.63 -167.23 1.83 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.712 . . . . 0.0 110.149 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.91 127.17 31.5 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.538 -0.726 . . . . 0.0 110.14 178.508 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.74 -30.28 9.68 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -79.69 137.41 37.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.617 -0.931 . . . . 0.0 110.289 178.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp -97.83 133.88 41.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.549 -0.72 . . . . 0.0 110.205 179.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.557 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.758 ' HG3' HG11 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.67 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.463 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.434 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.536 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -138.1 119.66 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.24 138.93 34.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.567 -0.708 . . . . 0.0 110.198 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -125.22 32.06 5.46 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.579 -0.7 . . . . 0.0 110.259 178.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.0 m -85.31 -64.64 1.12 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.527 -0.733 . . . . 0.0 110.252 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 178.03 67.36 0.06 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.5 pt -123.36 149.37 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.539 -0.977 . . . . 0.0 110.281 177.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -60.73 -32.34 71.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.559 -0.713 . . . . 0.0 110.33 -177.563 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.5 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.67 HG11 HD11 ' A' ' 10' ' ' ILE . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.433 ' HG3' HG22 ' A' ' 57' ' ' THR . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 55' ' ' ILE . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.579 ' ND2' HG23 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.579 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.5 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.622 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.508 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.622 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.758 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -114.51 46.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.69 -154.78 0.14 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.606 -0.683 . . . . 0.0 109.688 177.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.52 163.43 61.45 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.206 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.9 146.5 36.25 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.452 1.238 . . . . 0.0 110.948 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.4 tttm -167.74 90.24 0.32 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.25 178.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.54 139.78 32.67 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.562 -0.711 . . . . 0.0 110.191 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.4 mmtt -143.64 170.28 8.83 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.548 -0.72 . . . . 0.0 110.222 178.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 150.28 23.77 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.35 1.184 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.28 47.78 1.35 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.602 -0.686 . . . . 0.0 110.15 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.282 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.5 ptm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.079 0.466 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.7 p -70.03 71.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.525 -0.734 . . . . 0.0 110.167 -178.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -128.07 -169.28 2.03 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.606 -0.684 . . . . 0.0 110.237 177.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.7 ttt180 -61.32 131.83 51.59 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.537 -0.727 . . . . 0.0 110.195 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.49 29.86 67.46 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 177.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 t -100.03 136.31 40.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.933 . . . . 0.0 110.189 177.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -82.71 99.57 9.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.542 -0.724 . . . . 0.0 110.204 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.716 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.687 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.414 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -118.37 123.45 71.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -120.73 149.14 42.99 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.514 -0.741 . . . . 0.0 110.225 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.0 tp60 -134.64 48.01 2.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.552 -0.718 . . . . 0.0 110.21 178.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 p -98.47 29.07 3.8 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.26 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.33 57.12 1.7 Allowed Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 178.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.526 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.9 pt -121.98 144.72 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.499 -1.001 . . . . 0.0 110.24 177.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER -62.61 -28.58 69.99 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.534 -0.729 . . . . 0.0 110.256 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.526 ' O ' HD12 ' A' ' 32' ' ' ILE . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.521 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' N ' HD12 ' A' ' 37' ' ' ILE . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.687 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.488 HD21 HD12 ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.488 HD12 HD21 ' A' ' 44' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.667 ' ND2' HG23 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.734 HG22 ' HG2' ' A' ' 39' ' ' ARG . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.521 ' HB3' HG21 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.716 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -141.44 51.52 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -124.99 131.97 53.33 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.499 -0.75 . . . . 0.0 110.192 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.41 156.47 65.77 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 178.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.83 -177.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.429 1.226 . . . . 0.0 110.978 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -87.26 160.11 18.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.592 -0.693 . . . . 0.0 110.272 178.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.32 116.8 23.2 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.543 -0.723 . . . . 0.0 110.189 178.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.8 mtpp -142.19 157.77 62.75 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.566 -0.709 . . . . 0.0 110.173 178.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.91 -27.76 36.51 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.461 1.242 . . . . 0.0 111.011 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -111.08 131.56 54.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.505 -0.747 . . . . 0.0 110.229 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.7 mttp . . . . . 0 N--CA 1.494 1.744 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.183 178.74 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.3 ptt? . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.087 0.47 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 24' ' ' VAL . 67.7 t -80.41 162.66 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.607 -0.683 . . . . 0.0 109.913 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.403 ' N ' HG12 ' A' ' 2' ' ' VAL . 0.1 OUTLIER -97.39 156.82 16.29 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.645 -0.66 . . . . 0.0 110.25 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -68.58 109.43 3.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.13 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.01 8.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -99.97 161.28 13.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.525 -0.985 . . . . 0.0 110.254 177.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -105.01 102.45 11.95 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.481 -0.762 . . . . 0.0 110.194 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.512 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.69 ' HG3' HG11 ' A' ' 68' ' ' VAL . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.435 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.816 HG21 HG11 ' A' ' 2' ' ' VAL . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.409 ' O ' HD12 ' A' ' 37' ' ' ILE . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -102.47 119.65 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.693 ' O ' HD11 ' A' ' 32' ' ' ILE . 1.4 t0 -121.49 145.89 47.47 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -145.47 79.33 1.57 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.57 -0.706 . . . . 0.0 110.198 178.032 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -133.15 28.96 4.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.601 -0.687 . . . . 0.0 110.262 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.28 36.29 1.03 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.693 HD11 ' O ' ' A' ' 28' ' ' ASP . 44.4 pt -120.62 139.05 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.58 -0.953 . . . . 0.0 110.246 177.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -67.86 -27.53 66.77 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.582 -0.699 . . . . 0.0 110.33 -177.205 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.443 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 28' ' ' ASP . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.438 HG12 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.435 ' CE1' ' HB3' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.627 HD21 HD12 ' A' ' 55' ' ' ILE . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.627 HD12 HD21 ' A' ' 44' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.413 ' N ' HG22 ' A' ' 55' ' ' ILE . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASN . . . . . 0.402 ' O ' ' CD1' ' A' ' 60' ' ' PHE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.657 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.657 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.646 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.512 HD22 HG23 ' A' ' 8' ' ' VAL . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.69 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -140.93 52.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -151.4 80.48 1.3 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.63 -0.669 . . . . 0.0 110.239 178.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -89.99 161.16 38.96 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.597 -0.689 . . . . 0.0 110.281 178.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.92 151.07 21.33 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 O-C-N 123.471 1.248 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.1 tttp -166.37 47.75 0.07 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.163 178.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.99 133.17 34.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.585 -0.697 . . . . 0.0 110.191 178.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.414 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.8 OUTLIER -82.71 -50.3 0.76 Allowed Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.538 -0.726 . . . . 0.0 110.548 178.623 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.43 159.76 2.89 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 O-C-N 123.11 1.058 . . . . 0.0 111.091 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 10.9 ptpt -59.91 -26.47 65.94 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.454 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.19 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.142 0.496 . . . . 0.0 110.204 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.407 HG13 HG11 ' A' ' 8' ' ' VAL . 58.2 t -80.89 79.56 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.498 -0.751 . . . . 0.0 109.918 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -123.06 177.28 5.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.568 -0.707 . . . . 0.0 110.226 177.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -61.06 149.06 38.22 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.59 9.43 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.8 156.51 18.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.58 -0.953 . . . . 0.0 110.23 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.467 ' HB3' HG12 ' A' ' 21' ' ' VAL . 38.4 mtmt -108.26 118.53 37.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.558 -0.714 . . . . 0.0 110.175 178.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.708 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.471 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.467 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.467 HG12 ' HB3' ' A' ' 7' ' ' LYS . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.12 119.71 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -99.64 97.24 8.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.648 -0.658 . . . . 0.0 110.175 179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -84.08 81.38 8.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.576 -0.703 . . . . 0.0 110.207 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 p -135.11 -71.74 0.48 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.575 -0.703 . . . . 0.0 110.156 179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -174.77 60.88 0.12 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.504 HD12 ' O ' ' A' ' 34' ' ' TYR . 47.1 pt -120.1 145.71 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.553 -0.969 . . . . 0.0 110.294 177.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER -64.15 -27.58 69.17 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.536 -0.727 . . . . 0.0 110.363 -179.602 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.504 ' O ' HD12 ' A' ' 32' ' ' ILE . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.471 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.553 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.553 HD12 HD21 ' A' ' 44' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.475 ' N ' HG22 ' A' ' 55' ' ' ILE . 1.9 p30 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HA ' ' A' ' 39' ' ' ARG . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.687 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.463 ' HB3' HG21 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.687 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.421 ' CD ' ' HB3' ' A' ' 61' ' ' ALA . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.651 HD22 HG23 ' A' ' 8' ' ' VAL . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.708 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -144.62 28.77 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -85.09 -28.89 25.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.553 -0.717 . . . . 0.0 110.201 179.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -81.03 179.41 1.93 Allowed Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.57 -0.706 . . . . 0.0 110.239 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.3 Cg_exo -53.01 -175.89 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.382 1.201 . . . . 0.0 110.984 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 53.3 mttt -80.7 -168.06 1.61 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.54 -0.725 . . . . 0.0 110.221 178.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -79.91 144.43 33.4 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt 52.58 81.38 0.26 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.429 -0.794 . . . . 0.0 110.766 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.97 -59.55 1.0 Allowed 'Trans proline' 0 N--CA 1.491 1.363 0 O-C-N 123.476 1.251 . . . . 0.0 111.005 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -83.05 139.11 33.44 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.601 -0.687 . . . . 0.0 110.188 178.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.4 ptmm? . . . . . 0 N--CA 1.495 1.778 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.284 178.761 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.079 0.466 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.477 HG11 HG21 ' A' ' 24' ' ' VAL . 68.5 t -90.02 166.97 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.588 -0.695 . . . . 0.0 109.898 178.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.462 ' N ' HG12 ' A' ' 2' ' ' VAL . 13.0 mp0 -121.45 163.24 19.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.606 -0.684 . . . . 0.0 110.261 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.16 107.32 7.17 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.492 -0.755 . . . . 0.0 110.218 176.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 123.01 -30.2 5.12 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.21 162.18 7.86 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.525 -0.985 . . . . 0.0 110.188 179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt -112.84 129.1 56.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.554 -0.716 . . . . 0.0 110.143 177.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.52 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 1.026 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.483 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.477 HG21 HG11 ' A' ' 2' ' ' VAL . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -145.05 119.61 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -93.79 124.58 37.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.592 -0.693 . . . . 0.0 110.211 178.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -98.41 103.12 15.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 178.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 t -165.65 -45.13 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.504 -0.748 . . . . 0.0 110.192 178.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.7 75.75 0.2 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.448 HD11 ' O ' ' A' ' 34' ' ' TYR . 44.8 pt -118.38 177.63 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.931 . . . . 0.0 110.296 178.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt -61.14 -29.03 69.53 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.582 -0.699 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.448 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 1.026 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CE1' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.469 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.516 HG22 ' H ' ' A' ' 57' ' ' THR . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 83.9 m-20 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.567 ' HB2' HD11 ' A' ' 65' ' ' LEU . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.564 ' HB3' HG21 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.597 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m -145.43 71.35 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -61.2 158.26 14.42 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.207 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.88 111.47 3.94 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.523 -0.735 . . . . 0.0 110.204 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.15 -175.63 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.428 0 O-C-N 123.185 1.097 . . . . 0.0 111.043 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.2 mttp -78.96 -168.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.589 -0.694 . . . . 0.0 110.205 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.54 156.5 19.46 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.614 -0.679 . . . . 0.0 110.164 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -112.01 95.44 29.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.569 -0.707 . . . . 0.0 110.208 178.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.86 113.71 1.38 Allowed 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.332 1.174 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -91.11 49.14 1.59 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.663 -0.648 . . . . 0.0 110.152 178.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.223 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 ttt . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.081 0.467 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.58 ' O ' HG23 ' A' ' 2' ' ' VAL . 34.4 m -62.68 116.9 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.325 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -136.39 -175.2 3.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.561 -0.712 . . . . 0.0 110.211 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.0 mmm-85 -72.92 110.55 7.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 177.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.03 -30.27 8.16 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.643 ' O ' HG23 ' A' ' 24' ' ' VAL . 0.3 OUTLIER -61.91 130.57 46.27 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.605 -0.938 . . . . 0.0 110.154 179.122 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.4 127.95 38.08 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 178.099 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.654 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.726 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.703 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.703 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.466 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 6' ' ' SER . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.49 119.79 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -125.12 84.46 2.28 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.0 110.257 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -83.96 80.51 9.14 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 178.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 18.2 t -122.84 -50.74 1.94 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.606 -0.684 . . . . 0.0 110.238 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 174.64 54.67 0.05 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 178.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 35' ' ' PRO . 44.7 pt -121.24 163.07 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.605 -0.938 . . . . 0.0 110.245 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt -59.95 -26.95 66.39 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.442 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.538 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.524 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.531 ' HA ' HG22 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.467 HG22 ' N ' ' A' ' 56' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.467 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.467 ' O ' HG23 ' A' ' 37' ' ' ILE . 1.3 m120 -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.67 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.538 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.67 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.654 HD22 HG23 ' A' ' 8' ' ' VAL . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.726 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -140.76 49.5 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -108.96 -28.97 8.83 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.251 178.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.508 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -62.36 173.23 1.0 Allowed Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.61 -0.681 . . . . 0.0 110.197 178.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.91 178.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.353 1.186 . . . . 0.0 110.91 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.38 45.94 2.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.549 -0.719 . . . . 0.0 110.251 178.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.56 165.24 15.62 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.644 -0.66 . . . . 0.0 110.241 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.8 tttt -105.4 149.57 37.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.574 -0.704 . . . . 0.0 110.216 178.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.89 150.21 23.76 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.445 1.234 . . . . 0.0 111.001 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 15.3 tttt 52.85 92.83 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.467 -0.771 . . . . 0.0 110.787 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.3 tttt . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.257 178.672 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.8 mtt . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.112 0.482 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.622 HG11 HG21 ' A' ' 24' ' ' VAL . 57.9 t -89.97 167.01 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.479 -0.763 . . . . 0.0 110.02 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.463 ' N ' HG12 ' A' ' 2' ' ' VAL . 0.9 OUTLIER -118.09 162.89 17.46 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.508 -0.745 . . . . 0.0 110.229 178.746 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.0 ttm180 -68.77 109.98 4.11 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.541 -0.724 . . . . 0.0 110.137 176.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.12 29.74 8.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.43 ' O ' HG23 ' A' ' 23' ' ' THR . 0.3 OUTLIER -92.79 -159.26 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.515 -0.991 . . . . 0.0 110.116 177.317 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -148.39 104.72 3.54 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.578 -0.701 . . . . 0.0 110.133 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.765 HG23 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.47 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.673 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.543 ' H ' HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.415 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 6' ' ' SER . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.622 HG21 HG11 ' A' ' 2' ' ' VAL . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t -122.0 119.82 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -84.01 125.14 31.78 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.201 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -104.94 33.59 3.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.563 -0.711 . . . . 0.0 110.162 178.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.4 m -101.32 -52.99 3.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.614 -0.679 . . . . 0.0 110.231 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.34 83.96 0.04 OUTLIER Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.9 pt -127.3 159.75 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.579 -0.954 . . . . 0.0 110.252 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.408 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -59.97 -26.51 66.08 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.593 -0.692 . . . . 0.0 110.426 -178.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.43 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 65' ' ' LEU . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.681 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.547 ' HG3' HG22 ' A' ' 57' ' ' THR . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.528 HD21 HD13 ' A' ' 55' ' ' ILE . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HD11 ' A' ' 55' ' ' ILE . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.526 ' N ' HD12 ' A' ' 55' ' ' ILE . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 44' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.71 ' ND2' HG23 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.71 HG23 ' ND2' ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.403 ' CE1' ' HD3' ' A' ' 12' ' ' ARG . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.43 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.765 HD22 HG23 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.47 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -136.99 28.79 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -129.22 48.6 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.653 -0.655 . . . . 0.0 110.17 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -83.23 -177.04 0.88 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.231 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -53.07 -174.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.434 1.228 . . . . 0.0 111.024 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 23.8 mmtt -74.49 167.62 21.34 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.169 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.67 -158.88 0.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.547 -0.72 . . . . 0.0 110.238 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 15.5 mttt 52.67 85.33 0.19 Allowed Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.419 -0.8 . . . . 0.0 110.802 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.85 177.16 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.416 0 O-C-N 123.408 1.215 . . . . 0.0 111.038 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 mttt 52.91 -165.85 0.07 Allowed 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.481 -0.762 . . . . 0.0 110.814 178.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 33.0 tttt . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.209 178.6 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.4 ptp . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.122 0.487 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.573 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.7 p -69.55 72.68 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.57 -0.706 . . . . 0.0 110.216 -178.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.1 mp0 -133.86 -165.89 1.71 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.547 -0.721 . . . . 0.0 110.046 177.132 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -62.53 124.73 21.73 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.195 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.38 -30.31 8.67 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.8 155.71 29.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.587 -0.949 . . . . 0.0 110.225 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -110.1 125.82 53.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.504 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.769 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.474 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.428 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.428 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.46 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t -131.27 144.29 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -120.94 101.54 7.76 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.526 -0.733 . . . . 0.0 110.273 178.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.8 mt-30 -90.09 81.8 6.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.582 -0.699 . . . . 0.0 110.152 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.6 p -143.85 -70.32 0.31 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.457 -0.777 . . . . 0.0 110.191 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 167.26 64.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 34' ' ' TYR . 40.2 pt -116.17 172.01 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.567 -0.96 . . . . 0.0 110.281 178.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt -60.12 -26.56 66.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.526 -0.734 . . . . 0.0 110.379 -178.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.413 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.433 HG21 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 10' ' ' ILE . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.535 ' HG3' HG22 ' A' ' 57' ' ' THR . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.535 HD21 HD12 ' A' ' 55' ' ' ILE . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.535 HD12 HD21 ' A' ' 44' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.804 ' OD1' HG23 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.804 HG23 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.4 m120 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.433 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.415 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.504 HD22 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.408 ' HA ' HG12 ' A' ' 8' ' ' VAL . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.769 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m -110.78 38.82 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -92.85 92.55 7.96 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.152 175.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.17 111.13 3.3 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.648 -0.657 . . . . 0.0 110.239 -178.104 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.32 -175.14 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.472 0 O-C-N 123.105 1.055 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.7 mttm -108.63 48.57 0.85 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.577 -0.702 . . . . 0.0 110.299 177.389 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.64 -161.19 0.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.707 . . . . 0.0 110.257 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -115.28 165.65 13.75 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.584 -0.697 . . . . 0.0 110.219 178.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.94 153.12 16.04 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 O-C-N 123.435 1.229 . . . . 0.0 110.968 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -168.25 148.69 4.84 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.53 -0.731 . . . . 0.0 110.296 178.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.2 pttt . . . . . 0 N--CA 1.495 1.805 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.269 178.613 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.088 0.47 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 2' ' ' VAL . 9.8 p -70.58 69.52 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.57 -0.706 . . . . 0.0 110.173 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -130.1 -173.86 3.16 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.553 -0.717 . . . . 0.0 110.245 178.121 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.7 ptt180 -61.2 126.42 27.29 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.631 -0.668 . . . . 0.0 110.281 178.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 -30.58 7.03 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 153.02 26.02 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.585 -0.95 . . . . 0.0 110.177 178.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.519 ' HD2' HG12 ' A' ' 21' ' ' VAL . 17.6 mmtt -102.9 127.66 50.01 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.565 -0.71 . . . . 0.0 110.172 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.608 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.679 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.662 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.476 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.519 HG12 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t -117.6 135.11 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -84.06 110.08 18.18 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.579 -0.7 . . . . 0.0 110.177 178.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -93.71 82.32 4.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.505 -0.747 . . . . 0.0 110.252 178.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.1 m -164.35 -58.98 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.243 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.61 82.46 0.04 OUTLIER Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -123.88 165.66 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.605 -0.938 . . . . 0.0 110.246 178.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt -60.06 -26.5 66.2 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.557 -0.714 . . . . 0.0 110.46 -178.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.658 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.449 ' HA ' HG22 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.517 HD21 HD12 ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 44' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.449 HG22 ' HA ' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.701 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.615 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.701 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.662 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.42 ' OE1' ' HB2' ' A' ' 70' ' ' ALA . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.679 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -129.12 40.85 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -162.17 33.78 0.12 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.528 -0.733 . . . . 0.0 110.242 178.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.42 ' HB2' ' OE1' ' A' ' 67' ' ' GLU . . . -83.34 167.99 25.34 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.583 -0.698 . . . . 0.0 110.199 178.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 173.52 0.14 Allowed 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.436 1.229 . . . . 0.0 110.965 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 pttt -166.37 52.57 0.09 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.631 -0.668 . . . . 0.0 110.28 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -81.86 -176.0 5.88 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 110.186 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -113.75 91.68 22.26 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.654 . . . . 0.0 110.238 178.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.9 149.78 25.11 Favored 'Trans proline' 0 N--CA 1.491 1.338 0 O-C-N 123.404 1.212 . . . . 0.0 110.971 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? 52.83 -169.69 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.357 -0.839 . . . . 0.0 110.775 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.233 178.679 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.129 0.49 . . . . 0.0 110.195 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 57.7 t -90.08 79.15 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.558 -0.714 . . . . 0.0 109.998 178.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -116.26 -173.3 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.621 -0.675 . . . . 0.0 110.196 178.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -61.34 134.57 57.09 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 178.689 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.93 -29.71 9.47 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.5 p -60.57 125.09 22.4 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.491 -1.005 . . . . 0.0 110.286 -177.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -75.85 68.34 2.37 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.45 -0.781 . . . . 0.0 110.096 172.531 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.601 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.723 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.403 ' H ' HG22 ' A' ' 10' ' ' ILE . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.5 t -108.78 125.79 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -106.63 117.98 35.46 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 110.188 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -82.03 79.85 8.44 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.567 -0.708 . . . . 0.0 110.184 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.1 t -133.28 -159.15 0.94 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.609 -0.682 . . . . 0.0 110.199 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -91.87 50.1 2.83 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 37.0 pt -110.29 142.59 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.48 -1.012 . . . . 0.0 110.267 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -70.59 -26.39 63.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.611 -0.681 . . . . 0.0 110.459 -175.971 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.44 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . 1.4 p30 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.698 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.466 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.698 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.723 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -132.99 43.86 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.3 tt0 -87.0 160.28 18.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.546 -0.722 . . . . 0.0 110.155 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.27 161.0 55.99 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.631 -0.668 . . . . 0.0 110.164 178.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.97 174.6 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.371 0 O-C-N 123.411 1.216 . . . . 0.0 110.938 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -82.85 -159.16 0.31 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.574 -0.704 . . . . 0.0 110.206 178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.07 150.76 37.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.193 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 62.6 mttm 52.65 82.13 0.25 Allowed Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.383 -0.823 . . . . 0.0 110.719 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.92 -32.89 59.3 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 O-C-N 123.411 1.216 . . . . 0.0 111.036 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 61.7 mttt -83.2 161.39 21.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.523 -0.736 . . . . 0.0 110.23 178.631 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 pttt . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.229 178.898 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.5 mtt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.105 0.478 . . . . 0.0 110.265 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.3 t -83.85 79.0 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.615 -0.678 . . . . 0.0 109.941 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.3 mp0 -133.78 177.53 7.65 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 110.211 178.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -61.3 127.31 30.89 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.515 -0.741 . . . . 0.0 110.252 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.49 -31.5 5.95 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.46 155.86 20.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.649 -0.913 . . . . 0.0 110.215 178.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.9 mmmt -108.42 126.1 52.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.592 -0.693 . . . . 0.0 110.199 178.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.653 HG23 HD22 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.691 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.572 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.427 ' H ' HG22 ' A' ' 10' ' ' ILE . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.421 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.516 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.667 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -107.96 119.72 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -113.87 118.03 33.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.565 -0.709 . . . . 0.0 110.21 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -102.83 48.51 0.86 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.519 -0.738 . . . . 0.0 110.203 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.5 t -98.99 28.99 4.03 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.568 -0.707 . . . . 0.0 110.247 178.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.82 80.69 0.3 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 178.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -139.42 166.97 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.497 -1.002 . . . . 0.0 110.345 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? -59.96 -27.07 66.5 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.607 -0.683 . . . . 0.0 110.388 -178.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.667 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.572 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.567 HD21 HD12 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.567 HD12 HD21 ' A' ' 44' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.449 ' C ' HG23 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.502 ' H ' HG22 ' A' ' 55' ' ' ILE . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.433 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.695 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.585 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.695 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.653 HD22 HG23 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.691 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.8 m -141.35 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -79.94 164.97 23.09 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.461 -0.774 . . . . 0.0 110.231 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.49 149.04 60.25 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 179.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.98 169.12 0.4 Allowed 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.414 1.218 . . . . 0.0 111.006 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt 52.9 82.56 0.07 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.455 -0.778 . . . . 0.0 110.825 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 177.75 6.39 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.623 -0.673 . . . . 0.0 110.209 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt 52.62 94.97 0.05 OUTLIER Pre-proline 0 N--CA 1.501 2.092 0 O-C-N 121.458 -0.776 . . . . 0.0 110.782 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.9 173.66 0.13 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.37 1.195 . . . . 0.0 110.974 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -83.22 -41.01 18.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.516 -0.74 . . . . 0.0 110.202 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.495 1.781 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.132 178.784 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 tpt . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 120.993 0.425 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.468 ' CG1' HG11 ' A' ' 8' ' ' VAL . 34.2 m -61.13 -165.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.675 -0.641 . . . . 0.0 110.297 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -140.19 165.56 27.04 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.573 -0.704 . . . . 0.0 110.182 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.2 mtm180 -71.96 93.6 1.38 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.543 -0.723 . . . . 0.0 110.105 176.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.11 30.2 3.49 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.06 -167.8 1.57 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.456 -1.026 . . . . 0.0 110.18 178.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -136.04 113.77 11.06 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.581 -0.699 . . . . 0.0 110.253 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.563 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.63 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 38' ' ' VAL . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.436 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.438 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.405 HG22 HG21 ' A' ' 68' ' ' VAL . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -120.83 128.41 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -106.5 126.28 52.06 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.528 -0.733 . . . . 0.0 110.169 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -90.52 50.05 1.77 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.54 -0.725 . . . . 0.0 110.205 178.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.4 m -105.74 -159.32 0.7 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.576 -0.702 . . . . 0.0 110.222 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.22 62.52 0.43 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 178.457 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 pt -108.34 169.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.603 -0.94 . . . . 0.0 110.242 178.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.407 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -60.16 -26.6 66.43 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.548 -0.72 . . . . 0.0 110.41 -177.394 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.438 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.529 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.527 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.492 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.532 HG22 ' H ' ' A' ' 57' ' ' THR . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.41 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.417 ' HB3' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.563 HD22 HG23 ' A' ' 8' ' ' VAL . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.63 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -134.97 53.29 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -112.01 119.94 40.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.563 -0.71 . . . . 0.0 110.175 177.705 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -90.05 112.31 51.63 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.552 -0.717 . . . . 0.0 110.187 179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.06 -176.34 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.105 1.055 . . . . 0.0 111.03 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.4 tptt -82.19 160.72 22.97 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.539 -0.725 . . . . 0.0 110.21 178.121 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.73 84.33 7.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.541 -0.725 . . . . 0.0 110.165 178.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.5 mtmm 52.62 88.69 0.11 Allowed Pre-proline 0 N--CA 1.502 2.151 0 O-C-N 121.456 -0.777 . . . . 0.0 110.71 178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.01 -30.78 50.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.498 1.262 . . . . 0.0 110.974 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 6.3 ttmm -139.13 131.11 27.84 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.58 -0.7 . . . . 0.0 110.151 178.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.287 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.1 ttp . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.122 0.487 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.823 HG11 HG11 ' A' ' 8' ' ' VAL . 35.3 m -69.4 -165.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.573 -0.704 . . . . 0.0 110.232 178.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 18.7 mp0 -118.14 157.35 27.07 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.6 -0.687 . . . . 0.0 110.175 -179.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 29.8 mtp180 -75.44 110.15 9.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.524 -0.735 . . . . 0.0 110.152 176.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 119.39 -29.81 6.01 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.08 152.86 42.08 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.572 -0.958 . . . . 0.0 110.241 178.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 mtmt -104.36 127.08 51.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.591 -0.693 . . . . 0.0 110.245 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.823 HG11 HG11 ' A' ' 2' ' ' VAL . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.552 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.552 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.421 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.432 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 HG22 ' A' ' 36' ' ' VAL . 57.8 t -125.07 119.65 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -116.22 113.74 23.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.496 -0.753 . . . . 0.0 110.248 178.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -100.78 81.54 2.3 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.575 -0.703 . . . . 0.0 110.196 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.8 m -128.88 29.01 5.28 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.589 -0.695 . . . . 0.0 110.232 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.12 53.52 7.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 178.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.405 HD11 ' HA ' ' A' ' 35' ' ' PRO . 40.6 pt -114.15 166.19 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.635 -0.921 . . . . 0.0 110.23 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -59.88 -27.13 66.44 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.524 -0.735 . . . . 0.0 110.409 -177.989 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.403 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.405 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.501 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 57' ' ' THR . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.547 ' H ' HG22 ' A' ' 55' ' ' ILE . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.508 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.4 m120 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.582 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.501 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.582 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.617 HD22 HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m -134.03 -40.67 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.478 ' N ' HG23 ' A' ' 68' ' ' VAL . 0.3 OUTLIER 53.13 -171.37 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.306 -0.871 . . . . 0.0 110.547 179.092 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.58 151.49 94.43 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.46 -0.775 . . . . 0.0 110.128 178.375 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 146.55 36.23 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.427 1.225 . . . . 0.0 111.011 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -167.53 32.44 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.616 -0.677 . . . . 0.0 110.308 178.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.85 87.67 7.04 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.603 -0.685 . . . . 0.0 110.248 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.417 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.2 OUTLIER -84.12 -50.22 0.63 Allowed Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.655 -0.653 . . . . 0.0 110.593 178.497 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.5 179.58 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.486 0 O-C-N 123.15 1.079 . . . . 0.0 111.085 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 13.3 tptp -83.21 82.09 8.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.71 . . . . 0.0 110.269 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.202 178.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.3 ptt? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.082 0.468 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.4 p -61.46 117.46 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.601 -0.687 . . . . 0.0 110.084 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 32.1 tp60 -168.05 165.36 13.52 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 110.082 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.2 ttp180 -60.84 113.57 2.57 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.518 -0.739 . . . . 0.0 110.208 178.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.21 -30.13 6.68 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -178.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.72 151.18 34.28 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.532 -0.981 . . . . 0.0 110.143 178.444 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -106.75 125.26 50.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.552 -0.717 . . . . 0.0 110.196 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.591 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 21' ' ' VAL . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.428 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.45 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -107.36 119.83 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -130.22 148.22 52.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.58 -0.7 . . . . 0.0 110.284 178.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 23.1 tt0 -152.56 98.51 2.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.152 178.139 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -156.1 28.89 0.36 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.546 -0.721 . . . . 0.0 110.206 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.54 -30.51 2.77 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.9 pt -60.41 142.32 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.601 -0.941 . . . . 0.0 110.304 -177.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt -70.46 -26.75 63.78 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.516 -0.74 . . . . 0.0 110.394 -176.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.469 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.709 ' HG3' HG22 ' A' ' 57' ' ' THR . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.639 HD21 HD12 ' A' ' 55' ' ' ILE . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.639 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.794 ' ND2' HG23 ' A' ' 57' ' ' THR . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.794 HG23 ' ND2' ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.469 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.591 HD22 HG23 ' A' ' 8' ' ' VAL . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.48 ' HA ' HG12 ' A' ' 8' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.429 ' O ' HG23 ' A' ' 68' ' ' VAL . 35.7 m -138.5 61.7 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -61.7 165.32 5.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.583 -0.698 . . . . 0.0 110.193 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.35 159.72 63.96 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 178.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.02 154.93 12.24 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.437 1.23 . . . . 0.0 110.95 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -104.21 149.87 24.9 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.501 -0.75 . . . . 0.0 110.21 178.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.44 -174.32 5.22 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.569 -0.707 . . . . 0.0 110.22 178.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.2 mptt 52.6 94.54 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 O-C-N 121.43 -0.794 . . . . 0.0 110.775 179.005 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 -177.01 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.424 1.223 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.3 ttmt -99.42 130.12 45.66 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.569 -0.707 . . . . 0.0 110.194 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.3 pttt . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.325 -178.81 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.106 0.479 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.45 HG23 HG11 ' A' ' 24' ' ' VAL . 34.4 m -61.06 -165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.538 -0.726 . . . . 0.0 110.228 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.7 mp0 -122.43 149.06 44.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.599 -0.688 . . . . 0.0 110.168 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt-85 -61.4 117.54 5.81 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.56 -0.712 . . . . 0.0 110.286 178.221 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 23' ' ' THR . . . 119.32 -30.64 5.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.48 168.51 2.76 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.523 -0.987 . . . . 0.0 110.203 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -122.06 126.51 48.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.601 -0.687 . . . . 0.0 110.242 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.688 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.724 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.694 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.567 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.42 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 5' ' ' GLY . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.45 HG11 HG23 ' A' ' 2' ' ' VAL . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -144.58 121.78 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -99.84 106.21 18.04 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.532 -0.73 . . . . 0.0 110.24 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.3 tp60 -83.44 90.05 7.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.6 -0.687 . . . . 0.0 110.182 178.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -146.71 -67.97 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.557 -0.714 . . . . 0.0 110.279 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.27 72.08 0.02 OUTLIER Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -121.46 169.05 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.596 -0.943 . . . . 0.0 110.263 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 5.3 ptpt -59.82 -26.65 65.96 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.555 -0.715 . . . . 0.0 110.458 -178.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.401 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.505 HD21 HD12 ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.505 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HB3' HG21 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.558 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.729 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.694 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLU . . . . . 0.445 ' HA ' HG12 ' A' ' 8' ' ' VAL . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.724 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m -111.84 -26.16 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 52.93 -178.09 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.222 -0.924 . . . . 0.0 110.75 178.362 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -85.47 -177.11 0.87 Allowed Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.63 -0.669 . . . . 0.0 110.265 178.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -52.86 176.6 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.382 1.201 . . . . 0.0 111.038 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -84.09 108.88 17.28 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.598 -0.689 . . . . 0.0 110.159 178.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 -159.5 0.6 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.656 . . . . 0.0 110.19 178.248 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 6.1 ttmt -139.76 84.68 15.29 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 110.196 178.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.01 -176.69 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.404 1.213 . . . . 0.0 110.953 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.0 ptmt -111.88 166.36 11.27 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.605 -0.684 . . . . 0.0 110.275 178.533 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.221 178.691 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttm . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.094 0.473 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.593 HG11 HG21 ' A' ' 24' ' ' VAL . 61.6 t -80.83 167.02 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.541 -0.724 . . . . 0.0 109.964 178.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.464 ' N ' HG12 ' A' ' 2' ' ' VAL . 18.4 mp0 -115.33 166.36 11.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.58 -0.7 . . . . 0.0 110.246 -176.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -67.33 113.54 5.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.497 -0.752 . . . . 0.0 110.219 177.433 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.67 30.01 11.18 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.64 156.45 16.41 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.967 . . . . 0.0 110.187 177.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.6 ' NZ ' ' HB2' ' A' ' 70' ' ' ALA . 14.7 mtmt -106.8 106.01 16.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.584 -0.698 . . . . 0.0 110.204 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.641 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.551 ' HG2' HG22 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.445 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.445 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.41 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.551 HG22 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.593 HG21 HG11 ' A' ' 2' ' ' VAL . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.465 HG12 ' N ' ' A' ' 28' ' ' ASP . 58.2 t -136.05 166.97 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.465 ' N ' HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER -118.37 160.16 22.16 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.559 -0.713 . . . . 0.0 110.221 178.581 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -108.59 34.37 3.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 178.325 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.642 ' OG ' HG23 ' A' ' 32' ' ' ILE . 83.4 p -131.83 -163.61 1.35 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 110.253 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -114.0 45.15 1.36 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 178.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.642 HG23 ' OG ' ' A' ' 30' ' ' SER . 27.6 pt -61.03 178.98 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.561 -0.964 . . . . 0.0 110.334 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.43 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -61.31 -29.32 69.81 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 110.267 -179.736 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.501 ' O ' HD11 ' A' ' 32' ' ' ILE . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.471 ' ND2' HD12 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.471 HD12 ' ND2' ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.608 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.629 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.629 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.641 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.529 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m -133.98 -40.7 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 68' ' ' VAL . 0.7 OUTLIER 57.31 162.3 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.307 -0.871 . . . . 0.0 110.374 178.524 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.6 ' HB2' ' NZ ' ' A' ' 7' ' ' LYS . . . -89.11 173.13 6.39 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.344 -0.847 . . . . 0.0 110.199 -174.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.493 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.5 Cg_exo -52.9 151.16 21.02 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.435 1.229 . . . . 0.0 111.025 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.0 mtmt -127.27 48.59 2.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.563 -0.711 . . . . 0.0 110.2 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.68 110.96 18.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.561 -0.712 . . . . 0.0 110.207 178.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 15.9 mtpt -83.44 -50.41 0.68 Allowed Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 121.559 -0.713 . . . . 0.0 110.447 178.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.411 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.38 103.55 0.07 OUTLIER 'Trans proline' 0 N--CA 1.493 1.488 0 O-C-N 123.104 1.055 . . . . 0.0 111.078 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -124.94 29.03 6.26 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.518 -0.739 . . . . 0.0 110.273 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 tttp . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.136 178.786 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 34.0 mtm . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.065 0.46 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.904 HG11 HG21 ' A' ' 24' ' ' VAL . 57.8 t -83.15 166.87 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.546 -0.721 . . . . 0.0 110.042 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.469 ' N ' HG12 ' A' ' 2' ' ' VAL . 0.8 OUTLIER -93.73 149.02 21.58 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.522 -0.736 . . . . 0.0 110.195 178.898 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.0 ttt-85 -70.93 93.23 0.97 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.199 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.44 30.3 3.14 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.38 156.52 16.42 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.554 -0.968 . . . . 0.0 110.167 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm -100.31 109.76 21.98 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.579 -0.701 . . . . 0.0 110.209 178.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.588 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.635 ' HG3' HG11 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.696 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.606 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.904 HG21 HG11 ' A' ' 2' ' ' VAL . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.664 ' O ' HD12 ' A' ' 37' ' ' ILE . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.5 t -117.94 154.29 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.785 ' HB3' HD13 ' A' ' 32' ' ' ILE . 0.6 OUTLIER -94.79 -159.02 0.68 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.73 . . . . 0.0 110.218 177.605 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -126.8 -72.45 0.65 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.537 -0.727 . . . . 0.0 110.265 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.3 t -132.58 166.61 21.71 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.582 -0.699 . . . . 0.0 110.228 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 32' ' ' ILE . . . 65.48 54.46 26.17 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.785 HD13 ' HB3' ' A' ' 28' ' ' ASP . 43.3 pt -148.11 146.26 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.554 -0.968 . . . . 0.0 110.258 -178.155 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.09 -24.14 21.21 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.542 -0.724 . . . . 0.0 110.537 175.65 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.689 ' HA ' HD12 ' A' ' 32' ' ' ILE . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.664 HD12 ' O ' ' A' ' 26' ' ' SER . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.543 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.72 ' HG2' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.563 HD21 HD12 ' A' ' 55' ' ' ILE . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.563 HD12 HD21 ' A' ' 44' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.68 ' ND2' HG23 ' A' ' 57' ' ' THR . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.72 HG22 ' HG2' ' A' ' 39' ' ' ARG . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.653 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.653 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.696 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.635 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -113.3 36.3 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -116.39 135.52 53.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.534 -0.729 . . . . 0.0 110.214 178.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.97 111.44 3.93 Favored Pre-proline 0 N--CA 1.497 1.903 0 O-C-N 121.694 -0.629 . . . . 0.0 110.231 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.08 178.74 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.161 1.085 . . . . 0.0 110.999 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.0 155.46 19.36 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.24 178.719 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.1 82.85 8.07 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.582 -0.699 . . . . 0.0 110.229 178.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.423 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 3.1 mmtt -81.82 -50.42 0.87 Allowed Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.6 -0.687 . . . . 0.0 110.523 178.64 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.43 179.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.148 1.078 . . . . 0.0 111.089 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 11.1 tptm 52.88 45.64 28.36 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.383 -0.823 . . . . 0.0 110.859 178.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.222 178.721 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.052 0.454 . . . . 0.0 110.166 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.711 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.761 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.591 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.511 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.427 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.555 HG22 HG21 ' A' ' 68' ' ' VAL . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t . . . . . 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt . . . . . 0 N--CA 1.494 1.773 0 CA-C-O 120.848 0.356 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CE2' ' HD2' ' A' ' 33' ' ' LYS . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' A' ' 17' ' ' TRP . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.635 HD21 HD12 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.635 HD12 HD21 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.533 ' O ' HG23 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.533 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.711 HD22 HG23 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.761 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.78 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.808 ' HG3' HG11 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.8 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.462 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.499 1.979 0 CA-C-O 120.879 0.371 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.409 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.462 HD12 ' O ' ' A' ' 26' ' ' SER . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.8 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 57' ' ' THR . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.458 ' C ' HG23 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HG3' ' A' ' 39' ' ' ARG . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.444 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.78 HD22 HG23 ' A' ' 8' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 68' ' ' VAL . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 8' ' ' VAL . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.808 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.046 0.451 . . . . 0.0 110.155 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.709 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.56 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.442 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.473 ' H ' HG22 ' A' ' 10' ' ' ILE . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.434 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt . . . . . 0 N--CA 1.497 1.898 0 CA-C-O 120.988 0.423 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.434 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.539 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.56 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.562 ' HA ' HG22 ' A' ' 57' ' ' THR . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.573 HD21 HD12 ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 44' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' ILE . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 39' ' ' ARG . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.693 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.693 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.574 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.709 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.07 0.462 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.557 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.758 ' HG3' HG11 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.67 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.463 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.434 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.536 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.847 0 CA-C-O 120.985 0.422 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.5 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.67 HG11 HD11 ' A' ' 10' ' ' ILE . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.433 ' HG3' HG22 ' A' ' 57' ' ' THR . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 55' ' ' ILE . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.579 ' ND2' HG23 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.579 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.5 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.622 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.508 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.622 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.758 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.137 0.494 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.716 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.687 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.414 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER . . . . . 0 N--CA 1.496 1.831 0 CA-C-O 120.946 0.403 . . . . 0.0 110.256 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.441 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.521 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' N ' HD12 ' A' ' 37' ' ' ILE . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.687 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.488 HD21 HD12 ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.488 HD12 HD21 ' A' ' 44' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.667 ' ND2' HG23 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.734 HG22 ' HG2' ' A' ' 39' ' ' ARG . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.521 ' HB3' HG21 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.716 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.083 0.468 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.512 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.69 ' HG3' HG11 ' A' ' 68' ' ' VAL . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.435 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.409 ' O ' HD12 ' A' ' 37' ' ' ILE . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.006 0.431 . . . . 0.0 110.33 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.443 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.409 HD12 ' O ' ' A' ' 26' ' ' SER . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.438 HG12 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.435 ' CE1' ' HB3' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.627 HD21 HD12 ' A' ' 55' ' ' ILE . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.627 HD12 HD21 ' A' ' 44' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.413 ' N ' HG22 ' A' ' 55' ' ' ILE . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.402 ' O ' ' CD1' ' A' ' 60' ' ' PHE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.657 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.657 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.646 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.512 HD22 HG23 ' A' ' 8' ' ' VAL . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.69 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.467 ' HB3' HG12 ' A' ' 21' ' ' VAL . 38.4 mtmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.098 0.475 . . . . 0.0 110.175 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.708 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.471 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.447 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.467 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.467 HG12 ' HB3' ' A' ' 7' ' ' LYS . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 120.953 0.406 . . . . 0.0 110.363 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.471 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.553 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.553 HD12 HD21 ' A' ' 44' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.556 HD22 HG23 ' A' ' 57' ' ' THR . 9.9 p-10 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.556 HG23 HD22 ' A' ' 56' ' ' ASN . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.687 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.463 ' HB3' HG21 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.687 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.421 ' CD ' ' HB3' ' A' ' 61' ' ' ALA . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.651 HD22 HG23 ' A' ' 8' ' ' VAL . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.708 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 121.088 0.47 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.52 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 1.026 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.483 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.025 0.44 . . . . 0.0 110.294 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.446 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 1.026 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CE1' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.469 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.516 HG22 ' H ' ' A' ' 57' ' ' THR . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.567 ' HB2' HD11 ' A' ' 65' ' ' LEU . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.564 ' HB3' HG21 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.597 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 CA-C-O 121.098 0.475 . . . . 0.0 110.17 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.654 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.726 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.703 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.703 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.466 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 121.078 0.466 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.538 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.524 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.531 ' HA ' HG22 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.602 HG21 ' ND2' ' A' ' 58' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.467 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.602 ' ND2' HG21 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.67 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.538 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.67 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.654 HD22 HG23 ' A' ' 8' ' ' VAL . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.726 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.098 0.475 . . . . 0.0 110.133 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.765 HG23 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.47 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.673 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.543 ' H ' HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.415 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t . . . . . 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.408 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.999 0.428 . . . . 0.0 110.426 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.43 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 65' ' ' LEU . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.681 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.547 ' HG3' HG22 ' A' ' 57' ' ' THR . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.528 HD21 HD13 ' A' ' 55' ' ' ILE . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HD11 ' A' ' 55' ' ' ILE . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.526 ' N ' HD12 ' A' ' 55' ' ' ILE . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 44' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.71 ' ND2' HG23 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.71 HG23 ' ND2' ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.435 ' ND2' ' CZ3' ' A' ' 17' ' ' TRP . 1.5 m-80 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.403 ' CE1' ' HD3' ' A' ' 12' ' ' ARG . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.43 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.765 HD22 HG23 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.47 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.081 0.467 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.504 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.769 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.474 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.428 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.428 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.46 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt . . . . . 0 N--CA 1.498 1.93 0 CA-C-O 120.898 0.38 . . . . 0.0 110.379 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.433 HG21 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 10' ' ' ILE . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.535 ' HG3' HG22 ' A' ' 57' ' ' THR . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.535 HD21 HD12 ' A' ' 55' ' ' ILE . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.535 HD12 HD21 ' A' ' 44' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.804 ' OD1' HG23 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.804 HG23 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m-80 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.433 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.415 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.504 HD22 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.408 ' HA ' HG12 ' A' ' 8' ' ' VAL . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.769 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.519 ' HD2' HG12 ' A' ' 21' ' ' VAL . 17.6 mmtt . . . . . 0 N--CA 1.495 1.785 0 CA-C-O 121.092 0.472 . . . . 0.0 110.172 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.608 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.679 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.662 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.476 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.519 HG12 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.008 0.432 . . . . 0.0 110.46 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.658 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.449 ' HA ' HG22 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.517 HD21 HD12 ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 44' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.449 HG22 ' HA ' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.701 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.615 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.701 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.662 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.679 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.088 0.471 . . . . 0.0 110.096 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.601 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.723 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.403 ' H ' HG22 ' A' ' 10' ' ' ILE . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.5 t . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.882 0 CA-C-O 120.985 0.421 . . . . 0.0 110.459 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.44 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . 11.5 p-10 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.419 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.698 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.466 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.698 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.723 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m . . . . . 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.9 mmmt . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.036 0.446 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.653 HG23 HD22 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.691 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.572 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.427 ' H ' HG22 ' A' ' 10' ' ' ILE . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.421 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.516 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.667 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? . . . . . 0 N--CA 1.497 1.914 0 CA-C-O 120.966 0.412 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.667 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.572 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.567 HD21 HD12 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.567 HD12 HD21 ' A' ' 44' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.449 ' C ' HG23 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.502 ' H ' HG22 ' A' ' 55' ' ' ILE . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.433 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.695 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.585 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.695 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.653 HD22 HG23 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.691 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.8 m . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.058 0.456 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.563 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.63 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 38' ' ' VAL . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.436 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.438 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.405 HG22 HG21 ' A' ' 68' ' ' VAL . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.407 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 120.995 0.426 . . . . 0.0 110.41 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.438 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.529 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.527 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.492 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.532 HG22 ' H ' ' A' ' 57' ' ' THR . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.41 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.417 ' HB3' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.563 HD22 HG23 ' A' ' 8' ' ' VAL . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.63 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 mtmt . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.062 0.458 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.617 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.552 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.552 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.421 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.432 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 HG22 ' A' ' 36' ' ' VAL . 57.8 t . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.934 0 CA-C-O 121.056 0.455 . . . . 0.0 110.409 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.403 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.501 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 57' ' ' THR . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 57' ' ' THR . 2.5 p30 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.547 ' H ' HG22 ' A' ' 55' ' ' ILE . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.508 ' O ' HG23 ' A' ' 37' ' ' ILE . 1.7 m-80 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.582 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.501 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.582 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.617 HD22 HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.127 0.489 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.591 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 21' ' ' VAL . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.428 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.45 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 120.98 0.419 . . . . 0.0 110.394 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.469 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.709 ' HG3' HG22 ' A' ' 57' ' ' THR . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.639 HD21 HD12 ' A' ' 55' ' ' ILE . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.639 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.794 ' ND2' HG23 ' A' ' 57' ' ' THR . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.794 HG23 ' ND2' ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.469 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.591 HD22 HG23 ' A' ' 8' ' ' VAL . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.48 ' HA ' HG12 ' A' ' 8' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.429 ' O ' HG23 ' A' ' 68' ' ' VAL . 35.7 m . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 121.071 0.463 . . . . 0.0 110.242 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.688 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.724 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.694 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.567 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.42 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 5.3 ptpt . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.027 0.441 . . . . 0.0 110.458 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.401 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.505 HD21 HD12 ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.505 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.729 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HB3' HG21 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.558 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.729 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.694 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . 0.445 ' HA ' HG12 ' A' ' 8' ' ' VAL . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.724 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.7 mtmt . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.055 0.455 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.641 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.551 ' HG2' HG22 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.445 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.445 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.41 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.551 HG22 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.43 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 121.057 0.456 . . . . 0.0 110.267 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.43 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.471 ' ND2' HD12 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.471 HD12 ' ND2' ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.608 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.629 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.629 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.641 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.529 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.093 0.473 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.588 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.635 ' HG3' HG11 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.696 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.606 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.664 ' O ' HD12 ' A' ' 37' ' ' ILE . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.5 t . . . . . 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 120.893 0.378 . . . . 0.0 110.537 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.664 HD12 ' O ' ' A' ' 26' ' ' SER . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.543 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.72 ' HG2' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.563 HD21 HD12 ' A' ' 55' ' ' ILE . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.565 HG21 HD21 ' A' ' 58' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.68 ' ND2' HG23 ' A' ' 57' ' ' THR . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.72 HG22 ' HG2' ' A' ' 39' ' ' ARG . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.565 HD21 HG21 ' A' ' 55' ' ' ILE . 1.6 m-80 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.653 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . 0.653 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.696 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.635 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.5 mtm . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 121.029 0.443 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.961 HG11 HG21 ' A' ' 24' ' ' VAL . 61.6 t -90.02 167.0 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.602 -0.686 . . . . 0.0 110.033 178.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.48 ' N ' HG12 ' A' ' 2' ' ' VAL . 3.2 mp0 -107.3 165.96 11.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.561 -0.712 . . . . 0.0 110.19 -177.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -70.79 94.06 1.01 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.547 -0.721 . . . . 0.0 110.167 177.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.13 30.19 3.24 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.99 -177.6 4.54 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.577 -0.955 . . . . 0.0 110.177 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -125.33 99.14 5.93 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.616 -0.678 . . . . 0.0 110.166 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.711 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.89 152.2 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.593 -0.692 . . . . 0.0 110.286 178.459 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.761 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.5 mtt180 -81.47 162.82 23.12 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 110.207 178.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.591 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -100.9 129.13 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.593 -0.692 . . . . 0.0 110.072 179.026 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.85 38.64 1.87 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.157 177.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.511 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -115.01 87.17 14.79 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.597 -0.689 . . . . 0.0 110.175 179.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.84 -26.33 30.51 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.405 1.213 . . . . 0.0 110.959 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -75.37 -27.68 59.23 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.577 -0.702 . . . . 0.0 110.257 178.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.6 t -73.31 140.8 47.0 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.53 -0.731 . . . . 0.0 110.265 179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 43' ' ' VAL . 28.0 t80 -60.39 -27.9 67.8 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.611 -0.681 . . . . 0.0 110.311 177.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.427 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 9.4 m-90 -96.3 38.4 1.2 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.497 -0.752 . . . . 0.0 110.226 -177.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 42.0 t80 -66.92 154.8 40.13 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.538 -0.726 . . . . 0.0 110.162 176.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 16.4 mm-40 52.88 38.81 27.82 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.393 -0.817 . . . . 0.0 110.785 179.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -130.81 141.99 50.37 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.615 -0.678 . . . . 0.0 110.239 178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.555 HG22 HG21 ' A' ' 68' ' ' VAL . 58.4 t -87.24 87.29 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.577 -0.702 . . . . 0.0 109.965 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.85 171.79 54.64 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 178.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.2 m -109.18 141.7 41.05 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.653 -0.91 . . . . 0.0 110.141 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.961 HG21 HG11 ' A' ' 2' ' ' VAL . 58.6 t -81.78 130.89 35.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -97.21 -46.8 5.99 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.663 -0.648 . . . . 0.0 110.232 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.1 p -167.49 167.45 13.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.585 -0.697 . . . . 0.0 110.179 178.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.4 t -117.73 142.04 33.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.52 -0.737 . . . . 0.0 109.963 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -108.49 98.88 8.33 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.55 -0.719 . . . . 0.0 110.224 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -85.35 94.76 9.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.175 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 9.1 m -156.19 -51.91 0.08 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 110.218 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.65 76.63 0.02 OUTLIER Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.448 HD11 ' O ' ' A' ' 34' ' ' TYR . 40.9 pt -127.54 -164.62 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.996 . . . . 0.0 110.245 178.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 9.0 pttt -89.92 -24.1 21.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.559 -0.713 . . . . 0.0 110.586 179.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.448 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.8 m-85 -142.61 96.46 6.21 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.425 -0.797 . . . . 0.0 110.251 176.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.69 -46.33 34.2 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.344 1.181 . . . . 0.0 111.183 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -87.88 132.91 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.331 -0.855 . . . . 0.0 110.057 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.0 mt -98.06 126.86 50.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.586 -0.696 . . . . 0.0 109.915 176.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.586 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -109.45 131.25 60.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.626 -0.671 . . . . 0.0 110.072 -179.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -91.52 157.59 16.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.531 -0.731 . . . . 0.0 110.209 175.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.427 ' CE2' ' HB3' ' A' ' 17' ' ' TRP . 91.1 m-85 -137.6 146.69 44.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.531 -0.731 . . . . 0.0 110.252 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -86.97 -35.67 18.72 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.629 -0.67 . . . . 0.0 110.162 176.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 14.5 ttmt -80.91 176.71 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.562 -0.711 . . . . 0.0 110.266 176.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 16' ' ' TYR . 34.8 m -124.68 -173.5 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.539 -0.725 . . . . 0.0 110.322 176.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.635 HD21 HD12 ' A' ' 55' ' ' ILE . 43.7 p-10 -113.37 -164.34 0.92 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.605 -0.684 . . . . 0.0 110.209 178.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -61.2 -28.45 69.16 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -87.44 -72.23 0.53 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.567 -0.708 . . . . 0.0 110.281 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 152.26 65.92 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.635 HD12 HD21 ' A' ' 44' ' ' ASN . 69.1 mt -128.9 163.06 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.649 -0.913 . . . . 0.0 109.885 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.533 ' O ' HG23 ' A' ' 57' ' ' THR . 6.4 p-10 -151.02 27.83 0.69 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.484 -0.76 . . . . 0.0 110.372 178.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.533 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.5 p -155.13 102.14 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.165 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -118.52 -174.23 2.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.519 -0.738 . . . . 0.0 110.16 177.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.2 132.91 51.67 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.466 -0.772 . . . . 0.0 110.206 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 60.2 m-85 -129.65 161.09 31.37 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 177.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -91.65 154.29 19.11 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.556 -0.715 . . . . 0.0 110.196 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -59.62 -26.64 65.64 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.534 -0.729 . . . . 0.0 110.431 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -69.97 -25.76 63.78 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.44 177.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.69 28.34 3.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.342 -179.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.711 HD22 HG23 ' A' ' 8' ' ' VAL . 86.6 mt -138.67 126.91 22.82 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.547 -0.72 . . . . 0.0 110.235 178.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.94 141.61 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.516 -0.74 . . . . 0.0 109.883 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -78.0 114.1 16.55 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.626 -0.672 . . . . 0.0 110.248 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.761 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -114.88 50.31 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 110.276 178.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -80.85 164.95 22.29 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.665 -0.647 . . . . 0.0 110.213 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.595 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -82.41 176.56 3.71 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.548 -0.72 . . . . 0.0 110.228 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.93 146.58 36.15 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.323 1.17 . . . . 0.0 110.991 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -141.5 146.38 36.36 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.562 -0.711 . . . . 0.0 110.144 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.46 130.69 35.03 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.545 -0.722 . . . . 0.0 110.209 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.1 mttt -108.05 164.6 14.41 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.532 -0.73 . . . . 0.0 110.157 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 177.78 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.362 0 O-C-N 123.345 1.182 . . . . 0.0 110.973 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER 52.93 -178.29 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.388 -0.82 . . . . 0.0 110.768 178.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 3.7 tttt . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 117.917 -1.039 . . . . 0.0 110.305 178.687 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.042 0.449 . . . . 0.0 110.174 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.1 t -81.65 79.1 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.636 -0.665 . . . . 0.0 109.938 179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -116.55 168.22 10.37 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.608 -0.682 . . . . 0.0 110.203 177.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.5 ptt-85 -61.09 147.61 43.28 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.64 -0.662 . . . . 0.0 110.254 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.58 -30.65 9.25 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.47 169.41 12.87 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.594 -0.945 . . . . 0.0 110.224 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.6 mtpt -121.82 122.26 39.06 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.599 -0.688 . . . . 0.0 110.179 177.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.78 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -121.72 153.58 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 110.274 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.808 ' HG3' HG11 ' A' ' 68' ' ' VAL . 10.6 mtt-85 -79.52 150.08 31.27 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.556 -0.715 . . . . 0.0 110.211 178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.8 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -90.12 119.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.581 -0.7 . . . . 0.0 110.016 178.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.29 41.22 1.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.611 -0.681 . . . . 0.0 110.156 179.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.4 ttp180 -115.86 90.32 26.97 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.568 -0.708 . . . . 0.0 110.212 177.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.81 -26.44 30.71 Favored 'Trans proline' 0 N--CA 1.492 1.408 0 O-C-N 123.506 1.267 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.24 -27.7 61.74 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.528 -0.733 . . . . 0.0 110.249 177.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.8 t -73.19 139.76 46.51 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.55 -0.719 . . . . 0.0 110.253 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 75.0 t80 -60.4 -27.72 67.68 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.599 -0.688 . . . . 0.0 110.254 176.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.443 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.5 m-90 -96.04 39.17 1.15 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 51.9 t80 -70.3 160.01 33.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.544 -0.722 . . . . 0.0 110.141 175.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 52.9 32.67 12.95 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 121.438 -0.789 . . . . 0.0 110.812 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.36 157.99 41.91 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.511 -0.743 . . . . 0.0 110.211 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 57.6 t -99.72 98.12 6.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.573 -0.705 . . . . 0.0 109.975 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.54 155.05 27.75 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 178.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.0 m -94.94 136.93 34.66 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.576 -0.955 . . . . 0.0 110.26 178.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 67.1 t -80.25 121.22 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.606 -0.684 . . . . 0.0 109.922 178.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.58 -48.48 10.93 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.643 -0.66 . . . . 0.0 110.219 179.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.462 ' O ' HD12 ' A' ' 37' ' ' ILE . 1.2 m -162.54 146.51 11.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.528 -0.732 . . . . 0.0 110.258 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -93.02 119.54 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.639 -0.663 . . . . 0.0 110.012 178.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -108.01 114.57 28.58 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.656 -0.653 . . . . 0.0 110.172 179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 16.1 tt0 -106.17 49.05 0.81 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.566 -0.709 . . . . 0.0 110.198 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.3 t -97.57 29.03 3.46 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.56 -0.713 . . . . 0.0 110.242 178.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 74.68 62.41 2.85 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.41 HD11 ' HA ' ' A' ' 35' ' ' PRO . 45.1 pt -122.31 158.57 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.618 -0.931 . . . . 0.0 110.299 178.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.409 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -60.04 -26.45 66.12 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.537 -0.727 . . . . 0.0 110.403 -178.228 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.409 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 33.9 m-85 -133.86 95.75 17.01 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.178 177.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.41 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.2 Cg_exo -52.68 -41.98 65.59 Favored 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.461 1.243 . . . . 0.0 111.177 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -92.46 130.54 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.51 -0.744 . . . . 0.0 110.108 -174.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.462 HD12 ' O ' ' A' ' 26' ' ' SER . 10.1 mt -99.34 123.31 51.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.572 -0.705 . . . . 0.0 109.906 178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.8 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -104.37 143.03 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.577 -0.702 . . . . 0.0 110.03 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.7 ttm180 -113.23 129.07 56.63 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.578 -0.701 . . . . 0.0 110.214 177.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.443 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.7 m-85 -104.75 165.75 10.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.543 -0.723 . . . . 0.0 110.204 179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -110.8 -28.67 8.3 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.565 -0.709 . . . . 0.0 110.192 178.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -80.91 123.91 28.68 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.758 . . . . 0.0 110.269 178.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.4 m -61.11 -164.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.599 -0.688 . . . . 0.0 110.227 176.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -158.16 -164.68 1.55 Allowed 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.543 -0.723 . . . . 0.0 110.356 177.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -60.74 -28.38 68.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.584 -0.697 . . . . 0.0 110.288 -175.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.4 m -92.57 -28.61 16.64 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.519 -0.738 . . . . 0.0 110.243 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.27 56.99 1.08 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -177.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 57' ' ' THR . 73.2 mt -129.56 160.36 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.487 -1.008 . . . . 0.0 109.954 -177.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.458 ' C ' HG23 ' A' ' 57' ' ' THR . 3.3 p30 -145.99 26.95 1.2 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.58 -0.7 . . . . 0.0 110.394 177.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.556 HG22 ' HG3' ' A' ' 39' ' ' ARG . 28.9 p -152.58 133.41 14.01 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.557 -0.714 . . . . 0.0 110.155 176.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.444 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.4 m120 -146.59 -179.22 6.62 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.541 -0.724 . . . . 0.0 110.153 178.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.3 137.87 54.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.532 -0.73 . . . . 0.0 110.312 -179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 93.0 m-85 -137.57 159.66 41.35 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.628 -0.67 . . . . 0.0 110.182 178.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -88.49 156.78 18.91 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.546 -0.721 . . . . 0.0 110.23 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -60.78 -28.52 68.8 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.584 -0.697 . . . . 0.0 110.347 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -70.37 -25.86 63.46 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.565 -0.709 . . . . 0.0 110.334 177.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -96.35 26.95 4.0 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.451 -0.781 . . . . 0.0 110.369 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.78 HD22 HG23 ' A' ' 8' ' ' VAL . 76.3 mt -133.68 161.16 35.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.508 -0.745 . . . . 0.0 110.232 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 68' ' ' VAL . 58.9 t -139.4 122.9 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.644 -0.66 . . . . 0.0 109.897 176.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.444 ' HA ' HG12 ' A' ' 8' ' ' VAL . 0.7 OUTLIER -61.39 117.69 5.99 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.59 -0.694 . . . . 0.0 110.233 -179.091 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.808 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m -123.93 54.33 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.549 -0.719 . . . . 0.0 110.256 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -77.06 166.47 23.25 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.551 -0.718 . . . . 0.0 110.106 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.45 163.82 8.08 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.687 . . . . 0.0 110.236 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.81 156.9 8.54 Favored 'Trans proline' 0 N--CA 1.491 1.348 0 O-C-N 123.43 1.226 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 32.7 mttt -98.05 164.19 12.45 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.525 -0.734 . . . . 0.0 110.203 178.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.07 166.64 14.86 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.611 -0.681 . . . . 0.0 110.234 178.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mtpt -82.99 150.54 61.82 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.689 -0.632 . . . . 0.0 110.188 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 172.69 0.17 Allowed 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.405 1.213 . . . . 0.0 110.998 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.7 tptt -97.29 34.12 1.84 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.549 -0.719 . . . . 0.0 110.151 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.322 178.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.055 0.455 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.49 ' CG1' HG21 ' A' ' 24' ' ' VAL . 61.6 t -85.56 167.06 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.622 -0.674 . . . . 0.0 109.942 178.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 2' ' ' VAL . 3.2 mp0 -118.62 156.69 28.76 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.606 -0.684 . . . . 0.0 110.209 -177.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 68.8 mtt180 -74.99 110.28 9.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.516 -0.74 . . . . 0.0 110.135 176.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 127.62 -29.61 4.19 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -178.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.98 144.13 45.34 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.527 -0.984 . . . . 0.0 110.18 179.062 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -97.98 127.31 43.85 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.591 -0.693 . . . . 0.0 110.155 179.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.574 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -120.98 157.5 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.585 -0.697 . . . . 0.0 110.298 177.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.709 ' HG3' HG11 ' A' ' 68' ' ' VAL . 15.9 mtt-85 -81.67 155.39 25.61 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.529 -0.732 . . . . 0.0 110.181 178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.56 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -96.41 119.73 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.628 -0.67 . . . . 0.0 109.984 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.442 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.44 38.51 1.49 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.55 -0.719 . . . . 0.0 110.133 176.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.473 ' H ' HG22 ' A' ' 10' ' ' ILE . 8.9 ttt-85 -114.64 88.4 16.15 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.589 -0.694 . . . . 0.0 110.179 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.71 -25.54 26.84 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.347 1.183 . . . . 0.0 111.096 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -77.01 -27.75 54.75 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.562 -0.711 . . . . 0.0 110.262 179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.79 140.8 46.11 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.559 -0.713 . . . . 0.0 110.204 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -60.29 -26.8 66.78 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.572 -0.705 . . . . 0.0 110.367 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.6 m-90 -96.11 37.65 1.23 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 50.0 t80 -70.42 158.3 36.26 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 176.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 52.95 27.14 5.26 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.436 -0.79 . . . . 0.0 110.758 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -115.4 -168.37 1.39 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.576 -0.702 . . . . 0.0 110.231 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -137.54 99.71 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.507 -0.746 . . . . 0.0 109.944 177.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -95.49 159.74 22.54 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 m -96.97 147.1 24.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.535 -0.979 . . . . 0.0 110.139 177.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.49 HG21 ' CG1' ' A' ' 2' ' ' VAL . 58.4 t -79.97 119.94 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.604 -0.685 . . . . 0.0 109.974 178.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.0 -46.14 10.8 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.586 -0.696 . . . . 0.0 110.141 178.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 31.2 t -168.1 171.51 9.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.663 -0.648 . . . . 0.0 110.202 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -129.4 119.67 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.61 -0.681 . . . . 0.0 109.945 177.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -106.55 143.37 34.76 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.563 -0.711 . . . . 0.0 110.199 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -131.96 79.96 1.89 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.652 -0.655 . . . . 0.0 110.16 177.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.5 m -133.64 -69.86 0.54 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.558 -0.714 . . . . 0.0 110.22 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.67 49.63 0.52 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.6 pt -120.72 140.08 45.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.542 -0.975 . . . . 0.0 110.234 177.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.434 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 2.5 ptpt -65.96 -27.84 68.46 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.577 -0.702 . . . . 0.0 110.346 -178.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.434 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -115.25 95.75 43.48 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.615 -0.678 . . . . 0.0 110.241 178.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.99 -31.31 52.66 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.444 1.234 . . . . 0.0 111.14 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.3 t -99.71 139.43 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.507 -0.746 . . . . 0.0 110.091 -174.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.539 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -118.35 126.3 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.533 -0.729 . . . . 0.0 109.87 176.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.56 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -103.37 146.0 11.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 109.814 -178.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.562 ' HA ' HG22 ' A' ' 57' ' ' THR . 16.1 ttt85 -110.08 113.19 25.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.553 -0.717 . . . . 0.0 110.207 178.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.8 m-85 -90.53 169.17 11.26 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.711 . . . . 0.0 110.175 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -110.83 -28.7 8.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.529 -0.732 . . . . 0.0 110.201 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -84.41 131.9 34.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.218 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.7 m -66.87 -165.67 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.57 -0.706 . . . . 0.0 110.231 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.573 HD21 HD12 ' A' ' 55' ' ' ILE . 43.3 p-10 -155.84 -164.87 1.81 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.483 -0.76 . . . . 0.0 110.28 176.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -60.77 -30.2 69.88 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.567 -0.708 . . . . 0.0 110.296 -176.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -89.2 -28.54 19.91 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.535 -0.728 . . . . 0.0 110.303 -178.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.02 30.83 6.88 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 44' ' ' ASN . 51.3 mt -94.37 163.12 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.614 -0.933 . . . . 0.0 109.931 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.412 ' N ' HG22 ' A' ' 55' ' ' ILE . 16.9 p-10 -125.34 -39.55 2.19 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.591 -0.693 . . . . 0.0 110.398 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.562 HG22 ' HA ' ' A' ' 39' ' ' ARG . 10.3 p -117.14 156.98 26.7 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.542 -0.724 . . . . 0.0 110.217 -178.395 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m120 -151.22 -172.2 4.14 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.538 -0.726 . . . . 0.0 110.136 177.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -118.9 138.84 52.48 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.634 -0.666 . . . . 0.0 110.311 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -140.72 165.87 26.31 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.581 -0.699 . . . . 0.0 110.263 177.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.693 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -89.83 146.52 24.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.728 . . . . 0.0 110.159 178.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.59 -28.89 68.85 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.507 -0.746 . . . . 0.0 110.3 178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.693 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.6 p30 -68.84 -24.31 64.35 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.564 -0.71 . . . . 0.0 110.53 175.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.34 28.07 3.45 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.513 -0.742 . . . . 0.0 110.393 -178.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.574 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.26 128.32 25.65 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.5 -0.75 . . . . 0.0 110.256 178.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -105.05 149.88 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.596 -0.69 . . . . 0.0 109.96 176.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -82.37 132.36 35.22 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.595 -0.691 . . . . 0.0 110.251 179.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.709 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -143.18 58.29 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.561 -0.712 . . . . 0.0 110.241 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -77.86 -176.24 4.35 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.622 -0.674 . . . . 0.0 110.17 177.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.37 149.25 57.65 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.522 -0.736 . . . . 0.0 110.261 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 157.08 8.55 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 O-C-N 123.407 1.214 . . . . 0.0 110.951 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 7.1 tmtt? -167.67 47.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.578 -0.701 . . . . 0.0 110.207 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.98 148.86 25.98 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.518 -0.739 . . . . 0.0 110.198 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.1 pttt -156.3 62.98 3.17 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.553 -0.717 . . . . 0.0 110.271 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.93 -26.9 33.19 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.365 1.192 . . . . 0.0 110.975 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.2 pttt -155.34 154.8 32.6 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.546 -0.721 . . . . 0.0 110.348 178.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.9 tptt . . . . . 0 N--CA 1.494 1.752 0 CA-C-O 117.961 -1.018 . . . . 0.0 110.198 178.721 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.6 mtm . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.04 0.448 . . . . 0.0 110.193 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 2' ' ' VAL . 34.4 m -69.96 71.06 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.585 -0.697 . . . . 0.0 110.25 -178.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.63 -167.23 1.83 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.562 -0.712 . . . . 0.0 110.149 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.91 127.17 31.5 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.538 -0.726 . . . . 0.0 110.14 178.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.74 -30.28 9.68 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -79.69 137.41 37.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.617 -0.931 . . . . 0.0 110.289 178.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.2 mttp -97.83 133.88 41.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.549 -0.72 . . . . 0.0 110.205 179.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.557 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -131.65 152.55 37.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.284 178.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.758 ' HG3' HG11 ' A' ' 68' ' ' VAL . 24.0 mtt180 -79.41 155.89 28.16 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.547 -0.72 . . . . 0.0 110.254 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.67 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -91.21 119.85 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.622 -0.674 . . . . 0.0 109.974 178.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.463 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -104.05 39.27 1.67 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.709 . . . . 0.0 110.084 178.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -114.29 89.16 16.8 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.551 -0.718 . . . . 0.0 110.188 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.7 -25.78 27.66 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.446 1.235 . . . . 0.0 111.097 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -77.03 -27.64 54.6 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.478 -0.764 . . . . 0.0 110.229 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.5 p -73.83 139.75 45.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -59.94 -27.2 66.58 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.628 -0.67 . . . . 0.0 110.328 177.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 7.3 m-90 -95.65 40.01 1.12 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.589 -0.694 . . . . 0.0 110.233 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.434 ' CE2' ' HG2' ' A' ' 19' ' ' GLN . 46.8 t80 -71.52 160.55 32.51 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.489 -0.757 . . . . 0.0 110.139 175.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.434 ' HG2' ' CE2' ' A' ' 18' ' ' PHE . 42.4 mm-40 52.85 32.3 12.16 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.38 -0.825 . . . . 0.0 110.785 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -126.11 169.38 12.85 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.7 . . . . 0.0 110.212 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.536 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.0 t -114.33 105.88 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.556 -0.715 . . . . 0.0 109.985 178.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.18 159.16 18.07 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 178.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.7 m -94.64 143.74 26.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.623 -0.927 . . . . 0.0 110.178 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.89 119.95 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.526 -0.734 . . . . 0.0 109.851 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.29 -43.62 15.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.555 -0.716 . . . . 0.0 110.206 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 60.0 p -167.74 -175.77 2.88 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.581 -0.699 . . . . 0.0 110.222 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -138.1 119.66 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.93 178.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.24 138.93 34.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.567 -0.708 . . . . 0.0 110.198 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -125.22 32.06 5.46 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.579 -0.7 . . . . 0.0 110.259 178.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.0 m -85.31 -64.64 1.12 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.527 -0.733 . . . . 0.0 110.252 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 178.03 67.36 0.06 OUTLIER Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 178.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.5 pt -123.36 149.37 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.539 -0.977 . . . . 0.0 110.281 177.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -60.73 -32.34 71.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.559 -0.713 . . . . 0.0 110.33 -177.563 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.442 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.1 m-85 -112.89 95.68 34.85 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.475 -0.766 . . . . 0.0 110.228 174.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.57 -39.81 74.19 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.46 1.242 . . . . 0.0 111.122 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.8 t -96.3 161.68 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.46 -0.775 . . . . 0.0 110.008 -177.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.5 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -130.52 146.22 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.668 -0.645 . . . . 0.0 109.947 178.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.67 HG11 HD11 ' A' ' 10' ' ' ILE . 57.7 t -124.84 158.64 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.607 -0.683 . . . . 0.0 109.99 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.433 ' HG3' HG22 ' A' ' 57' ' ' THR . 5.6 ttp180 -121.7 129.79 52.99 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.579 -0.701 . . . . 0.0 110.201 177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 39.9 m-85 -109.01 172.71 6.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.653 -0.654 . . . . 0.0 110.234 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -110.06 -29.64 8.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 110.173 177.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -89.66 166.33 13.67 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.581 -0.7 . . . . 0.0 110.211 178.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -106.44 -164.93 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.595 -0.69 . . . . 0.0 110.302 176.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -140.77 -165.66 1.98 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.0 110.249 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -61.02 -28.33 68.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.542 -0.724 . . . . 0.0 110.241 -177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 65.5 m -80.79 -60.49 2.29 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.596 -0.69 . . . . 0.0 110.24 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 129.1 43.83 0.21 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 55' ' ' ILE . 4.8 mp -116.77 163.98 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.526 -0.985 . . . . 0.0 109.958 177.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.579 ' ND2' HG23 ' A' ' 57' ' ' THR . 14.0 p-10 -122.27 -39.32 2.59 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.577 -0.702 . . . . 0.0 110.295 179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.579 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -102.73 149.92 23.98 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.623 -0.673 . . . . 0.0 110.29 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.5 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m120 -147.5 -168.96 3.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.557 -0.715 . . . . 0.0 110.184 178.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.27 136.39 49.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.6 -0.688 . . . . 0.0 110.222 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -136.47 160.17 39.58 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.543 -0.723 . . . . 0.0 110.202 179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.622 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -84.73 150.05 25.36 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.508 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.6 pt-20 -60.74 -28.93 69.06 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.627 -0.671 . . . . 0.0 110.267 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.622 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -68.99 -24.89 64.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.536 -0.727 . . . . 0.0 110.498 175.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -96.45 27.69 3.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.449 -0.782 . . . . 0.0 110.346 -179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.557 HD22 HG23 ' A' ' 8' ' ' VAL . 86.5 mt -138.92 123.19 18.14 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.48 -0.763 . . . . 0.0 110.181 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.7 t -96.21 142.62 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.578 -0.701 . . . . 0.0 109.935 176.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -82.86 114.65 21.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.576 -0.703 . . . . 0.0 110.227 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.758 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -114.51 46.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.628 -0.67 . . . . 0.0 110.289 178.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -82.69 -154.78 0.14 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.606 -0.683 . . . . 0.0 109.688 177.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -78.52 163.43 61.45 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.206 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.9 146.5 36.25 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.452 1.238 . . . . 0.0 110.948 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.4 tttm -167.74 90.24 0.32 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.25 178.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.54 139.78 32.67 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.562 -0.711 . . . . 0.0 110.191 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.4 mmtt -143.64 170.28 8.83 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.548 -0.72 . . . . 0.0 110.222 178.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 150.28 23.77 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.35 1.184 . . . . 0.0 111.015 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.28 47.78 1.35 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.602 -0.686 . . . . 0.0 110.15 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.282 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.5 ptm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.079 0.466 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.7 p -70.03 71.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.525 -0.734 . . . . 0.0 110.167 -178.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.4 mm-40 -128.07 -169.28 2.03 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.606 -0.684 . . . . 0.0 110.237 177.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 10.7 ttt180 -61.32 131.83 51.59 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.537 -0.727 . . . . 0.0 110.195 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.49 29.86 67.46 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 177.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 t -100.03 136.31 40.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.933 . . . . 0.0 110.189 177.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.6 mmtt -82.71 99.57 9.71 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.542 -0.724 . . . . 0.0 110.204 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.3 155.82 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.533 -0.729 . . . . 0.0 110.333 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.716 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.6 mtm180 -79.21 158.67 27.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.54 -0.725 . . . . 0.0 110.158 176.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.687 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -101.13 119.63 49.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.58 -0.7 . . . . 0.0 110.067 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.32 43.07 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.463 -0.773 . . . . 0.0 110.136 175.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.414 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.8 tpt180 -115.65 83.6 11.49 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.57 -0.706 . . . . 0.0 110.204 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.73 -26.18 29.25 Favored 'Trans proline' 0 N--CA 1.492 1.414 0 O-C-N 123.396 1.208 . . . . 0.0 111.065 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -74.45 -27.16 60.47 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.576 -0.703 . . . . 0.0 110.329 179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.9 p -77.36 144.48 37.94 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.504 -0.747 . . . . 0.0 110.284 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 80.1 t80 -59.95 -24.77 64.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.52 -0.737 . . . . 0.0 110.468 173.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.3 34.33 1.62 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.4 -0.813 . . . . 0.0 110.35 -175.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.405 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 30.5 t80 -67.75 157.58 34.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.497 -0.752 . . . . 0.0 110.158 178.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 52.99 42.68 32.25 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.465 -0.772 . . . . 0.0 110.737 179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -139.87 160.76 39.18 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.496 -0.752 . . . . 0.0 110.184 178.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.97 91.53 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.729 . . . . 0.0 109.969 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -82.55 154.97 33.34 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 m -95.15 137.75 33.79 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.567 -0.96 . . . . 0.0 110.214 178.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -79.67 129.58 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.547 -0.72 . . . . 0.0 109.963 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.38 -49.49 9.94 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.617 -0.677 . . . . 0.0 110.195 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.5 m -167.83 173.82 8.0 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.529 -0.732 . . . . 0.0 110.194 178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -118.37 123.45 71.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.645 -0.659 . . . . 0.0 109.968 178.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -120.73 149.14 42.99 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.514 -0.741 . . . . 0.0 110.225 179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 3.0 tp60 -134.64 48.01 2.34 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.552 -0.718 . . . . 0.0 110.21 178.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 p -98.47 29.07 3.8 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.26 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.33 57.12 1.7 Allowed Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 178.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.526 HD12 ' O ' ' A' ' 34' ' ' TYR . 44.9 pt -121.98 144.72 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.499 -1.001 . . . . 0.0 110.24 177.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.441 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.2 OUTLIER -62.61 -28.58 69.99 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.534 -0.729 . . . . 0.0 110.256 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.526 ' O ' HD12 ' A' ' 32' ' ' ILE . 32.4 m-85 -113.99 95.42 38.01 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.552 -0.718 . . . . 0.0 110.224 175.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.53 -25.69 26.25 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.364 1.192 . . . . 0.0 111.184 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.521 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.5 t -113.22 164.58 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.466 -0.771 . . . . 0.0 110.001 -177.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' N ' HD12 ' A' ' 37' ' ' ILE . 4.9 mp -129.03 138.93 53.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.559 -0.713 . . . . 0.0 109.886 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.687 HG11 HD11 ' A' ' 10' ' ' ILE . 61.6 t -116.39 137.55 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.591 -0.693 . . . . 0.0 109.883 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.734 ' HG2' HG22 ' A' ' 57' ' ' THR . 0.8 OUTLIER -108.38 125.66 51.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.584 -0.698 . . . . 0.0 110.192 178.461 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 41.0 m-85 -101.42 165.1 11.43 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.637 -0.664 . . . . 0.0 110.258 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -109.51 -28.75 8.74 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.552 -0.717 . . . . 0.0 110.221 176.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 3.2 ttmm -86.4 129.77 34.74 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.594 -0.691 . . . . 0.0 110.23 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.2 m -67.73 -173.27 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.481 -0.762 . . . . 0.0 110.178 175.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.488 HD21 HD12 ' A' ' 55' ' ' ILE . 47.3 p30 -146.51 -164.93 2.09 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.501 -0.749 . . . . 0.0 110.296 176.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 -60.68 -28.35 68.54 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.519 -0.738 . . . . 0.0 110.285 -175.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -88.21 -28.83 20.91 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.595 -0.69 . . . . 0.0 110.254 -178.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.74 36.57 5.0 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.488 HD12 HD21 ' A' ' 44' ' ' ASN . 62.3 mt -99.81 164.01 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.614 -0.933 . . . . 0.0 109.865 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.667 ' ND2' HG23 ' A' ' 57' ' ' THR . 11.3 p-10 -128.91 -39.97 1.55 Allowed 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.645 -0.659 . . . . 0.0 110.463 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.734 HG22 ' HG2' ' A' ' 39' ' ' ARG . 7.0 p -113.02 154.19 26.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.426 -0.796 . . . . 0.0 110.333 -176.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -149.03 -167.87 2.95 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.562 -0.711 . . . . 0.0 110.23 176.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -134.63 132.55 39.11 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.507 -0.746 . . . . 0.0 110.313 -179.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 88.4 m-85 -135.0 160.22 39.01 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.611 -0.681 . . . . 0.0 110.173 176.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.2 151.93 22.75 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.531 -0.73 . . . . 0.0 110.193 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.521 ' HB3' HG21 ' A' ' 36' ' ' VAL . 1.6 pp20? -61.04 -30.63 70.43 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.586 -0.696 . . . . 0.0 110.267 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.63 -23.08 63.45 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.513 -0.742 . . . . 0.0 110.508 176.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -96.47 27.91 3.58 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.394 -0.816 . . . . 0.0 110.324 -179.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 90.2 mt -138.19 136.65 36.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.508 -0.745 . . . . 0.0 110.168 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.8 t -106.6 144.79 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.539 -0.725 . . . . 0.0 110.001 177.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -82.8 132.83 35.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.62 -0.675 . . . . 0.0 110.206 179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.716 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -141.44 51.52 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.605 -0.684 . . . . 0.0 110.362 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -124.99 131.97 53.33 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.499 -0.75 . . . . 0.0 110.192 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -83.41 156.47 65.77 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 178.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.83 -177.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.429 1.226 . . . . 0.0 110.978 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 5.9 mptt -87.26 160.11 18.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.592 -0.693 . . . . 0.0 110.272 178.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.32 116.8 23.2 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.543 -0.723 . . . . 0.0 110.189 178.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 7.8 mtpp -142.19 157.77 62.75 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.566 -0.709 . . . . 0.0 110.173 178.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.91 -27.76 36.51 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.461 1.242 . . . . 0.0 111.011 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -111.08 131.56 54.97 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.505 -0.747 . . . . 0.0 110.229 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.7 mttp . . . . . 0 N--CA 1.494 1.744 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.183 178.74 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.3 ptt? . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.087 0.47 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 24' ' ' VAL . 67.7 t -80.41 162.66 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.607 -0.683 . . . . 0.0 109.913 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.403 ' N ' HG12 ' A' ' 2' ' ' VAL . 1.2 mp0 -97.39 156.82 16.29 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.645 -0.66 . . . . 0.0 110.25 178.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 45.6 mtt180 -68.58 109.43 3.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.13 177.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.01 8.49 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.1 t -99.97 161.28 13.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.525 -0.985 . . . . 0.0 110.254 177.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -105.01 102.45 11.95 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.481 -0.762 . . . . 0.0 110.194 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.512 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -110.68 155.35 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.512 -0.743 . . . . 0.0 110.265 178.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.69 ' HG3' HG11 ' A' ' 68' ' ' VAL . 22.1 mtt-85 -80.64 139.22 36.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.583 -0.698 . . . . 0.0 110.238 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.8 mm -81.42 119.81 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.59 -0.694 . . . . 0.0 109.969 179.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.17 36.53 2.22 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.584 -0.698 . . . . 0.0 110.076 177.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' HG22 ' A' ' 10' ' ' ILE . 3.0 ttp85 -114.17 90.24 19.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.506 -0.746 . . . . 0.0 110.179 178.318 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.12 29.77 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.404 1.213 . . . . 0.0 111.041 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -74.81 -27.73 60.42 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.494 -0.754 . . . . 0.0 110.3 178.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -73.02 139.8 46.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.577 -0.702 . . . . 0.0 110.201 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -60.37 -27.08 67.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.522 -0.736 . . . . 0.0 110.259 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.435 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . 8.6 m-90 -96.25 37.63 1.24 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.562 -0.711 . . . . 0.0 110.236 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.416 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 54.7 t80 -70.99 159.27 35.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.598 -0.688 . . . . 0.0 110.138 176.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 44.6 mt-30 52.99 30.01 8.76 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.368 -0.832 . . . . 0.0 110.73 179.054 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -129.02 -173.87 3.11 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.525 -0.734 . . . . 0.0 110.212 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.41 110.36 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.556 -0.715 . . . . 0.0 110.02 178.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.84 161.14 15.91 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 m -99.79 138.42 36.9 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.539 -0.977 . . . . 0.0 110.247 178.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.816 HG21 HG11 ' A' ' 2' ' ' VAL . 57.5 t -79.77 126.92 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.586 -0.696 . . . . 0.0 109.948 178.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.28 -52.04 7.33 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.6 -0.687 . . . . 0.0 110.196 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.409 ' O ' HD12 ' A' ' 37' ' ' ILE . 78.0 p -167.72 167.24 13.37 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.589 -0.694 . . . . 0.0 110.225 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -102.47 119.65 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 109.906 177.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.693 ' O ' HD11 ' A' ' 32' ' ' ILE . 1.4 t0 -121.49 145.89 47.47 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.8 tt0 -145.47 79.33 1.57 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.57 -0.706 . . . . 0.0 110.198 178.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -133.15 28.96 4.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.601 -0.687 . . . . 0.0 110.262 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 117.28 36.29 1.03 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.693 HD11 ' O ' ' A' ' 28' ' ' ASP . 44.4 pt -120.62 139.05 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.58 -0.953 . . . . 0.0 110.246 177.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.443 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -67.86 -27.53 66.77 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.582 -0.699 . . . . 0.0 110.33 -177.205 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.443 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 26.2 m-85 -112.61 96.04 35.06 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.532 -0.73 . . . . 0.0 110.289 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.26 -39.14 81.9 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.385 1.203 . . . . 0.0 111.11 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.9 t -88.55 126.71 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.479 -0.763 . . . . 0.0 110.096 -172.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 28' ' ' ASP . 8.4 mt -102.25 147.4 8.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.51 -0.744 . . . . 0.0 109.914 177.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.438 HG12 ' N ' ' A' ' 39' ' ' ARG . 60.1 t -137.04 164.63 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.48 -0.763 . . . . 0.0 109.987 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.438 ' N ' HG12 ' A' ' 38' ' ' VAL . 15.0 ttp180 -122.81 157.19 32.99 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.622 -0.674 . . . . 0.0 110.182 177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.435 ' CE1' ' HB3' ' A' ' 17' ' ' TRP . 55.7 m-85 -130.03 155.5 46.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.525 -0.734 . . . . 0.0 110.213 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -93.68 -29.09 15.6 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.598 -0.689 . . . . 0.0 110.188 175.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -87.5 168.95 12.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.605 -0.684 . . . . 0.0 110.251 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.94 -166.59 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.533 -0.729 . . . . 0.0 110.223 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.627 HD21 HD12 ' A' ' 55' ' ' ILE . 43.8 p-10 -145.48 -165.32 2.15 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.599 -0.688 . . . . 0.0 110.264 177.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -61.0 -28.8 69.29 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.55 -0.719 . . . . 0.0 110.307 -175.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -87.87 -43.62 11.68 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.504 -0.748 . . . . 0.0 110.205 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 110.13 56.59 0.52 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.627 HD12 HD21 ' A' ' 44' ' ' ASN . 11.2 mt -123.09 163.67 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.64 -0.917 . . . . 0.0 109.861 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.413 ' N ' HG22 ' A' ' 55' ' ' ILE . 17.7 p-10 -124.38 -39.56 2.32 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.594 -0.691 . . . . 0.0 110.367 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.8 p -106.21 154.85 20.13 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.45 -0.781 . . . . 0.0 110.242 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -156.54 -168.55 2.73 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.602 -0.686 . . . . 0.0 110.19 177.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.402 ' O ' ' CD1' ' A' ' 60' ' ' PHE . 5.7 m120 -130.36 144.12 51.19 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.543 -0.723 . . . . 0.0 110.174 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 59' ' ' ASN . 38.3 m-85 -139.84 165.84 26.22 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.609 -0.682 . . . . 0.0 110.176 178.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.657 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.82 143.92 26.87 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.551 -0.718 . . . . 0.0 110.142 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -60.84 -31.64 71.07 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.559 -0.713 . . . . 0.0 110.322 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.657 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 9.8 p-10 -70.18 -23.04 62.9 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.562 -0.711 . . . . 0.0 110.528 178.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.646 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 67.9 mt-10 -96.43 28.08 3.48 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.501 -0.749 . . . . 0.0 110.358 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.512 HD22 HG23 ' A' ' 8' ' ' VAL . 90.6 mt -138.36 129.81 27.62 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.451 -0.781 . . . . 0.0 110.226 176.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -108.51 149.51 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.588 -0.695 . . . . 0.0 109.966 176.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 17.0 tt0 -80.66 127.32 32.34 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.69 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -140.93 52.6 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.58 -0.7 . . . . 0.0 110.231 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.6 tp10 -151.4 80.48 1.3 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.63 -0.669 . . . . 0.0 110.239 178.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -89.99 161.16 38.96 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.597 -0.689 . . . . 0.0 110.281 178.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.92 151.07 21.33 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 O-C-N 123.471 1.248 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.1 tttp -166.37 47.75 0.07 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.163 178.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.99 133.17 34.96 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.585 -0.697 . . . . 0.0 110.191 178.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.414 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.8 OUTLIER -82.71 -50.3 0.76 Allowed Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.538 -0.726 . . . . 0.0 110.548 178.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.43 159.76 2.89 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 O-C-N 123.11 1.058 . . . . 0.0 111.091 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 10.9 ptpt -59.91 -26.47 65.94 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.454 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.19 178.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.142 0.496 . . . . 0.0 110.204 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.407 HG13 HG11 ' A' ' 8' ' ' VAL . 58.2 t -80.89 79.56 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.498 -0.751 . . . . 0.0 109.918 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -123.06 177.28 5.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.568 -0.707 . . . . 0.0 110.226 177.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -61.06 149.06 38.22 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.483 -0.761 . . . . 0.0 110.199 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.59 9.43 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.8 156.51 18.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.58 -0.953 . . . . 0.0 110.23 179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.467 ' HB3' HG12 ' A' ' 21' ' ' VAL . 38.4 mtmt -108.26 118.53 37.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.558 -0.714 . . . . 0.0 110.175 178.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -109.48 158.91 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.568 -0.707 . . . . 0.0 110.214 178.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.708 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.4 mtt-85 -78.79 155.47 29.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.545 -0.722 . . . . 0.0 110.178 177.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.471 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -98.7 122.81 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.576 -0.702 . . . . 0.0 110.042 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -103.46 39.4 1.6 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.686 -0.633 . . . . 0.0 110.076 176.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.467 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.77 87.46 14.74 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.541 -0.724 . . . . 0.0 110.22 178.704 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.77 -26.66 31.23 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 O-C-N 123.383 1.201 . . . . 0.0 111.047 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -74.88 -27.33 60.2 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.573 -0.704 . . . . 0.0 110.3 177.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.3 t -76.5 140.28 41.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.549 -0.719 . . . . 0.0 110.286 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 27.8 t80 -58.91 -24.6 62.55 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.595 -0.691 . . . . 0.0 110.515 176.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.55 37.22 1.2 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.418 -0.801 . . . . 0.0 110.344 -176.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -72.9 156.63 38.67 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.446 -0.784 . . . . 0.0 110.192 176.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 60.3 mt-30 52.87 27.22 5.24 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.347 -0.846 . . . . 0.0 110.782 178.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.15 177.85 5.17 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.635 -0.665 . . . . 0.0 110.276 178.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.467 HG12 ' HB3' ' A' ' 7' ' ' LYS . 59.2 t -124.36 104.39 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.534 -0.729 . . . . 0.0 109.952 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.66 173.53 22.86 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.1 m -102.96 144.92 30.62 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.608 -0.936 . . . . 0.0 110.229 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -80.46 133.09 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.57 -0.706 . . . . 0.0 109.952 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.86 -59.17 2.5 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.512 -0.743 . . . . 0.0 110.295 178.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.1 p -167.91 -176.44 3.04 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.568 -0.708 . . . . 0.0 110.244 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -118.12 119.71 62.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 109.868 178.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.4 t0 -99.64 97.24 8.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.648 -0.658 . . . . 0.0 110.175 179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -84.08 81.38 8.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.576 -0.703 . . . . 0.0 110.207 178.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.5 p -135.11 -71.74 0.48 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.575 -0.703 . . . . 0.0 110.156 179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -174.77 60.88 0.12 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.504 HD12 ' O ' ' A' ' 34' ' ' TYR . 47.1 pt -120.1 145.71 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.553 -0.969 . . . . 0.0 110.294 177.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.5 OUTLIER -64.15 -27.58 69.17 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.536 -0.727 . . . . 0.0 110.363 -179.602 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.504 ' O ' HD12 ' A' ' 32' ' ' ILE . 33.3 m-85 -113.52 92.14 22.72 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.457 -0.777 . . . . 0.0 110.232 175.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.94 -36.21 74.23 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.461 1.243 . . . . 0.0 111.125 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.8 t -97.9 131.71 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.425 -0.797 . . . . 0.0 109.97 -173.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.4 mt -98.43 160.21 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.502 -0.749 . . . . 0.0 109.794 175.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.471 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -141.16 161.69 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.565 -0.709 . . . . 0.0 109.957 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.556 ' HA ' HG22 ' A' ' 57' ' ' THR . 22.4 ttm180 -122.94 152.29 40.99 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.581 -0.699 . . . . 0.0 110.161 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.3 m-85 -136.72 164.69 27.65 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.601 -0.687 . . . . 0.0 110.296 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -109.74 -28.94 8.56 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.518 -0.739 . . . . 0.0 110.295 176.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -83.31 124.18 30.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.589 -0.694 . . . . 0.0 110.277 179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -64.6 -165.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.573 -0.705 . . . . 0.0 110.182 175.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.553 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.85 -165.04 1.94 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.503 -0.748 . . . . 0.0 110.325 177.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -61.14 -31.93 71.64 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.652 -0.655 . . . . 0.0 110.247 -176.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 m -86.62 -28.67 23.09 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.601 -0.687 . . . . 0.0 110.334 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.95 43.08 3.93 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.553 HD12 HD21 ' A' ' 44' ' ' ASN . 85.7 mt -100.03 166.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.607 -0.937 . . . . 0.0 109.964 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.556 HD22 HG23 ' A' ' 57' ' ' THR . 9.9 p-10 -122.44 -39.51 2.55 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.67 -0.644 . . . . 0.0 110.381 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.556 HG23 HD22 ' A' ' 56' ' ' ASN . 32.7 p -129.61 160.69 32.5 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.512 -0.743 . . . . 0.0 110.259 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 5.2 t-20 -148.69 -159.2 1.0 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.503 -0.748 . . . . 0.0 110.185 176.101 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -130.56 145.16 51.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.465 -0.772 . . . . 0.0 110.218 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 97.0 m-85 -140.96 154.23 45.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.499 -0.751 . . . . 0.0 110.221 -177.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.687 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -80.02 143.47 34.05 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.555 -0.716 . . . . 0.0 110.22 177.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.463 ' HB3' HG21 ' A' ' 36' ' ' VAL . 11.8 pt-20 -59.51 -27.84 66.52 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.612 -0.68 . . . . 0.0 110.429 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.687 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.6 p-10 -70.28 -23.94 62.96 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.458 -0.776 . . . . 0.0 110.498 175.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.421 ' CD ' ' HB3' ' A' ' 61' ' ' ALA . 11.8 mt-10 -96.24 27.69 3.59 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.486 -0.759 . . . . 0.0 110.385 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.651 HD22 HG23 ' A' ' 8' ' ' VAL . 87.3 mt -138.83 129.37 26.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.271 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.9 t -107.39 149.53 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.572 -0.705 . . . . 0.0 109.896 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -81.41 128.78 34.22 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.561 -0.712 . . . . 0.0 110.193 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.708 HG11 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -144.62 28.77 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.57 -0.706 . . . . 0.0 110.248 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -85.09 -28.89 25.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.553 -0.717 . . . . 0.0 110.201 179.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -81.03 179.41 1.93 Allowed Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.57 -0.706 . . . . 0.0 110.239 178.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.3 Cg_exo -53.01 -175.89 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.382 1.201 . . . . 0.0 110.984 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 53.3 mttt -80.7 -168.06 1.61 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.54 -0.725 . . . . 0.0 110.221 178.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -79.91 144.43 33.4 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.194 178.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt 52.58 81.38 0.26 Allowed Pre-proline 0 N--CA 1.501 2.105 0 O-C-N 121.429 -0.794 . . . . 0.0 110.766 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.97 -59.55 1.0 Allowed 'Trans proline' 0 N--CA 1.491 1.363 0 O-C-N 123.476 1.251 . . . . 0.0 111.005 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 24.4 mttt -83.05 139.11 33.44 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.601 -0.687 . . . . 0.0 110.188 178.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.4 ptmm? . . . . . 0 N--CA 1.495 1.778 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.284 178.761 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ttt . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.079 0.466 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.477 HG11 HG21 ' A' ' 24' ' ' VAL . 68.5 t -90.02 166.97 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.588 -0.695 . . . . 0.0 109.898 178.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.462 ' N ' HG12 ' A' ' 2' ' ' VAL . 13.0 mp0 -121.45 163.24 19.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.606 -0.684 . . . . 0.0 110.261 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.16 107.32 7.17 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.492 -0.755 . . . . 0.0 110.218 176.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 123.01 -30.2 5.12 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.21 162.18 7.86 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.525 -0.985 . . . . 0.0 110.188 179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.6 mtmt -112.84 129.1 56.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.554 -0.716 . . . . 0.0 110.143 177.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.52 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -122.75 159.55 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.592 -0.692 . . . . 0.0 110.291 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 5.9 mtt180 -81.96 153.36 26.3 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.6 -0.687 . . . . 0.0 110.258 178.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 1.026 HD11 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -99.3 121.67 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 O-C-N 121.618 -0.676 . . . . 0.0 110.015 179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -101.51 40.62 1.28 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.584 -0.698 . . . . 0.0 110.218 178.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.446 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 0.9 OUTLIER -113.96 90.23 18.75 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.649 -0.657 . . . . 0.0 110.197 178.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.84 -26.22 30.11 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.322 1.169 . . . . 0.0 111.022 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -75.58 -27.5 58.58 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.562 -0.711 . . . . 0.0 110.272 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 66.7 m -74.65 141.66 44.59 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -60.04 -27.18 66.72 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.595 -0.691 . . . . 0.0 110.293 176.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 8.8 m-90 -96.27 38.3 1.2 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.492 -0.755 . . . . 0.0 110.196 -177.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.9 t80 -71.19 158.71 35.94 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 0.0 110.102 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 5.8 mt-30 52.59 27.13 4.83 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.428 -0.795 . . . . 0.0 110.788 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -125.68 170.31 11.66 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.623 -0.673 . . . . 0.0 110.163 178.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.483 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.9 t -111.31 114.58 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.977 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.6 170.4 20.17 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -103.71 143.41 32.83 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.548 -0.972 . . . . 0.0 110.174 178.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.477 HG21 HG11 ' A' ' 2' ' ' VAL . 58.7 t -80.28 120.73 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.621 -0.674 . . . . 0.0 109.94 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.98 -48.93 10.12 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.498 -0.751 . . . . 0.0 110.174 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 46.3 t -167.76 -164.83 0.59 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.641 -0.662 . . . . 0.0 110.191 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -145.05 119.61 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.585 -0.697 . . . . 0.0 109.935 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -93.79 124.58 37.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.592 -0.693 . . . . 0.0 110.211 178.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.1 tt0 -98.41 103.12 15.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.527 -0.733 . . . . 0.0 110.21 178.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.0 t -165.65 -45.13 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.504 -0.748 . . . . 0.0 110.192 178.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 127.7 75.75 0.2 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.448 HD11 ' O ' ' A' ' 34' ' ' TYR . 44.8 pt -118.38 177.63 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.931 . . . . 0.0 110.296 178.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.427 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 1.2 ptpt -61.14 -29.03 69.53 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.582 -0.699 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.448 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.7 m-85 -143.59 97.11 5.55 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.562 -0.711 . . . . 0.0 110.197 176.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.65 -45.41 40.49 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 O-C-N 123.366 1.193 . . . . 0.0 111.272 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.564 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -90.13 141.01 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.482 -0.761 . . . . 0.0 110.055 -173.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.4 mt -102.99 132.47 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.529 -0.732 . . . . 0.0 109.903 178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 1.026 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -117.1 140.88 37.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.504 -0.747 . . . . 0.0 109.976 177.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 2.5 ttm-85 -103.81 162.98 12.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.546 -0.721 . . . . 0.0 110.178 177.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.42 ' CE1' HG13 ' A' ' 10' ' ' ILE . 37.9 m-85 -137.16 142.23 42.21 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.579 -0.701 . . . . 0.0 110.245 178.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -84.72 -29.21 25.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.498 -0.751 . . . . 0.0 110.13 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 8.1 ttmt -83.58 163.71 20.21 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.594 -0.691 . . . . 0.0 110.215 178.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -105.84 -172.68 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.55 -0.719 . . . . 0.0 110.237 174.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.469 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -135.44 -164.91 1.61 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.503 -0.748 . . . . 0.0 110.326 178.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -61.14 -28.49 69.15 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.588 -0.695 . . . . 0.0 110.253 -177.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 m -86.85 -46.33 10.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.551 -0.718 . . . . 0.0 110.303 -177.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.66 57.52 0.31 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 -177.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.516 HG22 ' H ' ' A' ' 57' ' ' THR . 75.2 mt -129.6 159.11 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.613 -0.933 . . . . 0.0 109.863 -177.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 13.7 p-10 -141.8 27.75 1.81 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.513 -0.742 . . . . 0.0 110.372 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 6.1 p -154.95 137.52 15.13 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.155 176.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -149.05 -167.88 2.95 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.633 -0.667 . . . . 0.0 110.229 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -134.82 132.66 38.91 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.611 -0.68 . . . . 0.0 110.204 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.567 ' HB2' HD11 ' A' ' 65' ' ' LEU . 80.0 m-85 -133.17 161.8 33.46 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.504 -0.747 . . . . 0.0 110.219 178.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -85.4 147.37 26.53 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.56 -0.712 . . . . 0.0 110.136 177.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.564 ' HB3' HG21 ' A' ' 36' ' ' VAL . 9.9 pt-20 -60.1 -28.17 67.62 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.531 -0.731 . . . . 0.0 110.38 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.597 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 7.2 p-10 -72.57 -24.33 61.09 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.558 -0.714 . . . . 0.0 110.527 177.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 28.8 mt-10 -96.4 27.92 3.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.499 -0.75 . . . . 0.0 110.384 178.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.682 ' CD2' HD13 ' A' ' 10' ' ' ILE . 87.3 mt -138.51 122.23 17.54 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.575 -0.703 . . . . 0.0 110.293 178.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.0 t -94.55 150.98 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.568 -0.708 . . . . 0.0 109.958 175.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -83.25 127.92 34.05 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.4 m -145.43 71.35 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.558 -0.714 . . . . 0.0 110.228 177.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -61.2 158.26 14.42 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.207 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.88 111.47 3.94 Favored Pre-proline 0 N--CA 1.497 1.894 0 O-C-N 121.523 -0.735 . . . . 0.0 110.204 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.15 -175.63 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.428 0 O-C-N 123.185 1.097 . . . . 0.0 111.043 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 10.2 mttp -78.96 -168.14 1.36 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.589 -0.694 . . . . 0.0 110.205 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.54 156.5 19.46 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.614 -0.679 . . . . 0.0 110.164 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 30.2 mtmt -112.01 95.44 29.49 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.569 -0.707 . . . . 0.0 110.208 178.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -52.86 113.71 1.38 Allowed 'Trans proline' 0 N--CA 1.491 1.375 0 O-C-N 123.332 1.174 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -91.11 49.14 1.59 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.663 -0.648 . . . . 0.0 110.152 178.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.79 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.223 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 ttt . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.081 0.467 . . . . 0.0 110.247 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.58 ' O ' HG23 ' A' ' 2' ' ' VAL . 34.4 m -62.68 116.9 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.325 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -136.39 -175.2 3.92 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.561 -0.712 . . . . 0.0 110.211 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 8.0 mmm-85 -72.92 110.55 7.31 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 177.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.03 -30.27 8.16 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.643 ' O ' HG23 ' A' ' 24' ' ' VAL . 0.3 OUTLIER -61.91 130.57 46.27 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.605 -0.938 . . . . 0.0 110.154 179.122 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.4 127.95 38.08 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 178.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.654 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -118.32 162.48 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.62 -0.675 . . . . 0.0 110.258 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.726 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -78.69 152.08 31.81 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.594 -0.691 . . . . 0.0 110.164 177.066 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.703 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.9 mm -98.42 133.45 40.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.555 -0.716 . . . . 0.0 110.045 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.703 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -117.31 41.6 2.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.485 -0.759 . . . . 0.0 110.123 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.466 ' H ' HG22 ' A' ' 10' ' ' ILE . 4.7 ttt180 -114.95 86.7 13.86 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.613 -0.68 . . . . 0.0 110.151 178.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.74 -26.31 29.76 Favored 'Trans proline' 0 N--CA 1.491 1.364 0 O-C-N 123.454 1.239 . . . . 0.0 111.093 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -74.28 -27.67 60.84 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.529 -0.732 . . . . 0.0 110.284 177.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 6.2 t -78.97 140.18 38.07 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.552 -0.718 . . . . 0.0 110.202 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.45 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.7 t80 -59.24 -23.87 62.7 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.572 -0.705 . . . . 0.0 110.5 176.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 9.2 m0 -95.27 38.54 1.14 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.326 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -68.53 150.73 47.71 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.453 -0.78 . . . . 0.0 110.216 176.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 52.73 27.12 4.99 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.433 -0.792 . . . . 0.0 110.81 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -110.14 173.46 6.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.655 -0.653 . . . . 0.0 110.208 179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 59.2 t -118.29 101.89 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.584 -0.697 . . . . 0.0 109.958 176.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -98.59 170.61 24.41 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -102.21 148.52 25.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.585 -0.95 . . . . 0.0 110.174 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 6' ' ' SER . 66.2 t -78.49 119.65 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.625 -0.672 . . . . 0.0 109.924 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -87.01 -44.55 11.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.535 -0.728 . . . . 0.0 110.193 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -167.67 161.58 13.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.49 119.79 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.59 -0.694 . . . . 0.0 109.846 178.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -125.12 84.46 2.28 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.0 110.257 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -83.96 80.51 9.14 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 178.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 18.2 t -122.84 -50.74 1.94 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.606 -0.684 . . . . 0.0 110.238 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 174.64 54.67 0.05 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 178.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 35' ' ' PRO . 44.7 pt -121.24 163.07 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.605 -0.938 . . . . 0.0 110.245 178.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 52.5 pttt -59.95 -26.95 66.39 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 26.2 m-85 -140.74 97.1 7.34 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.465 -0.772 . . . . 0.0 110.283 179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.442 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.5 Cg_exo -52.67 -28.01 35.74 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.44 1.232 . . . . 0.0 111.159 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.538 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -104.84 142.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.42 -0.8 . . . . 0.0 110.065 -175.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.524 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -122.0 153.38 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.527 -0.733 . . . . 0.0 109.993 177.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 58.2 t -137.39 162.36 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.639 -0.663 . . . . 0.0 110.0 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.531 ' HA ' HG22 ' A' ' 57' ' ' THR . 5.1 ttp180 -119.15 158.84 25.13 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.567 -0.708 . . . . 0.0 110.168 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 98.9 m-85 -138.52 177.7 7.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 110.246 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -119.14 -38.31 3.07 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.595 -0.691 . . . . 0.0 110.239 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.1 tmtt? -80.27 128.98 34.17 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.603 -0.686 . . . . 0.0 110.219 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.8 m -66.33 -165.48 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.488 -0.758 . . . . 0.0 110.192 175.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.45 ' CB ' ' CG ' ' A' ' 16' ' ' TYR . 15.4 p30 -158.24 -163.43 1.29 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.516 -0.74 . . . . 0.0 110.247 177.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 39.9 m-85 -59.49 -28.4 67.0 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.503 -0.748 . . . . 0.0 110.311 -176.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.7 m -96.32 -31.0 13.11 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.455 -0.778 . . . . 0.0 110.216 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.59 71.41 1.29 Allowed Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 178.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.602 HG21 ' ND2' ' A' ' 58' ' ' ASN . 9.3 mt -123.55 167.03 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.616 -0.932 . . . . 0.0 109.832 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.467 ' N ' HG22 ' A' ' 55' ' ' ILE . 28.8 p-10 -116.64 -35.59 4.17 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.557 -0.714 . . . . 0.0 110.373 177.473 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 39' ' ' ARG . 25.0 p -132.01 134.63 45.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.52 -0.738 . . . . 0.0 110.299 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.602 ' ND2' HG21 ' A' ' 55' ' ' ILE . 0.8 OUTLIER -123.05 -170.75 2.16 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 175.858 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -123.75 132.98 53.92 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.603 -0.685 . . . . 0.0 110.252 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 58.6 m-85 -129.64 162.95 27.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.542 -0.724 . . . . 0.0 110.327 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.67 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -87.75 145.0 26.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.594 -0.691 . . . . 0.0 110.226 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.538 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.4 pt-20 -59.56 -27.83 66.58 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.568 -0.707 . . . . 0.0 110.359 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 4.8 p-10 -70.96 -23.78 62.29 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.473 -0.767 . . . . 0.0 110.54 176.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.67 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 21.4 mt-10 -96.21 27.48 3.68 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.427 -0.796 . . . . 0.0 110.43 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.654 HD22 HG23 ' A' ' 8' ' ' VAL . 88.6 mt -138.7 133.46 32.32 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.477 -0.764 . . . . 0.0 110.222 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.98 152.81 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.477 -0.764 . . . . 0.0 109.862 175.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -82.11 123.87 29.35 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.566 -0.709 . . . . 0.0 110.188 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.726 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -140.76 49.5 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.632 -0.667 . . . . 0.0 110.323 177.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -108.96 -28.97 8.83 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.597 -0.689 . . . . 0.0 110.251 178.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.508 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -62.36 173.23 1.0 Allowed Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.61 -0.681 . . . . 0.0 110.197 178.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.2 Cg_exo -52.91 178.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.353 1.186 . . . . 0.0 110.91 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -130.38 45.94 2.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.549 -0.719 . . . . 0.0 110.251 178.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -87.56 165.24 15.62 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.644 -0.66 . . . . 0.0 110.241 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.8 tttt -105.4 149.57 37.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.574 -0.704 . . . . 0.0 110.216 178.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.89 150.21 23.76 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.445 1.234 . . . . 0.0 111.001 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 15.3 tttt 52.85 92.83 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.467 -0.771 . . . . 0.0 110.787 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 27.3 tttt . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.257 178.672 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.8 mtt . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 121.112 0.482 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.622 HG11 HG21 ' A' ' 24' ' ' VAL . 57.9 t -89.97 167.01 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.479 -0.763 . . . . 0.0 110.02 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.463 ' N ' HG12 ' A' ' 2' ' ' VAL . 7.0 mp0 -118.09 162.89 17.46 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.508 -0.745 . . . . 0.0 110.229 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.0 ttm180 -68.77 109.98 4.11 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.541 -0.724 . . . . 0.0 110.137 176.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.12 29.74 8.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.43 ' O ' HG23 ' A' ' 23' ' ' THR . 0.3 OUTLIER -92.79 -159.26 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.515 -0.991 . . . . 0.0 110.116 177.317 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 5.3 mttp -148.39 104.72 3.54 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.578 -0.701 . . . . 0.0 110.133 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.765 HG23 HD22 ' A' ' 65' ' ' LEU . 35.0 m -116.1 156.24 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.57 -0.706 . . . . 0.0 110.245 178.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.47 ' HG3' HG11 ' A' ' 68' ' ' VAL . 6.8 mtt180 -78.77 145.73 34.22 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.603 -0.685 . . . . 0.0 110.237 178.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -87.77 141.27 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.548 -0.72 . . . . 0.0 109.996 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.673 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -115.79 37.87 3.49 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.515 -0.74 . . . . 0.0 110.171 178.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.543 ' H ' HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -114.23 89.85 18.62 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.577 -0.702 . . . . 0.0 110.166 178.586 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.79 -40.88 73.3 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.437 1.23 . . . . 0.0 111.043 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -60.82 -27.08 67.79 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.602 -0.686 . . . . 0.0 110.321 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.5 m -78.68 140.4 38.37 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.554 -0.716 . . . . 0.0 110.219 -178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -59.11 -25.33 63.73 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.496 -0.752 . . . . 0.0 110.444 176.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.493 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 6.9 m-90 -96.02 37.66 1.22 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.486 -0.759 . . . . 0.0 110.31 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.4 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 46.4 t80 -72.23 155.0 40.69 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.519 -0.738 . . . . 0.0 110.259 175.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 52.59 27.16 4.86 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.371 -0.831 . . . . 0.0 110.786 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -119.59 141.03 49.65 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 178.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.415 HG22 HG21 ' A' ' 68' ' ' VAL . 59.4 t -85.74 92.16 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.646 -0.658 . . . . 0.0 109.957 179.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -83.75 163.67 40.48 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 6' ' ' SER . 18.0 m -99.01 148.32 24.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.531 -0.982 . . . . 0.0 110.207 178.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.622 HG21 HG11 ' A' ' 2' ' ' VAL . 66.7 t -81.89 119.8 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.468 -0.77 . . . . 0.0 109.91 178.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.62 -46.01 13.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.582 -0.699 . . . . 0.0 110.189 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 72.8 p -167.5 162.12 14.24 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.54 -0.725 . . . . 0.0 110.199 178.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.3 t -122.0 119.82 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.606 -0.684 . . . . 0.0 109.904 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -84.01 125.14 31.78 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.587 -0.696 . . . . 0.0 110.201 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -104.94 33.59 3.56 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.563 -0.711 . . . . 0.0 110.162 178.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 49.4 m -101.32 -52.99 3.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.614 -0.679 . . . . 0.0 110.231 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 154.34 83.96 0.04 OUTLIER Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.9 pt -127.3 159.75 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.579 -0.954 . . . . 0.0 110.252 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.408 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.1 ptpt -59.97 -26.51 66.08 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.593 -0.692 . . . . 0.0 110.426 -178.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.43 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.2 m-85 -134.95 96.17 14.72 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.565 -0.709 . . . . 0.0 110.195 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.99 -26.45 31.95 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 O-C-N 123.44 1.231 . . . . 0.0 111.115 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 65' ' ' LEU . 57.6 t -108.54 113.38 43.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.434 -0.791 . . . . 0.0 110.153 -174.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 11.9 mt -92.78 121.03 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.743 . . . . 0.0 109.844 174.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.681 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -101.67 159.79 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.547 ' HG3' HG22 ' A' ' 57' ' ' THR . 14.3 ttp180 -121.96 151.99 40.17 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.662 . . . . 0.0 110.192 177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.493 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -129.57 153.64 47.85 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.59 -0.694 . . . . 0.0 110.215 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.7 mt-10 -85.44 -41.98 14.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.488 -0.758 . . . . 0.0 110.177 176.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 148.56 31.55 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.541 -0.724 . . . . 0.0 110.16 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.1 m -86.28 -173.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.575 -0.703 . . . . 0.0 110.21 174.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.528 HD21 HD13 ' A' ' 55' ' ' ILE . 43.1 p-10 -129.58 -174.03 3.18 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.576 -0.702 . . . . 0.0 110.338 178.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 37.7 m-85 -61.04 -28.39 69.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.605 -0.684 . . . . 0.0 110.278 -176.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.46 ' HB3' HD11 ' A' ' 55' ' ' ILE . 34.3 m -80.96 -40.34 24.6 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.488 -0.758 . . . . 0.0 110.223 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.526 ' N ' HD12 ' A' ' 55' ' ' ILE . . . 109.57 62.98 0.53 Allowed Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 178.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 44' ' ' ASN . 4.9 mp -140.04 162.45 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.519 -0.989 . . . . 0.0 109.99 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.71 ' ND2' HG23 ' A' ' 57' ' ' THR . 17.1 p-10 -121.26 -39.31 2.69 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.503 -0.748 . . . . 0.0 110.298 178.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.71 HG23 ' ND2' ' A' ' 56' ' ' ASN . 41.4 p -103.81 125.7 50.44 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.55 -0.719 . . . . 0.0 110.202 179.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.435 ' ND2' ' CZ3' ' A' ' 17' ' ' TRP . 1.5 m-80 -122.03 -168.76 1.76 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 178.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -126.58 140.46 52.41 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.518 -0.739 . . . . 0.0 110.312 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.403 ' CE1' ' HD3' ' A' ' 12' ' ' ARG . 98.7 m-85 -145.07 152.77 40.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.614 -0.678 . . . . 0.0 110.148 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.43 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.75 149.04 27.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 110.125 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -60.75 -29.94 69.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.531 -0.731 . . . . 0.0 110.292 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -70.2 -23.11 62.9 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.481 -0.762 . . . . 0.0 110.556 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -95.83 26.5 4.03 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.409 -0.807 . . . . 0.0 110.461 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.765 HD22 HG23 ' A' ' 8' ' ' VAL . 74.6 mt -134.02 139.67 46.18 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 110.214 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 61.4 t -113.0 139.2 39.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.498 -0.752 . . . . 0.0 109.881 174.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -77.84 126.1 30.34 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.578 -0.701 . . . . 0.0 110.153 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.47 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -136.99 28.79 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.659 -0.651 . . . . 0.0 110.299 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -129.22 48.6 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.653 -0.655 . . . . 0.0 110.17 178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -83.23 -177.04 0.88 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.231 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -53.07 -174.59 0.02 OUTLIER 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.434 1.228 . . . . 0.0 111.024 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 23.8 mmtt -74.49 167.62 21.34 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.169 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.67 -158.88 0.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.547 -0.72 . . . . 0.0 110.238 179.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 15.5 mttt 52.67 85.33 0.19 Allowed Pre-proline 0 N--CA 1.499 2.021 0 O-C-N 121.419 -0.8 . . . . 0.0 110.802 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.85 177.16 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.416 0 O-C-N 123.408 1.215 . . . . 0.0 111.038 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 mttt 52.91 -165.85 0.07 Allowed 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.481 -0.762 . . . . 0.0 110.814 178.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 33.0 tttt . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.209 178.6 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.4 ptp . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.122 0.487 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.573 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.7 p -69.55 72.68 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.57 -0.706 . . . . 0.0 110.216 -178.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -133.86 -165.89 1.71 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.547 -0.721 . . . . 0.0 110.046 177.132 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.5 tmm_? -62.53 124.73 21.73 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.195 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.38 -30.31 8.67 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.8 155.71 29.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.587 -0.949 . . . . 0.0 110.225 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.1 mttt -110.1 125.82 53.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.673 . . . . 0.0 110.175 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.504 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -126.98 141.23 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.568 -0.707 . . . . 0.0 110.273 178.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.769 ' HG3' HG11 ' A' ' 68' ' ' VAL . 14.3 mtm180 -71.84 142.42 49.6 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.695 . . . . 0.0 110.239 177.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 HG11 ' A' ' 38' ' ' VAL . 49.8 mm -79.46 119.7 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.6 -0.687 . . . . 0.0 109.975 178.123 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -98.61 36.2 1.69 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.557 -0.714 . . . . 0.0 110.099 177.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.474 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.4 ttt-85 -113.92 90.68 19.78 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.6 -0.688 . . . . 0.0 110.207 179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.4 Cg_exo -52.83 -39.51 77.54 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 O-C-N 123.444 1.234 . . . . 0.0 111.015 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -61.09 -27.41 68.34 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.61 -0.681 . . . . 0.0 110.282 178.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.4 t -75.65 139.85 42.23 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.546 -0.721 . . . . 0.0 110.233 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -60.03 -25.69 65.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.519 -0.738 . . . . 0.0 110.42 175.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.5 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.1 m-90 -96.33 36.3 1.36 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.49 -0.756 . . . . 0.0 110.276 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.428 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 53.4 t80 -73.27 160.05 32.48 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.541 -0.725 . . . . 0.0 110.171 177.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.428 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 4.4 mt-30 52.65 27.12 4.9 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.391 -0.818 . . . . 0.0 110.865 179.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -129.0 143.15 50.78 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.597 -0.689 . . . . 0.0 110.134 178.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.46 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.5 t -86.3 101.01 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.578 -0.701 . . . . 0.0 110.027 178.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.22 159.84 27.8 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.4 m -94.41 144.75 25.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.629 -0.924 . . . . 0.0 110.228 178.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -79.85 119.53 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.575 -0.703 . . . . 0.0 109.981 178.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.89 -43.6 15.13 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.672 . . . . 0.0 110.249 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -167.68 175.32 7.06 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.566 -0.709 . . . . 0.0 110.214 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.7 t -131.27 144.29 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.497 -0.752 . . . . 0.0 110.014 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -120.94 101.54 7.76 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.526 -0.733 . . . . 0.0 110.273 178.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 29.8 mt-30 -90.09 81.8 6.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.582 -0.699 . . . . 0.0 110.152 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.6 p -143.85 -70.32 0.31 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.457 -0.777 . . . . 0.0 110.191 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 167.26 64.45 0.03 OUTLIER Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.413 HD11 ' O ' ' A' ' 34' ' ' TYR . 40.2 pt -116.17 172.01 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.567 -0.96 . . . . 0.0 110.281 178.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 2.2 pttt -60.12 -26.56 66.35 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.526 -0.734 . . . . 0.0 110.379 -178.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.413 ' O ' HD11 ' A' ' 32' ' ' ILE . 34.9 m-85 -141.47 95.92 7.11 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 178.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.91 -26.97 33.33 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.457 1.241 . . . . 0.0 111.137 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.433 HG21 ' HB3' ' A' ' 62' ' ' GLU . 58.1 t -111.6 159.56 11.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.507 -0.746 . . . . 0.0 110.088 -177.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 58' ' ' ASN . 4.9 mp -134.08 144.48 35.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.571 -0.706 . . . . 0.0 109.899 178.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 10' ' ' ILE . 57.5 t -122.98 155.63 28.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.601 -0.687 . . . . 0.0 109.918 179.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.535 ' HG3' HG22 ' A' ' 57' ' ' THR . 63.4 ttt180 -115.9 134.54 54.88 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.589 -0.694 . . . . 0.0 110.228 177.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.5 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.6 m-85 -114.58 165.46 12.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.598 -0.689 . . . . 0.0 110.201 179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -109.21 -29.11 8.66 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.506 -0.746 . . . . 0.0 110.156 176.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.9 tmtt? -84.56 131.82 34.58 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.58 -0.7 . . . . 0.0 110.193 178.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.3 m -66.47 -165.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 110.144 175.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.535 HD21 HD12 ' A' ' 55' ' ' ILE . 43.4 p-10 -153.14 -171.35 3.89 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.517 -0.739 . . . . 0.0 110.3 177.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -61.02 -28.37 68.99 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.549 -0.72 . . . . 0.0 110.246 -177.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.1 m -83.62 -28.53 28.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.525 -0.735 . . . . 0.0 110.241 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.45 49.7 2.52 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -178.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.535 HD12 HD21 ' A' ' 44' ' ' ASN . 64.8 mt -120.05 167.02 13.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.606 -0.938 . . . . 0.0 109.962 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.804 ' OD1' HG23 ' A' ' 57' ' ' THR . 4.0 p30 -126.1 -39.91 2.04 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.618 -0.676 . . . . 0.0 110.463 178.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.804 HG23 ' OD1' ' A' ' 56' ' ' ASN . 41.6 p -113.54 150.95 32.24 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.528 -0.733 . . . . 0.0 110.292 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.6 m-80 -146.68 -174.37 4.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.596 -0.69 . . . . 0.0 110.177 177.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -126.18 134.63 51.21 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.514 -0.741 . . . . 0.0 110.253 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.408 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 75.2 m-85 -132.47 155.49 48.45 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.604 -0.685 . . . . 0.0 110.214 179.449 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.415 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -80.85 148.97 29.7 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.568 -0.707 . . . . 0.0 110.185 178.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.433 ' HB3' HG21 ' A' ' 36' ' ' VAL . 12.2 pt-20 -59.62 -27.39 66.28 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.581 -0.699 . . . . 0.0 110.32 -179.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.415 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -69.42 -23.96 63.77 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.561 -0.712 . . . . 0.0 110.478 176.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -96.08 27.4 3.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.486 -0.758 . . . . 0.0 110.437 -178.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.504 HD22 HG23 ' A' ' 8' ' ' VAL . 92.1 mt -138.27 148.07 44.32 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.46 -0.775 . . . . 0.0 110.208 176.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -128.76 131.71 68.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.624 -0.672 . . . . 0.0 109.947 177.101 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.408 ' HA ' HG12 ' A' ' 8' ' ' VAL . 3.7 tt0 -71.12 117.84 13.14 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.53 -0.731 . . . . 0.0 110.125 177.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.769 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.0 m -110.78 38.82 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.566 -0.709 . . . . 0.0 110.336 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.8 tt0 -92.85 92.55 7.96 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.152 175.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.17 111.13 3.3 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.648 -0.657 . . . . 0.0 110.239 -178.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.32 -175.14 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.472 0 O-C-N 123.105 1.055 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.7 mttm -108.63 48.57 0.85 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.577 -0.702 . . . . 0.0 110.299 177.389 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -84.64 -161.19 0.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.707 . . . . 0.0 110.257 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 17.1 mmtt -115.28 165.65 13.75 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.584 -0.697 . . . . 0.0 110.219 178.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.94 153.12 16.04 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 O-C-N 123.435 1.229 . . . . 0.0 110.968 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -168.25 148.69 4.84 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.53 -0.731 . . . . 0.0 110.296 178.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.2 pttt . . . . . 0 N--CA 1.495 1.805 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.269 178.613 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.088 0.47 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 2' ' ' VAL . 9.8 p -70.58 69.52 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.57 -0.706 . . . . 0.0 110.173 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -130.1 -173.86 3.16 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.553 -0.717 . . . . 0.0 110.245 178.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.7 ptt180 -61.2 126.42 27.29 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.631 -0.668 . . . . 0.0 110.281 178.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 -30.58 7.03 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 153.02 26.02 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.585 -0.95 . . . . 0.0 110.177 178.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.519 ' HD2' HG12 ' A' ' 21' ' ' VAL . 17.6 mmtt -102.9 127.66 50.01 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.565 -0.71 . . . . 0.0 110.172 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.608 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -120.71 155.21 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.575 -0.703 . . . . 0.0 110.344 178.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.679 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.1 mmt85 -82.88 144.06 30.33 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.597 -0.689 . . . . 0.0 110.151 178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.662 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.7 mm -87.82 119.71 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.501 -0.75 . . . . 0.0 109.986 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.476 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.25 40.23 1.44 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.51 -0.744 . . . . 0.0 110.184 178.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.5 ttt180 -114.51 88.44 15.91 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.581 -0.7 . . . . 0.0 110.223 178.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.67 -25.78 27.5 Favored 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.421 1.221 . . . . 0.0 111.019 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -77.32 -27.59 52.93 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.54 -0.725 . . . . 0.0 110.282 179.533 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.6 p -72.99 141.08 47.73 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.508 -0.745 . . . . 0.0 110.211 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -60.08 -27.44 66.99 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.604 -0.685 . . . . 0.0 110.304 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 9.3 m-90 -96.3 38.09 1.22 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 -176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.418 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 45.9 t80 -70.27 157.87 36.9 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 177.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.418 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 20.6 mt-30 52.74 27.13 5.0 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.443 -0.786 . . . . 0.0 110.829 178.531 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -126.09 134.21 51.43 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.578 -0.701 . . . . 0.0 110.181 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.519 HG12 ' HD2' ' A' ' 7' ' ' LYS . 61.4 t -81.49 106.35 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.533 -0.729 . . . . 0.0 109.88 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -97.33 170.83 26.15 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.0 m -104.54 142.06 35.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.626 -0.926 . . . . 0.0 110.188 178.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -80.46 125.09 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.574 -0.704 . . . . 0.0 110.001 178.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.16 -51.17 6.81 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.592 -0.693 . . . . 0.0 110.258 178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.4 p -167.82 -176.96 3.25 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.6 -0.687 . . . . 0.0 110.201 178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.2 t -117.6 135.11 59.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.58 -0.7 . . . . 0.0 110.007 178.473 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -84.06 110.08 18.18 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.579 -0.7 . . . . 0.0 110.177 178.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -93.71 82.32 4.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.505 -0.747 . . . . 0.0 110.252 178.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.1 m -164.35 -58.98 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.243 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 147.61 82.46 0.04 OUTLIER Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -123.88 165.66 20.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.605 -0.938 . . . . 0.0 110.246 178.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.41 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 17.5 pttt -60.06 -26.5 66.2 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.557 -0.714 . . . . 0.0 110.46 -178.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.41 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 34.9 m-85 -134.81 96.3 14.86 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.472 -0.768 . . . . 0.0 110.203 178.356 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.89 -45.35 41.5 Favored 'Trans proline' 0 N--CA 1.493 1.45 0 O-C-N 123.466 1.245 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -88.56 130.96 37.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -0.761 . . . . 0.0 110.038 -173.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.3 mt -99.61 133.33 42.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.573 -0.705 . . . . 0.0 109.941 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.658 HG11 HD11 ' A' ' 10' ' ' ILE . 57.6 t -114.1 137.83 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.51 -0.744 . . . . 0.0 109.995 178.083 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.449 ' HA ' HG22 ' A' ' 57' ' ' THR . 8.3 ttm180 -106.31 117.77 34.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.653 -0.654 . . . . 0.0 110.212 178.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.1 m-85 -95.91 149.2 21.81 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.492 -0.755 . . . . 0.0 110.212 179.144 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -84.12 -29.19 26.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.497 -0.752 . . . . 0.0 110.132 175.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.8 tttp -82.53 169.19 16.61 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.621 -0.675 . . . . 0.0 110.238 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.6 m -107.82 -164.79 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.505 -0.747 . . . . 0.0 110.218 174.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.517 HD21 HD12 ' A' ' 55' ' ' ILE . 43.2 p-10 -142.77 -162.87 1.51 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.563 -0.71 . . . . 0.0 110.207 176.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -73.82 -27.77 61.28 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.586 -0.696 . . . . 0.0 110.375 -177.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 m -99.16 22.82 9.89 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.537 -0.727 . . . . 0.0 110.732 -175.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.92 60.69 8.23 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 172.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 44' ' ' ASN . 84.0 mt -134.41 148.5 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.491 -1.006 . . . . 0.0 109.955 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.1 p-10 -114.48 -26.28 8.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.607 -0.683 . . . . 0.0 110.512 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.449 HG22 ' HA ' ' A' ' 39' ' ' ARG . 72.0 p -130.88 153.18 49.41 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.564 -0.71 . . . . 0.0 110.217 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -145.12 -167.44 2.68 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.675 -0.641 . . . . 0.0 110.079 177.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -126.89 132.6 50.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.62 -0.675 . . . . 0.0 110.201 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.2 m-85 -131.54 160.86 34.02 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.556 -0.715 . . . . 0.0 110.285 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.701 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -82.87 149.97 26.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.537 -0.727 . . . . 0.0 110.175 178.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -60.69 -28.49 68.66 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.518 -0.739 . . . . 0.0 110.251 178.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.615 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.8 p30 -68.37 -25.39 65.05 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.555 -0.716 . . . . 0.0 110.436 176.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.701 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.5 mt-10 -96.56 27.94 3.61 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.493 -0.755 . . . . 0.0 110.379 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.662 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.0 mt -138.95 127.34 22.91 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.551 -0.718 . . . . 0.0 110.219 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.5 t -102.26 142.85 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.535 -0.728 . . . . 0.0 109.917 176.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.42 ' OE1' ' HB2' ' A' ' 70' ' ' ALA . 4.4 tm-20 -81.73 120.13 24.74 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.623 -0.673 . . . . 0.0 110.214 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.679 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -129.12 40.85 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.584 -0.698 . . . . 0.0 110.206 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -162.17 33.78 0.12 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.528 -0.733 . . . . 0.0 110.242 178.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.42 ' HB2' ' OE1' ' A' ' 67' ' ' GLU . . . -83.34 167.99 25.34 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.583 -0.698 . . . . 0.0 110.199 178.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.94 173.52 0.14 Allowed 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.436 1.229 . . . . 0.0 110.965 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 pttt -166.37 52.57 0.09 Allowed 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.631 -0.668 . . . . 0.0 110.28 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -81.86 -176.0 5.88 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 110.186 178.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -113.75 91.68 22.26 Favored Pre-proline 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.654 . . . . 0.0 110.238 178.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.9 149.78 25.11 Favored 'Trans proline' 0 N--CA 1.491 1.338 0 O-C-N 123.404 1.212 . . . . 0.0 110.971 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? 52.83 -169.69 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.357 -0.839 . . . . 0.0 110.775 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 16.2 mtmm . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.233 178.679 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.129 0.49 . . . . 0.0 110.195 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 57.7 t -90.08 79.15 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.558 -0.714 . . . . 0.0 109.998 178.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -116.26 -173.3 2.34 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.621 -0.675 . . . . 0.0 110.196 178.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -61.34 134.57 57.09 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 178.689 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.93 -29.71 9.47 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.5 p -60.57 125.09 22.4 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.491 -1.005 . . . . 0.0 110.286 -177.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -75.85 68.34 2.37 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.45 -0.781 . . . . 0.0 110.096 172.531 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.0 147.54 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.5 -0.75 . . . . 0.0 110.287 -173.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.601 ' HG3' HG21 ' A' ' 68' ' ' VAL . 5.4 mtt-85 -79.3 157.25 27.75 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.625 -0.672 . . . . 0.0 110.231 176.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.723 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -102.23 119.75 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.559 -0.713 . . . . 0.0 110.05 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.5 mm? -101.83 40.25 1.35 Allowed 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.577 -0.702 . . . . 0.0 110.112 177.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.403 ' H ' HG22 ' A' ' 10' ' ' ILE . 10.4 ttt-85 -115.4 85.82 13.82 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.571 -0.706 . . . . 0.0 110.218 -179.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.78 -26.28 29.91 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.433 1.228 . . . . 0.0 111.039 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.97 -27.87 63.05 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.61 -0.681 . . . . 0.0 110.22 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.0 m -78.34 142.26 37.83 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.573 -0.705 . . . . 0.0 110.221 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 42.8 t80 -60.15 -25.1 65.24 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.507 -0.745 . . . . 0.0 110.392 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.501 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.77 36.9 1.24 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.405 -0.81 . . . . 0.0 110.317 -177.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 35.5 t80 -65.46 156.54 32.09 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.499 -0.75 . . . . 0.0 110.181 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 52.81 27.16 5.11 Favored 'General case' 0 N--CA 1.501 2.103 0 O-C-N 121.476 -0.765 . . . . 0.0 110.859 179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.49 155.46 24.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.515 -0.741 . . . . 0.0 110.239 178.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.521 HG22 ' HG2' ' A' ' 9' ' ' ARG . 58.7 t -100.2 85.67 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.561 -0.712 . . . . 0.0 109.955 177.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.85 161.73 42.29 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.2 m -105.57 140.7 38.25 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.965 . . . . 0.0 110.26 178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.9 t -78.61 130.58 35.97 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.585 -0.697 . . . . 0.0 109.87 178.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -90.25 -49.88 6.3 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.589 -0.695 . . . . 0.0 110.223 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.2 m -167.72 156.65 9.65 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.57 -0.706 . . . . 0.0 110.214 178.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.5 t -108.78 125.79 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.561 -0.712 . . . . 0.0 109.96 178.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -106.63 117.98 35.46 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.642 -0.661 . . . . 0.0 110.188 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -82.03 79.85 8.44 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.567 -0.708 . . . . 0.0 110.184 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.1 t -133.28 -159.15 0.94 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.609 -0.682 . . . . 0.0 110.199 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -91.87 50.1 2.83 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 178.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 37.0 pt -110.29 142.59 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.48 -1.012 . . . . 0.0 110.267 177.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.3 OUTLIER -70.59 -26.39 63.49 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.611 -0.681 . . . . 0.0 110.459 -175.971 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.44 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 32.2 m-85 -113.84 91.16 20.87 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.421 -0.799 . . . . 0.0 110.179 176.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.96 -40.75 75.06 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.362 1.191 . . . . 0.0 111.109 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.6 t -93.41 128.23 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.428 -0.795 . . . . 0.0 110.106 -173.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 10.8 mt -95.69 127.08 48.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.433 -0.792 . . . . 0.0 109.868 175.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -107.23 143.36 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.606 -0.684 . . . . 0.0 110.026 -179.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 1.3 ttt180 -109.23 142.12 40.51 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.577 -0.702 . . . . 0.0 110.136 177.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.501 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 56.4 m-85 -120.99 173.18 7.41 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.528 -0.733 . . . . 0.0 110.213 179.136 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -110.23 -28.88 8.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.559 -0.713 . . . . 0.0 110.216 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.4 tttp -93.47 173.41 7.72 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.588 -0.695 . . . . 0.0 110.292 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -116.3 -173.36 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.609 -0.682 . . . . 0.0 110.221 176.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -119.88 -164.54 1.08 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.578 -0.702 . . . . 0.0 110.263 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -63.62 -28.6 70.03 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.607 -0.683 . . . . 0.0 110.203 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -83.71 -62.25 1.62 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.587 -0.695 . . . . 0.0 110.211 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 133.48 74.06 0.09 OUTLIER Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.462 HG22 ' N ' ' A' ' 56' ' ' ASN . 69.6 mt -128.96 166.03 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.592 -0.946 . . . . 0.0 109.954 178.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.462 ' N ' HG22 ' A' ' 55' ' ' ILE . 11.5 p-10 -126.4 -39.52 2.03 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.517 -0.739 . . . . 0.0 110.352 -178.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.419 HG23 ' ND2' ' A' ' 56' ' ' ASN . 7.0 p -123.91 151.88 43.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.598 -0.689 . . . . 0.0 110.318 -177.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -147.73 -167.4 2.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.582 -0.699 . . . . 0.0 110.18 176.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -130.07 132.15 46.06 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.58 -0.7 . . . . 0.0 110.258 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.423 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 70.1 m-85 -131.7 156.99 44.93 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.588 -0.695 . . . . 0.0 110.267 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.698 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -80.26 146.42 31.67 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.504 -0.748 . . . . 0.0 110.147 175.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.466 ' HB3' HG21 ' A' ' 36' ' ' VAL . 0.1 OUTLIER -60.59 -27.05 67.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.579 -0.701 . . . . 0.0 110.401 178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.2 p30 -69.59 -24.08 63.62 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.59 -0.694 . . . . 0.0 110.56 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.698 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 9.9 mt-10 -96.0 27.1 3.76 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.435 -0.79 . . . . 0.0 110.438 -178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.723 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.1 mt -138.54 146.44 41.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.451 -0.781 . . . . 0.0 110.214 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.7 t -126.11 130.99 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.552 -0.717 . . . . 0.0 109.937 176.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.14 123.73 22.35 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.59 -0.694 . . . . 0.0 110.126 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 9' ' ' ARG . 36.0 m -132.99 43.86 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.603 -0.685 . . . . 0.0 110.293 178.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 32.3 tt0 -87.0 160.28 18.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.546 -0.722 . . . . 0.0 110.155 178.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -84.27 161.0 55.99 Favored Pre-proline 0 N--CA 1.494 1.748 0 O-C-N 121.631 -0.668 . . . . 0.0 110.164 178.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.97 174.6 0.11 Allowed 'Trans proline' 0 N--CA 1.491 1.371 0 O-C-N 123.411 1.216 . . . . 0.0 110.938 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.8 tttt -82.85 -159.16 0.31 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.574 -0.704 . . . . 0.0 110.206 178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.07 150.76 37.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.193 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 62.6 mttm 52.65 82.13 0.25 Allowed Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.383 -0.823 . . . . 0.0 110.719 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.92 -32.89 59.3 Favored 'Trans proline' 0 N--CA 1.491 1.351 0 O-C-N 123.411 1.216 . . . . 0.0 111.036 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 61.7 mttt -83.2 161.39 21.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.523 -0.736 . . . . 0.0 110.23 178.631 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 pttt . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.229 178.898 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.5 mtt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.105 0.478 . . . . 0.0 110.265 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.3 t -83.85 79.0 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.615 -0.678 . . . . 0.0 109.941 178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.3 mp0 -133.78 177.53 7.65 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 110.211 178.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.7 ptp180 -61.3 127.31 30.89 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.515 -0.741 . . . . 0.0 110.252 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.49 -31.5 5.95 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.46 155.86 20.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.649 -0.913 . . . . 0.0 110.215 178.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.9 mmmt -108.42 126.1 52.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.592 -0.693 . . . . 0.0 110.199 178.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.653 HG23 HD22 ' A' ' 65' ' ' LEU . 35.1 m -122.77 159.38 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.676 -0.64 . . . . 0.0 110.293 178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.691 ' HG3' HG11 ' A' ' 68' ' ' VAL . 4.7 mmt85 -82.25 155.39 24.9 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.553 -0.717 . . . . 0.0 110.236 178.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.572 HD11 HG11 ' A' ' 38' ' ' VAL . 49.7 mm -95.57 119.77 44.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 0.0 110.002 177.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.441 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -103.14 36.86 2.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.553 -0.717 . . . . 0.0 110.149 177.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.427 ' H ' HG22 ' A' ' 10' ' ' ILE . 2.3 ttt85 -114.62 88.52 16.32 Favored Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.587 -0.696 . . . . 0.0 110.184 178.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.406 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.3 Cg_exo -52.75 -26.45 30.31 Favored 'Trans proline' 0 N--CA 1.491 1.382 0 O-C-N 123.443 1.233 . . . . 0.0 111.07 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -75.16 -27.58 59.75 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.1 t -73.34 139.39 45.98 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.549 -0.719 . . . . 0.0 110.284 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -59.89 -26.72 66.12 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.586 -0.696 . . . . 0.0 110.33 177.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 7.9 m-90 -96.06 38.66 1.17 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.537 -0.727 . . . . 0.0 110.235 -177.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.421 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 52.8 t80 -72.5 159.17 34.39 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.483 -0.761 . . . . 0.0 110.15 176.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 19.4 mt-30 52.55 27.38 5.03 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.421 -0.799 . . . . 0.0 110.795 179.342 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -127.57 146.53 50.49 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.594 -0.691 . . . . 0.0 110.206 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.516 HG22 ' HG2' ' A' ' 9' ' ' ARG . 59.1 t -91.95 102.62 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.583 -0.698 . . . . 0.0 109.936 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.68 176.8 35.35 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.1 m -111.32 147.96 33.98 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.611 -0.935 . . . . 0.0 110.168 178.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.0 t -83.44 124.78 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.645 -0.659 . . . . 0.0 109.927 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.61 -43.9 13.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.554 -0.716 . . . . 0.0 110.273 178.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.667 ' O ' HD12 ' A' ' 37' ' ' ILE . 3.6 m -167.71 149.46 5.56 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.545 -0.722 . . . . 0.0 110.176 178.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -107.96 119.72 58.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.576 -0.703 . . . . 0.0 109.953 178.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -113.87 118.03 33.08 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.565 -0.709 . . . . 0.0 110.21 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -102.83 48.51 0.86 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.519 -0.738 . . . . 0.0 110.203 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.5 t -98.99 28.99 4.03 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.568 -0.707 . . . . 0.0 110.247 178.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 70.82 80.69 0.3 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 178.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -139.42 166.97 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.497 -1.002 . . . . 0.0 110.345 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.402 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 9.3 ptpp? -59.96 -27.07 66.5 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.607 -0.683 . . . . 0.0 110.388 -178.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 34.9 m-85 -142.08 96.55 6.54 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.494 -0.754 . . . . 0.0 110.157 177.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.75 -40.82 73.11 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 O-C-N 123.422 1.222 . . . . 0.0 111.19 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.12 132.25 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.475 -0.766 . . . . 0.0 110.013 -174.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.667 HD12 ' O ' ' A' ' 26' ' ' SER . 10.2 mt -99.17 131.94 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.596 -0.69 . . . . 0.0 109.917 177.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.572 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -115.2 136.71 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.54 -0.725 . . . . 0.0 109.964 179.186 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -106.56 125.98 51.69 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.557 -0.714 . . . . 0.0 110.186 177.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 39.5 m-85 -99.99 156.65 17.04 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.562 -0.711 . . . . 0.0 110.294 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 mt-10 -98.53 -29.1 13.28 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.587 -0.696 . . . . 0.0 110.195 176.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.1 ttpt -80.74 169.35 17.71 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.541 -0.725 . . . . 0.0 110.202 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -107.93 -165.55 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.589 -0.695 . . . . 0.0 110.236 177.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.567 HD21 HD12 ' A' ' 55' ' ' ILE . 17.5 p-10 -153.11 -169.66 3.39 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.588 -0.695 . . . . 0.0 110.258 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -60.6 -28.45 68.52 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.521 -0.737 . . . . 0.0 110.36 -173.566 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -87.67 -28.3 21.9 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.419 -0.8 . . . . 0.0 110.247 -176.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.84 30.93 6.52 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -176.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.567 HD12 HD21 ' A' ' 44' ' ' ASN . 72.4 mt -95.4 160.42 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.967 . . . . 0.0 109.904 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.449 ' C ' HG23 ' A' ' 57' ' ' THR . 43.1 p-10 -140.05 14.74 2.45 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.488 -0.757 . . . . 0.0 111.0 176.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.502 ' H ' HG22 ' A' ' 55' ' ' ILE . 25.4 p -152.5 139.06 18.67 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.224 -0.923 . . . . 0.0 110.229 178.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.433 ' HB3' ' CE1' ' A' ' 60' ' ' PHE . 2.5 m120 -149.43 176.06 10.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.52 -0.738 . . . . 0.0 110.217 177.075 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -120.36 137.89 54.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.602 -0.687 . . . . 0.0 110.284 179.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CE1' ' HB3' ' A' ' 58' ' ' ASN . 82.9 m-85 -133.76 159.73 39.7 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.577 -0.702 . . . . 0.0 110.233 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.695 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -83.03 148.13 27.74 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.448 -0.782 . . . . 0.0 110.132 178.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -59.58 -26.79 65.71 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.575 -0.703 . . . . 0.0 110.502 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.585 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 3.4 p30 -69.85 -25.05 63.55 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.5 -0.75 . . . . 0.0 110.452 176.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.695 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.8 mt-10 -96.46 27.95 3.56 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.521 -0.737 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.653 HD22 HG23 ' A' ' 8' ' ' VAL . 86.9 mt -138.8 122.08 17.04 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.472 -0.767 . . . . 0.0 110.255 178.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.29 149.37 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.599 -0.688 . . . . 0.0 109.922 176.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -81.99 129.06 34.67 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.588 -0.695 . . . . 0.0 110.272 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.691 HG11 ' HG3' ' A' ' 9' ' ' ARG . 35.8 m -141.35 65.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.657 -0.652 . . . . 0.0 110.27 178.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -79.94 164.97 23.09 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.461 -0.774 . . . . 0.0 110.231 177.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.49 149.04 60.25 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 179.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.98 169.12 0.4 Allowed 'Trans proline' 0 N--CA 1.493 1.457 0 O-C-N 123.414 1.218 . . . . 0.0 111.006 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.4 ttmt 52.9 82.56 0.07 Allowed 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.455 -0.778 . . . . 0.0 110.825 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 177.75 6.39 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.623 -0.673 . . . . 0.0 110.209 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt 52.62 94.97 0.05 OUTLIER Pre-proline 0 N--CA 1.501 2.092 0 O-C-N 121.458 -0.776 . . . . 0.0 110.782 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.9 173.66 0.13 Allowed 'Trans proline' 0 N--CA 1.492 1.405 0 O-C-N 123.37 1.195 . . . . 0.0 110.974 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -83.22 -41.01 18.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.516 -0.74 . . . . 0.0 110.202 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.8 tptt . . . . . 0 N--CA 1.495 1.781 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.132 178.784 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 tpt . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 120.993 0.425 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.468 ' CG1' HG11 ' A' ' 8' ' ' VAL . 34.2 m -61.13 -165.18 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.675 -0.641 . . . . 0.0 110.297 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -140.19 165.56 27.04 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.573 -0.704 . . . . 0.0 110.182 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.2 mtm180 -71.96 93.6 1.38 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.543 -0.723 . . . . 0.0 110.105 176.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.11 30.2 3.49 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.06 -167.8 1.57 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.456 -1.026 . . . . 0.0 110.18 178.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.7 mptt -136.04 113.77 11.06 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.581 -0.699 . . . . 0.0 110.253 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.563 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -124.68 158.09 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.534 -0.729 . . . . 0.0 110.278 178.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.63 ' HG3' HG11 ' A' ' 68' ' ' VAL . 0.2 OUTLIER -77.65 145.42 36.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.575 -0.703 . . . . 0.0 110.197 177.374 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 38' ' ' VAL . 50.3 mm -90.14 119.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.584 -0.698 . . . . 0.0 110.022 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.436 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.5 mm? -100.9 38.3 1.57 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.602 -0.686 . . . . 0.0 110.125 179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.438 ' NH1' ' CE2' ' A' ' 34' ' ' TYR . 1.8 ttt180 -115.44 85.09 12.77 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.615 -0.678 . . . . 0.0 110.13 178.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.6 -26.49 29.48 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.372 1.196 . . . . 0.0 111.023 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -72.59 -27.26 62.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.56 -0.712 . . . . 0.0 110.304 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.8 m -77.61 141.98 39.18 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.479 -0.763 . . . . 0.0 110.227 -179.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -59.26 -25.85 64.42 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.585 -0.697 . . . . 0.0 110.454 175.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 8.9 m-90 -96.34 36.33 1.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.498 -0.751 . . . . 0.0 110.349 -175.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -72.17 160.31 32.65 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.58 -0.7 . . . . 0.0 110.206 175.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 52.78 27.19 5.11 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.399 -0.813 . . . . 0.0 110.848 178.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -129.51 160.51 32.96 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.577 -0.702 . . . . 0.0 110.223 178.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.405 HG22 HG21 ' A' ' 68' ' ' VAL . 58.6 t -100.59 106.79 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.556 -0.715 . . . . 0.0 110.01 178.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -92.48 164.25 27.95 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 m -100.37 139.46 36.01 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.586 -0.95 . . . . 0.0 110.16 179.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.94 120.09 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.568 -0.707 . . . . 0.0 109.916 178.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.6 -44.32 14.72 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.599 -0.688 . . . . 0.0 110.165 178.725 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 25.4 p -165.99 168.21 15.87 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.602 -0.686 . . . . 0.0 110.278 178.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -120.83 128.41 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.613 -0.679 . . . . 0.0 109.941 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -106.5 126.28 52.06 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.528 -0.733 . . . . 0.0 110.169 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -90.52 50.05 1.77 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.54 -0.725 . . . . 0.0 110.205 178.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.4 m -105.74 -159.32 0.7 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.576 -0.702 . . . . 0.0 110.222 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -118.22 62.52 0.43 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 178.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 pt -108.34 169.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.603 -0.94 . . . . 0.0 110.242 178.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.407 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -60.16 -26.6 66.43 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.548 -0.72 . . . . 0.0 110.41 -177.394 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.438 ' CE2' ' NH1' ' A' ' 12' ' ' ARG . 35.8 m-85 -139.17 96.05 9.13 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.472 -0.768 . . . . 0.0 110.282 179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.91 -45.25 42.23 Favored 'Trans proline' 0 N--CA 1.491 1.347 0 O-C-N 123.355 1.187 . . . . 0.0 111.089 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.42 159.54 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.733 . . . . 0.0 110.029 -176.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.529 ' N ' HD12 ' A' ' 37' ' ' ILE . 5.2 mp -123.65 146.7 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 109.953 179.219 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.527 HG11 HD11 ' A' ' 10' ' ' ILE . 57.3 t -129.71 147.84 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.574 -0.704 . . . . 0.0 109.991 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HG3' HG22 ' A' ' 57' ' ' THR . 1.8 ttt180 -110.78 150.72 28.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.621 -0.674 . . . . 0.0 110.213 177.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 40.0 m-85 -127.96 143.88 51.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.496 -0.752 . . . . 0.0 110.236 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -90.0 -29.1 18.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.51 -0.744 . . . . 0.0 110.22 175.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.9 tmtt? -81.21 121.98 26.82 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.669 -0.644 . . . . 0.0 110.22 177.479 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.54 -165.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.149 175.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.492 HD21 HD12 ' A' ' 55' ' ' ILE . 42.9 p-10 -154.33 -165.61 2.13 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.623 -0.673 . . . . 0.0 110.365 177.131 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -60.87 -28.6 68.98 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.599 -0.688 . . . . 0.0 110.278 -175.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 m -92.29 -28.45 16.96 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.499 -0.751 . . . . 0.0 110.292 -178.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 96.59 58.17 1.07 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -177.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.532 HG22 ' H ' ' A' ' 57' ' ' THR . 70.3 mt -129.11 158.58 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.537 -0.978 . . . . 0.0 109.937 -176.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.543 ' O ' HG23 ' A' ' 57' ' ' THR . 4.9 p-10 -143.15 26.86 1.63 Allowed 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.481 -0.762 . . . . 0.0 110.414 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.543 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.4 p -155.26 125.67 6.81 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.528 -0.733 . . . . 0.0 110.176 176.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -139.79 -171.36 3.14 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.579 -0.7 . . . . 0.0 110.241 178.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -127.85 134.79 49.43 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.612 -0.68 . . . . 0.0 110.267 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.41 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 89.1 m-85 -135.22 160.28 38.87 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.453 -0.779 . . . . 0.0 110.198 177.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.417 ' HB3' ' OD1' ' A' ' 63' ' ' ASP . . . -91.89 155.76 17.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.601 -0.687 . . . . 0.0 110.156 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -65.47 -28.64 69.36 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.6 -0.687 . . . . 0.0 110.311 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.417 ' OD1' ' HB3' ' A' ' 61' ' ' ALA . 32.2 p-10 -70.59 -26.36 63.48 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 110.5 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -97.1 28.56 3.52 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.537 -0.727 . . . . 0.0 110.312 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.563 HD22 HG23 ' A' ' 8' ' ' VAL . 89.4 mt -138.09 122.52 18.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.562 -0.711 . . . . 0.0 110.24 176.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.8 t -98.27 148.61 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.539 -0.725 . . . . 0.0 109.941 177.476 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -81.97 127.22 32.83 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.567 -0.708 . . . . 0.0 110.18 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.63 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -134.97 53.29 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.284 178.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -112.01 119.94 40.19 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.563 -0.71 . . . . 0.0 110.175 177.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -90.05 112.31 51.63 Favored Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.552 -0.717 . . . . 0.0 110.187 179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.06 -176.34 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.105 1.055 . . . . 0.0 111.03 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 20.4 tptt -82.19 160.72 22.97 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.539 -0.725 . . . . 0.0 110.21 178.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -82.73 84.33 7.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.541 -0.725 . . . . 0.0 110.165 178.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 12.5 mtmm 52.62 88.69 0.11 Allowed Pre-proline 0 N--CA 1.502 2.151 0 O-C-N 121.456 -0.777 . . . . 0.0 110.71 178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.01 -30.78 50.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.498 1.262 . . . . 0.0 110.974 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 6.3 ttmm -139.13 131.11 27.84 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.58 -0.7 . . . . 0.0 110.151 178.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.287 178.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.1 ttp . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.122 0.487 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.823 HG11 HG11 ' A' ' 8' ' ' VAL . 35.3 m -69.4 -165.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.573 -0.704 . . . . 0.0 110.232 178.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 3.3 mp0 -118.14 157.35 27.07 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.6 -0.687 . . . . 0.0 110.175 -179.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 29.8 mtp180 -75.44 110.15 9.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.524 -0.735 . . . . 0.0 110.152 176.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 119.39 -29.81 6.01 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -178.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.08 152.86 42.08 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.572 -0.958 . . . . 0.0 110.241 178.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 mtmt -104.36 127.08 51.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.591 -0.693 . . . . 0.0 110.245 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.823 HG11 HG11 ' A' ' 2' ' ' VAL . 34.9 m -121.43 159.68 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.513 -0.742 . . . . 0.0 110.269 178.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.657 ' HG3' HG11 ' A' ' 68' ' ' VAL . 2.1 mmt180 -81.64 157.3 24.72 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.569 -0.707 . . . . 0.0 110.265 178.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.552 ' C ' HD22 ' A' ' 11' ' ' LEU . 49.8 mm -99.64 127.15 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.59 -0.694 . . . . 0.0 110.019 178.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.552 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.15 37.95 2.44 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.525 -0.735 . . . . 0.0 110.176 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.421 ' H ' HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -114.69 87.92 15.39 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.548 -0.72 . . . . 0.0 110.221 179.02 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.76 -26.33 30.0 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.375 1.197 . . . . 0.0 111.057 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -74.96 -27.26 60.1 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.552 -0.718 . . . . 0.0 110.342 178.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 71.0 m -74.74 141.45 44.45 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.552 -0.717 . . . . 0.0 110.248 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -59.85 -27.56 66.75 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.528 -0.733 . . . . 0.0 110.333 176.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.432 ' HB3' ' CE2' ' A' ' 40' ' ' PHE . 10.5 m-90 -96.33 38.6 1.19 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.462 -0.774 . . . . 0.0 110.213 -177.11 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 46.3 t80 -70.53 157.41 37.93 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.589 -0.694 . . . . 0.0 110.136 176.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 53.5 mt-30 52.84 28.47 6.48 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.387 -0.821 . . . . 0.0 110.804 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -124.51 155.96 38.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.598 -0.689 . . . . 0.0 110.215 177.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.1 t -99.35 104.2 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.517 -0.739 . . . . 0.0 110.025 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.89 164.73 25.21 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.3 m -97.35 143.56 27.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.57 -0.959 . . . . 0.0 110.19 178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -80.27 119.67 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.552 -0.717 . . . . 0.0 109.946 178.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -86.61 -44.8 11.6 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.597 -0.69 . . . . 0.0 110.237 179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -165.07 163.89 20.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.65 -0.656 . . . . 0.0 110.193 179.191 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 HG22 ' A' ' 36' ' ' VAL . 57.8 t -125.07 119.65 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.554 -0.716 . . . . 0.0 110.043 178.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -116.22 113.74 23.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.496 -0.753 . . . . 0.0 110.248 178.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.5 tt0 -100.78 81.54 2.3 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.575 -0.703 . . . . 0.0 110.196 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.8 m -128.88 29.01 5.28 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.589 -0.695 . . . . 0.0 110.232 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.12 53.52 7.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 178.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.405 HD11 ' HA ' ' A' ' 35' ' ' PRO . 40.6 pt -114.15 166.19 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.635 -0.921 . . . . 0.0 110.23 178.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.403 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 0.1 OUTLIER -59.88 -27.13 66.44 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.524 -0.735 . . . . 0.0 110.409 -177.989 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.403 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.4 m-85 -141.11 95.23 7.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.477 -0.764 . . . . 0.0 110.167 177.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.405 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.3 Cg_exo -52.76 -27.34 33.74 Favored 'Trans proline' 0 N--CA 1.491 1.34 0 O-C-N 123.396 1.208 . . . . 0.0 111.131 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.501 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.4 t -111.41 159.54 11.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.545 -0.722 . . . . 0.0 110.048 -177.139 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.1 mp -130.94 149.5 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 110.007 178.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.41 134.14 66.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.493 -0.754 . . . . 0.0 109.942 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.0 ttp85 -96.08 132.59 41.3 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.5 -0.75 . . . . 0.0 110.157 175.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 40' ' ' PHE . 59.9 m-85 -113.2 150.0 32.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.55 -0.719 . . . . 0.0 110.233 -178.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -91.38 -33.31 15.32 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.501 -0.749 . . . . 0.0 110.181 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 24.8 tttt -83.99 160.37 21.04 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.696 -0.628 . . . . 0.0 110.216 177.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 36.0 m -107.03 -172.8 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.463 -0.773 . . . . 0.0 110.235 175.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -125.26 -161.88 1.06 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.562 -0.711 . . . . 0.0 110.165 177.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -59.08 -26.9 65.05 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.486 -0.759 . . . . 0.0 110.484 -177.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 64.7 m -86.35 -72.43 0.5 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.544 -0.723 . . . . 0.0 110.281 179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 144.86 57.9 0.02 OUTLIER Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 57' ' ' THR . 11.1 mt -123.74 158.25 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.493 -1.004 . . . . 0.0 109.825 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.539 ' O ' HG23 ' A' ' 57' ' ' THR . 2.5 p30 -140.47 26.28 2.16 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.565 -0.71 . . . . 0.0 110.504 177.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.547 ' H ' HG22 ' A' ' 55' ' ' ILE . 6.5 p -155.09 110.75 3.11 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.508 -0.745 . . . . 0.0 110.145 177.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.508 ' O ' HG23 ' A' ' 37' ' ' ILE . 1.7 m-80 -124.27 -174.13 2.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.546 -0.721 . . . . 0.0 110.25 179.09 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.0 m120 -128.82 136.03 49.93 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.5 -0.75 . . . . 0.0 110.252 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -134.9 155.7 50.25 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 110.274 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.582 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -81.56 149.08 28.81 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.546 -0.721 . . . . 0.0 110.187 178.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.501 ' HB3' HG21 ' A' ' 36' ' ' VAL . 3.8 pt-20 -60.69 -29.01 69.06 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.597 -0.689 . . . . 0.0 110.228 178.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.582 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -68.84 -24.77 64.4 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.602 -0.686 . . . . 0.0 110.498 175.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -96.4 27.96 3.53 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.434 -0.791 . . . . 0.0 110.338 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.617 HD22 HG23 ' A' ' 8' ' ' VAL . 86.7 mt -138.65 128.22 24.73 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.57 -0.706 . . . . 0.0 110.258 178.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -103.81 144.44 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.517 -0.74 . . . . 0.0 109.919 176.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -80.04 125.13 29.39 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 110.189 178.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.657 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m -134.03 -40.67 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.538 -0.726 . . . . 0.0 110.624 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.478 ' N ' HG23 ' A' ' 68' ' ' VAL . 0.3 OUTLIER 53.13 -171.37 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.306 -0.871 . . . . 0.0 110.547 179.092 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.58 151.49 94.43 Favored Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.46 -0.775 . . . . 0.0 110.128 178.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 146.55 36.23 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.427 1.225 . . . . 0.0 111.011 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -167.53 32.44 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.616 -0.677 . . . . 0.0 110.308 178.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.85 87.67 7.04 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.603 -0.685 . . . . 0.0 110.248 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.417 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 0.2 OUTLIER -84.12 -50.22 0.63 Allowed Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.655 -0.653 . . . . 0.0 110.593 178.497 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.5 179.58 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.486 0 O-C-N 123.15 1.079 . . . . 0.0 111.085 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 13.3 tptp -83.21 82.09 8.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.71 . . . . 0.0 110.269 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.202 178.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.3 ptt? . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 121.082 0.468 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 2' ' ' VAL . 8.4 p -61.46 117.46 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.601 -0.687 . . . . 0.0 110.084 178.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -168.05 165.36 13.52 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 110.082 179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.2 ttp180 -60.84 113.57 2.57 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.518 -0.739 . . . . 0.0 110.208 178.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.21 -30.13 6.68 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -178.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.72 151.18 34.28 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.532 -0.981 . . . . 0.0 110.143 178.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mttp -106.75 125.26 50.78 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.552 -0.717 . . . . 0.0 110.196 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.591 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -123.31 156.44 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.561 -0.712 . . . . 0.0 110.221 178.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.522 ' HG2' HG22 ' A' ' 21' ' ' VAL . 10.5 mtm-85 -77.04 162.43 27.53 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.574 -0.704 . . . . 0.0 110.108 176.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.428 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -104.09 119.68 53.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.48 -0.762 . . . . 0.0 110.024 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.45 ' HA ' HD13 ' A' ' 11' ' ' LEU . 4.5 mm? -100.82 42.85 1.09 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.591 -0.693 . . . . 0.0 110.088 177.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HD3' ' CE1' ' A' ' 60' ' ' PHE . 5.6 ttt180 -115.33 85.43 13.02 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.576 -0.702 . . . . 0.0 110.223 179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.79 -26.32 30.15 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.374 1.197 . . . . 0.0 110.989 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -76.62 -27.8 55.85 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.58 -0.7 . . . . 0.0 110.261 177.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.7 t -72.3 137.14 46.48 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.577 -0.702 . . . . 0.0 110.229 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 31.7 t80 -59.88 -26.49 65.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.558 -0.714 . . . . 0.0 110.365 177.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.497 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 6.4 m0 -94.98 41.41 1.09 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.501 -0.749 . . . . 0.0 110.263 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -71.01 158.06 37.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.488 -0.758 . . . . 0.0 110.17 176.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 52.8 41.83 31.75 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.407 -0.808 . . . . 0.0 110.809 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -135.91 160.0 39.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.505 -0.747 . . . . 0.0 110.29 178.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 9' ' ' ARG . 57.8 t -103.37 97.17 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.529 -0.732 . . . . 0.0 109.983 178.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.56 175.55 42.41 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.5 m -112.96 149.95 32.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.648 -0.913 . . . . 0.0 110.166 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -79.81 119.6 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.5 -0.75 . . . . 0.0 109.943 178.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.75 -40.02 19.33 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.585 -0.697 . . . . 0.0 110.213 179.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -167.83 152.98 6.9 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.587 -0.696 . . . . 0.0 110.177 178.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -107.36 119.83 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.599 -0.688 . . . . 0.0 109.886 178.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -130.22 148.22 52.03 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.58 -0.7 . . . . 0.0 110.284 178.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 23.1 tt0 -152.56 98.51 2.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.565 -0.709 . . . . 0.0 110.152 178.139 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 17.8 m -156.1 28.89 0.36 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.546 -0.721 . . . . 0.0 110.206 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.54 -30.51 2.77 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 177.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.9 pt -60.41 142.32 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.601 -0.941 . . . . 0.0 110.304 -177.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.442 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 8.0 pttt -70.46 -26.75 63.78 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.516 -0.74 . . . . 0.0 110.394 -176.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.469 ' HD1' ' HB2' ' A' ' 61' ' ' ALA . 33.1 m-85 -111.66 96.0 30.44 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.504 -0.748 . . . . 0.0 110.176 177.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.09 -26.45 32.84 Favored 'Trans proline' 0 N--CA 1.491 1.342 0 O-C-N 123.405 1.213 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.7 t -110.65 123.24 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.413 -0.804 . . . . 0.0 109.999 -173.068 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.2 mt -96.48 143.33 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 O-C-N 121.539 -0.725 . . . . 0.0 109.818 173.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.476 HG12 ' N ' ' A' ' 39' ' ' ARG . 58.0 t -129.8 166.65 26.86 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.571 -0.706 . . . . 0.0 110.063 -178.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.709 ' HG3' HG22 ' A' ' 57' ' ' THR . 37.8 ttp85 -131.3 161.26 32.71 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.543 -0.723 . . . . 0.0 110.165 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 70.5 m-85 -137.02 -177.55 4.8 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.581 -0.7 . . . . 0.0 110.201 179.097 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -112.05 -31.96 6.73 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.553 -0.717 . . . . 0.0 110.222 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -85.58 165.21 17.25 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.554 -0.716 . . . . 0.0 110.247 178.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -109.08 -165.63 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.544 -0.722 . . . . 0.0 110.279 176.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.639 HD21 HD12 ' A' ' 55' ' ' ILE . 25.8 p30 -141.07 -165.0 1.86 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.523 -0.736 . . . . 0.0 110.301 178.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -60.37 -32.94 71.76 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.479 -0.763 . . . . 0.0 110.331 -175.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -81.62 -52.9 6.71 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.543 -0.723 . . . . 0.0 110.225 178.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.09 67.44 0.38 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.639 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.52 167.1 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.572 -0.957 . . . . 0.0 109.936 178.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.794 ' ND2' HG23 ' A' ' 57' ' ' THR . 15.8 p-10 -119.6 -37.87 3.08 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.631 -0.668 . . . . 0.0 110.312 179.443 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.794 HG23 ' ND2' ' A' ' 56' ' ' ASN . 72.1 p -117.32 163.07 16.9 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.6 -0.688 . . . . 0.0 110.179 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 60' ' ' PHE . 0.1 OUTLIER -153.86 -157.1 0.74 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.619 -0.676 . . . . 0.0 110.077 177.354 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -133.68 145.25 49.75 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.541 -0.724 . . . . 0.0 110.224 179.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.429 ' CE2' ' HB3' ' A' ' 58' ' ' ASN . 98.9 m-85 -146.29 148.64 32.63 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.625 -0.672 . . . . 0.0 110.229 -179.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.469 ' HB2' ' HD1' ' A' ' 34' ' ' TYR . . . -82.17 150.23 27.51 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.534 -0.729 . . . . 0.0 110.164 178.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -60.69 -30.52 69.98 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 110.343 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -69.78 -23.26 63.33 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.577 -0.702 . . . . 0.0 110.536 175.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -96.24 27.65 3.61 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.382 -0.824 . . . . 0.0 110.328 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.591 HD22 HG23 ' A' ' 8' ' ' VAL . 87.8 mt -138.57 130.75 28.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.526 -0.733 . . . . 0.0 110.263 178.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.71 138.93 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.547 -0.721 . . . . 0.0 109.908 175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.48 ' HA ' HG12 ' A' ' 8' ' ' VAL . 2.9 tm-20 -79.57 123.44 27.6 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.619 -0.676 . . . . 0.0 110.164 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.429 ' O ' HG23 ' A' ' 68' ' ' VAL . 35.7 m -138.5 61.7 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.604 -0.685 . . . . 0.0 110.246 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -61.7 165.32 5.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.583 -0.698 . . . . 0.0 110.193 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -82.35 159.72 63.96 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 178.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.02 154.93 12.24 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 O-C-N 123.437 1.23 . . . . 0.0 110.95 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 4.9 mtpm? -104.21 149.87 24.9 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.501 -0.75 . . . . 0.0 110.21 178.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.44 -174.32 5.22 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.569 -0.707 . . . . 0.0 110.22 178.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 8.2 mptt 52.6 94.54 0.05 OUTLIER Pre-proline 0 N--CA 1.5 2.067 0 O-C-N 121.43 -0.794 . . . . 0.0 110.775 179.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.93 -177.01 0.03 OUTLIER 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.424 1.223 . . . . 0.0 110.981 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.3 ttmt -99.42 130.12 45.66 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.569 -0.707 . . . . 0.0 110.194 178.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.3 pttt . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.325 -178.81 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.9 ttt . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.106 0.479 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.45 HG23 HG11 ' A' ' 24' ' ' VAL . 34.4 m -61.06 -165.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.538 -0.726 . . . . 0.0 110.228 179.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -122.43 149.06 44.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.599 -0.688 . . . . 0.0 110.168 -179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.1 ptt-85 -61.4 117.54 5.81 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.56 -0.712 . . . . 0.0 110.286 178.221 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.426 ' O ' HG23 ' A' ' 23' ' ' THR . . . 119.32 -30.64 5.73 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.48 168.51 2.76 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.523 -0.987 . . . . 0.0 110.203 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -122.06 126.51 48.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.601 -0.687 . . . . 0.0 110.242 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.688 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -128.72 152.83 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.565 -0.71 . . . . 0.0 110.304 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.724 ' HG3' HG11 ' A' ' 68' ' ' VAL . 11.9 mtp180 -64.26 137.97 58.2 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.424 -0.798 . . . . 0.0 110.201 174.024 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.694 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.9 mm -89.63 119.29 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.418 -0.801 . . . . 0.0 109.851 169.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.567 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -108.45 38.24 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 109.947 -174.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.2 ttt180 -113.91 90.58 19.47 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.557 -0.714 . . . . 0.0 110.236 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.78 -26.46 30.58 Favored 'Trans proline' 0 N--CA 1.491 1.366 0 O-C-N 123.37 1.195 . . . . 0.0 111.022 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -74.14 -27.9 61.07 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.55 -0.718 . . . . 0.0 110.282 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 t -75.77 137.67 40.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.547 -0.721 . . . . 0.0 110.237 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.44 ' CG ' ' CB ' ' A' ' 44' ' ' ASN . 35.1 t80 -59.83 -25.34 64.92 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.554 -0.716 . . . . 0.0 110.428 178.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.494 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.3 m-90 -95.48 38.9 1.13 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.471 -0.768 . . . . 0.0 110.345 -178.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.42 ' CE2' ' HG3' ' A' ' 19' ' ' GLN . 47.5 t80 -70.9 157.7 37.7 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.447 -0.783 . . . . 0.0 110.117 175.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 18' ' ' PHE . 39.1 mt-30 52.89 27.53 5.59 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.481 -0.762 . . . . 0.0 110.805 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -127.31 131.91 50.37 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.544 -0.723 . . . . 0.0 110.145 177.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.5 t -80.0 108.59 13.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.557 -0.714 . . . . 0.0 109.936 178.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -100.12 174.56 26.47 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 5' ' ' GLY . 9.5 m -104.17 150.06 24.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.584 -0.951 . . . . 0.0 110.14 178.48 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.45 HG11 HG23 ' A' ' 2' ' ' VAL . 59.3 t -80.28 126.44 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.541 -0.724 . . . . 0.0 109.92 178.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -88.62 -49.82 6.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 110.226 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 80.9 p -166.9 -174.45 2.72 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.561 -0.712 . . . . 0.0 110.188 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -144.58 121.78 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.601 -0.687 . . . . 0.0 110.002 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -99.84 106.21 18.04 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.532 -0.73 . . . . 0.0 110.24 178.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 14.3 tp60 -83.44 90.05 7.14 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.6 -0.687 . . . . 0.0 110.182 178.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -146.71 -67.97 0.27 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.557 -0.714 . . . . 0.0 110.279 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.27 72.08 0.02 OUTLIER Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -121.46 169.05 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.596 -0.943 . . . . 0.0 110.263 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' CD1' ' A' ' 34' ' ' TYR . 5.3 ptpt -59.82 -26.65 65.96 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.555 -0.715 . . . . 0.0 110.458 -178.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.401 ' CD1' ' O ' ' A' ' 33' ' ' LYS . 35.9 m-85 -140.99 93.87 8.09 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.145 178.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -52.92 -44.19 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 O-C-N 123.496 1.261 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.482 HG21 ' HB3' ' A' ' 62' ' ' GLU . 57.9 t -89.9 128.85 41.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.484 -0.76 . . . . 0.0 110.151 -173.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.6 mt -98.58 140.9 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.508 -0.745 . . . . 0.0 109.922 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.452 HG11 HD11 ' A' ' 10' ' ' ILE . 58.0 t -123.19 150.69 27.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.599 -0.688 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -111.88 144.44 41.19 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.48 -0.763 . . . . 0.0 110.123 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.494 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 40.1 m-85 -124.46 171.74 9.72 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.646 -0.659 . . . . 0.0 110.238 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -109.33 -29.04 8.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.617 -0.677 . . . . 0.0 110.182 176.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 9.5 ttmm -93.34 169.07 10.65 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.606 -0.684 . . . . 0.0 110.205 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.9 m -113.33 -170.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.519 -0.738 . . . . 0.0 110.242 177.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.505 HD21 HD12 ' A' ' 55' ' ' ILE . 7.4 p30 -126.35 -164.62 1.35 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.656 -0.652 . . . . 0.0 110.302 178.402 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -61.34 -28.6 69.34 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.485 -0.76 . . . . 0.0 110.284 -179.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -83.32 -62.44 1.59 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.599 -0.688 . . . . 0.0 110.27 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 130.84 66.1 0.1 OUTLIER Glycine 0 N--CA 1.494 2.537 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.505 HD12 HD21 ' A' ' 44' ' ' ASN . 11.0 mt -123.56 159.3 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.587 -0.949 . . . . 0.0 109.869 177.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.5 p-10 -116.12 -26.04 7.39 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.47 -0.768 . . . . 0.0 110.634 -178.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 34.7 p -137.85 150.96 47.6 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.405 -0.809 . . . . 0.0 110.207 -178.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -145.4 -170.69 3.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 110.089 176.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -124.15 133.96 53.45 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.557 -0.714 . . . . 0.0 110.195 179.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 62.1 m-85 -130.07 157.68 41.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.621 -0.674 . . . . 0.0 110.264 179.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.729 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -81.52 145.07 30.88 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.56 -0.712 . . . . 0.0 110.109 177.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' HB3' HG21 ' A' ' 36' ' ' VAL . 10.9 pt-20 -59.49 -26.46 65.29 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.521 -0.737 . . . . 0.0 110.467 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.558 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.5 p30 -68.6 -24.34 64.57 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.55 -0.719 . . . . 0.0 110.485 176.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.729 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 6.4 mt-10 -96.15 27.28 3.74 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 110.421 -179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.694 ' CD2' HD13 ' A' ' 10' ' ' ILE . 90.0 mt -138.85 131.19 28.5 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.47 -0.769 . . . . 0.0 110.22 177.355 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 57.6 t -110.07 139.26 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.513 -0.742 . . . . 0.0 109.926 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . 0.445 ' HA ' HG12 ' A' ' 8' ' ' VAL . 23.4 mt-10 -79.0 110.98 14.74 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.582 -0.699 . . . . 0.0 110.226 -178.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.724 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.8 m -111.84 -26.16 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.527 -0.733 . . . . 0.0 110.506 177.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 52.93 -178.09 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.222 -0.924 . . . . 0.0 110.75 178.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 71' ' ' PRO . . . -85.47 -177.11 0.87 Allowed Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.63 -0.669 . . . . 0.0 110.265 178.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.4 Cg_exo -52.86 176.6 0.07 OUTLIER 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.382 1.201 . . . . 0.0 111.038 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -84.09 108.88 17.28 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.598 -0.689 . . . . 0.0 110.159 178.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -89.95 -159.5 0.6 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.656 . . . . 0.0 110.19 178.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 6.1 ttmt -139.76 84.68 15.29 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 110.196 178.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.01 -176.69 0.03 OUTLIER 'Trans proline' 0 N--CA 1.492 1.404 0 O-C-N 123.404 1.213 . . . . 0.0 110.953 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.0 ptmt -111.88 166.36 11.27 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.605 -0.684 . . . . 0.0 110.275 178.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.8 mtmm . . . . . 0 N--CA 1.494 1.747 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.221 178.691 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttm . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.094 0.473 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.593 HG11 HG21 ' A' ' 24' ' ' VAL . 61.6 t -80.83 167.02 2.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.541 -0.724 . . . . 0.0 109.964 178.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.464 ' N ' HG12 ' A' ' 2' ' ' VAL . 3.2 mp0 -115.33 166.36 11.95 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.58 -0.7 . . . . 0.0 110.246 -176.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.7 ttt180 -67.33 113.54 5.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.497 -0.752 . . . . 0.0 110.219 177.433 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.67 30.01 11.18 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.64 156.45 16.41 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.967 . . . . 0.0 110.187 177.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.6 ' NZ ' ' HB2' ' A' ' 70' ' ' ALA . 14.7 mtmt -106.8 106.01 16.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.584 -0.698 . . . . 0.0 110.204 179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.641 HG23 HD22 ' A' ' 65' ' ' LEU . 34.8 m -119.11 152.29 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.559 -0.713 . . . . 0.0 110.241 177.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.551 ' HG2' HG22 ' A' ' 21' ' ' VAL . 0.6 OUTLIER -77.49 143.53 38.41 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.648 -0.658 . . . . 0.0 110.236 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.445 HG22 ' H ' ' A' ' 12' ' ' ARG . 49.7 mm -85.78 119.8 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.542 -0.724 . . . . 0.0 110.011 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.5 mm? -102.42 38.97 1.58 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.567 -0.708 . . . . 0.0 110.107 176.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.445 ' H ' HG22 ' A' ' 10' ' ' ILE . 5.8 ttt180 -114.48 88.87 16.6 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.609 -0.682 . . . . 0.0 110.183 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CG ' ' A' ' 18' ' ' PHE . 50.2 Cg_exo -52.69 -26.53 30.24 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 O-C-N 123.369 1.194 . . . . 0.0 111.042 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -76.13 -27.72 57.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 0.0 110.363 177.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.41 ' HG ' ' HE2' ' A' ' 60' ' ' PHE . 11.7 t -71.07 138.38 49.73 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.564 -0.71 . . . . 0.0 110.267 179.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.1 t80 -60.42 -27.79 67.75 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.537 -0.727 . . . . 0.0 110.254 177.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.484 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 7.4 m-90 -95.65 40.34 1.11 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.51 -0.743 . . . . 0.0 110.207 -179.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.402 ' CG ' ' HA ' ' A' ' 13' ' ' PRO . 49.6 t80 -71.58 159.39 34.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.577 -0.702 . . . . 0.0 110.164 176.217 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 52.88 28.64 6.72 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.471 -0.768 . . . . 0.0 110.787 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -130.36 146.18 51.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.582 -0.699 . . . . 0.0 110.207 178.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.551 HG22 ' HG2' ' A' ' 9' ' ' ARG . 67.3 t -87.35 100.14 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.549 -0.719 . . . . 0.0 109.957 178.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.66 160.54 23.5 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.1 m -98.34 151.89 20.04 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.544 -0.974 . . . . 0.0 110.175 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.593 HG21 HG11 ' A' ' 2' ' ' VAL . 67.3 t -80.64 124.57 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.533 -0.73 . . . . 0.0 109.925 178.452 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.54 -43.42 17.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.568 -0.708 . . . . 0.0 110.181 178.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 21.5 t -167.7 -177.89 3.67 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.578 -0.701 . . . . 0.0 110.226 178.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.465 HG12 ' N ' ' A' ' 28' ' ' ASP . 58.2 t -136.05 166.97 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.603 -0.685 . . . . 0.0 110.019 178.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.465 ' N ' HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER -118.37 160.16 22.16 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.559 -0.713 . . . . 0.0 110.221 178.581 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -108.59 34.37 3.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.572 -0.705 . . . . 0.0 110.194 178.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.642 ' OG ' HG23 ' A' ' 32' ' ' ILE . 83.4 p -131.83 -163.61 1.35 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 110.253 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -114.0 45.15 1.36 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 178.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.642 HG23 ' OG ' ' A' ' 30' ' ' SER . 27.6 pt -61.03 178.98 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.561 -0.964 . . . . 0.0 110.334 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.43 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 0.0 OUTLIER -61.31 -29.32 69.81 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 110.267 -179.736 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.501 ' O ' HD11 ' A' ' 32' ' ' ILE . 32.9 m-85 -144.75 95.57 5.27 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.538 -0.726 . . . . 0.0 110.218 178.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.99 -30.32 48.22 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.402 1.211 . . . . 0.0 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 57.6 t -104.49 149.88 7.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.534 -0.729 . . . . 0.0 110.071 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 58' ' ' ASN . 5.3 mp -129.33 146.21 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.547 -0.721 . . . . 0.0 109.839 177.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.6 t -126.96 147.34 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.617 -0.677 . . . . 0.0 109.961 -178.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 38.9 ttt-85 -107.74 145.91 32.85 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.54 -0.725 . . . . 0.0 110.122 175.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.484 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 73.1 m-85 -119.29 150.58 39.89 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.534 -0.729 . . . . 0.0 110.204 -178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -87.45 -37.25 17.15 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.568 -0.707 . . . . 0.0 110.2 177.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 1.4 ttmt -79.44 172.17 14.16 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.537 -0.727 . . . . 0.0 110.162 176.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.87 -173.63 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.592 -0.692 . . . . 0.0 110.25 177.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.471 ' ND2' HD12 ' A' ' 55' ' ' ILE . 22.3 p-10 -116.35 -161.84 0.82 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.626 -0.671 . . . . 0.0 110.275 177.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 68.5 m-85 -60.17 -27.53 67.19 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.519 -0.738 . . . . 0.0 110.322 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.4 m -98.21 -62.87 1.18 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.556 -0.715 . . . . 0.0 110.317 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 147.74 76.57 0.02 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.471 HD12 ' ND2' ' A' ' 44' ' ' ASN . 86.1 mt -134.07 165.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.588 -0.948 . . . . 0.0 109.933 -177.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 57' ' ' THR . 9.1 p-10 -156.27 26.95 0.35 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.584 -0.697 . . . . 0.0 110.439 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 56' ' ' ASN . 5.0 p -155.42 118.07 4.25 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.466 -0.772 . . . . 0.0 110.184 176.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.608 ' O ' HG23 ' A' ' 37' ' ' ILE . 2.3 m-20 -136.14 177.57 7.74 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.593 -0.692 . . . . 0.0 110.188 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.95 139.04 50.64 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.517 -0.739 . . . . 0.0 110.164 179.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CE2' ' HD3' ' A' ' 12' ' ' ARG . 92.1 m-85 -137.0 158.56 44.18 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.567 -0.708 . . . . 0.0 110.223 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.629 ' HB1' ' OD2' ' A' ' 63' ' ' ASP . . . -83.76 148.0 27.29 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 177.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -60.54 -28.59 68.54 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.53 -0.731 . . . . 0.0 110.325 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.629 ' OD2' ' HB1' ' A' ' 61' ' ' ALA . 2.9 p30 -69.03 -24.28 64.18 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.583 -0.698 . . . . 0.0 110.5 176.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 13.2 mt-10 -96.24 27.74 3.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.438 -0.789 . . . . 0.0 110.401 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.641 HD22 HG23 ' A' ' 8' ' ' VAL . 88.7 mt -138.52 125.82 21.66 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.475 -0.766 . . . . 0.0 110.342 177.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.53 140.71 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.495 -0.753 . . . . 0.0 109.909 176.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 128.14 32.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.612 -0.68 . . . . 0.0 110.145 178.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.529 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.5 m -133.98 -40.7 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.558 -0.714 . . . . 0.0 110.661 179.241 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 68' ' ' VAL . 0.7 OUTLIER 57.31 162.3 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.307 -0.871 . . . . 0.0 110.374 178.524 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.6 ' HB2' ' NZ ' ' A' ' 7' ' ' LYS . . . -89.11 173.13 6.39 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.344 -0.847 . . . . 0.0 110.199 -174.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.493 ' HD2' ' HB1' ' A' ' 70' ' ' ALA . 50.5 Cg_exo -52.9 151.16 21.02 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 O-C-N 123.435 1.229 . . . . 0.0 111.025 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.0 mtmt -127.27 48.59 2.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.563 -0.711 . . . . 0.0 110.2 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.68 110.96 18.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.561 -0.712 . . . . 0.0 110.207 178.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 15.9 mtpt -83.44 -50.41 0.68 Allowed Pre-proline 0 N--CA 1.495 1.799 0 O-C-N 121.559 -0.713 . . . . 0.0 110.447 178.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.411 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.2 Cg_exo -51.38 103.55 0.07 OUTLIER 'Trans proline' 0 N--CA 1.493 1.488 0 O-C-N 123.104 1.055 . . . . 0.0 111.078 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -124.94 29.03 6.26 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.518 -0.739 . . . . 0.0 110.273 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 25.9 tttp . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.136 178.786 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 34.0 mtm . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.065 0.46 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.904 HG11 HG21 ' A' ' 24' ' ' VAL . 57.8 t -83.15 166.87 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.546 -0.721 . . . . 0.0 110.042 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.469 ' N ' HG12 ' A' ' 2' ' ' VAL . 0.8 OUTLIER -93.73 149.02 21.58 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.522 -0.736 . . . . 0.0 110.195 178.898 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.0 ttt-85 -70.93 93.23 0.97 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.575 -0.703 . . . . 0.0 110.199 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.44 30.3 3.14 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.38 156.52 16.42 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.554 -0.968 . . . . 0.0 110.167 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm -100.31 109.76 21.98 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.579 -0.701 . . . . 0.0 110.209 178.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.588 HG23 HD22 ' A' ' 65' ' ' LEU . 34.7 m -119.59 155.96 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.548 -0.72 . . . . 0.0 110.313 178.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.635 ' HG3' HG11 ' A' ' 68' ' ' VAL . 1.4 mmt-85 -80.87 140.77 35.18 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.617 -0.677 . . . . 0.0 110.171 178.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.696 HD13 ' CD2' ' A' ' 65' ' ' LEU . 49.8 mm -86.81 127.08 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.555 -0.716 . . . . 0.0 110.015 178.103 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.606 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -112.65 39.42 2.5 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.632 -0.667 . . . . 0.0 110.237 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.2 ttp180 -114.35 89.83 18.95 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.525 -0.734 . . . . 0.0 110.258 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -52.83 -26.43 30.79 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 O-C-N 123.408 1.215 . . . . 0.0 111.049 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -73.75 -27.61 61.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.506 -0.746 . . . . 0.0 110.231 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 40.9 t -75.49 142.76 42.83 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.47 -0.769 . . . . 0.0 110.233 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -60.41 -26.88 67.03 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.542 -0.724 . . . . 0.0 110.312 175.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.498 ' CD2' ' CD2' ' A' ' 40' ' ' PHE . 10.2 m-90 -96.59 35.72 1.47 Allowed 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.48 -0.763 . . . . 0.0 110.241 -175.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 39.1 t80 -66.66 155.44 37.95 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.572 -0.705 . . . . 0.0 110.233 177.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 52.92 27.16 5.24 Favored 'General case' 0 N--CA 1.501 2.107 0 O-C-N 121.396 -0.815 . . . . 0.0 110.789 179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.51 176.25 5.34 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.635 -0.666 . . . . 0.0 110.181 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 58.0 t -117.73 107.36 21.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.572 -0.705 . . . . 0.0 110.031 177.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -103.14 159.09 17.36 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 40.2 m -101.97 142.81 32.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.637 -0.92 . . . . 0.0 110.203 178.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.904 HG21 HG11 ' A' ' 2' ' ' VAL . 58.7 t -79.78 122.65 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.576 -0.703 . . . . 0.0 110.017 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.83 -51.27 7.8 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.566 -0.709 . . . . 0.0 110.262 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.664 ' O ' HD12 ' A' ' 37' ' ' ILE . 28.1 t -167.99 177.89 5.4 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.64 -0.663 . . . . 0.0 110.15 178.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 68.5 t -117.94 154.29 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.575 -0.703 . . . . 0.0 109.937 177.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.785 ' HB3' HD13 ' A' ' 32' ' ' ILE . 0.6 OUTLIER -94.79 -159.02 0.68 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.73 . . . . 0.0 110.218 177.605 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 4.0 mp0 -126.8 -72.45 0.65 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.537 -0.727 . . . . 0.0 110.265 -179.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.3 t -132.58 166.61 21.71 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.582 -0.699 . . . . 0.0 110.228 -178.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 32' ' ' ILE . . . 65.48 54.46 26.17 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.785 HD13 ' HB3' ' A' ' 28' ' ' ASP . 43.3 pt -148.11 146.26 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.554 -0.968 . . . . 0.0 110.258 -178.155 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.09 -24.14 21.21 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.542 -0.724 . . . . 0.0 110.537 175.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 61' ' ' ALA . 20.5 m-85 -134.9 98.82 12.87 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.463 -0.773 . . . . 0.0 110.177 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.689 ' HA ' HD12 ' A' ' 32' ' ' ILE . 50.4 Cg_exo -52.6 -36.57 71.99 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.402 1.212 . . . . 0.0 111.229 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 62' ' ' GLU . 61.9 t -92.94 123.41 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.46 -0.775 . . . . 0.0 109.937 -175.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.664 HD12 ' O ' ' A' ' 26' ' ' SER . 10.3 mt -98.62 124.91 52.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.525 -0.734 . . . . 0.0 109.928 177.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.543 HG11 HD11 ' A' ' 10' ' ' ILE . 58.1 t -108.63 162.82 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.499 -0.75 . . . . 0.0 109.961 -179.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.72 ' HG2' HG22 ' A' ' 57' ' ' THR . 4.3 tmm_? -128.46 149.77 50.43 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.488 -0.757 . . . . 0.0 110.204 177.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.498 ' CD2' ' CD2' ' A' ' 17' ' ' TRP . 60.6 m-85 -128.52 167.82 16.56 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.585 -0.697 . . . . 0.0 110.257 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -108.63 -29.04 8.94 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.545 -0.722 . . . . 0.0 110.196 176.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 6.1 tmtt? -81.23 129.66 34.69 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.555 -0.716 . . . . 0.0 110.164 177.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.1 m -66.86 -165.05 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.515 -0.74 . . . . 0.0 110.217 175.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.563 HD21 HD12 ' A' ' 55' ' ' ILE . 17.6 p-10 -157.12 -165.77 1.91 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.586 -0.696 . . . . 0.0 110.271 178.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -60.21 -27.92 67.57 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.466 -0.771 . . . . 0.0 110.45 -173.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 m -94.69 -27.68 15.72 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.515 -0.741 . . . . 0.0 110.437 -176.475 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.91 30.6 7.04 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -175.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.565 HG21 HD21 ' A' ' 58' ' ' ASN . 68.5 mt -90.64 163.58 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.59 -0.947 . . . . 0.0 109.909 179.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.68 ' ND2' HG23 ' A' ' 57' ' ' THR . 12.5 p-10 -125.16 -39.73 2.2 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.586 -0.697 . . . . 0.0 110.463 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.72 HG22 ' HG2' ' A' ' 39' ' ' ARG . 24.1 p -119.26 146.11 45.52 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.535 -0.728 . . . . 0.0 110.269 -178.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.565 HD21 HG21 ' A' ' 55' ' ' ILE . 1.6 m-80 -139.67 -172.58 3.41 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.587 -0.696 . . . . 0.0 110.068 176.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.79 133.26 53.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.51 -0.744 . . . . 0.0 110.196 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 68.4 m-85 -131.29 169.48 15.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.611 -0.68 . . . . 0.0 110.267 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.653 ' HB3' ' OE1' ' A' ' 64' ' ' GLU . . . -92.09 148.35 22.25 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.558 -0.714 . . . . 0.0 110.204 179.152 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.474 ' HB3' HG21 ' A' ' 36' ' ' VAL . 2.2 pp20? -61.32 -29.43 69.87 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.595 -0.69 . . . . 0.0 110.304 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.652 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 6.0 p-10 -72.01 -23.04 61.33 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.583 -0.698 . . . . 0.0 110.569 178.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.653 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 30.2 mt-10 -96.1 27.46 3.64 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.481 -0.762 . . . . 0.0 110.418 178.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.696 ' CD2' HD13 ' A' ' 10' ' ' ILE . 86.3 mt -138.96 119.45 13.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.526 -0.734 . . . . 0.0 110.137 178.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.94 144.18 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.535 -0.728 . . . . 0.0 109.965 177.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -82.09 109.58 16.54 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.57 -0.706 . . . . 0.0 110.206 179.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.635 HG11 ' HG3' ' A' ' 9' ' ' ARG . 34.9 m -113.3 36.3 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.565 -0.709 . . . . 0.0 110.332 178.522 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -116.39 135.52 53.78 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.534 -0.729 . . . . 0.0 110.214 178.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.97 111.44 3.93 Favored Pre-proline 0 N--CA 1.497 1.903 0 O-C-N 121.694 -0.629 . . . . 0.0 110.231 179.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.08 178.74 0.05 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 O-C-N 123.161 1.085 . . . . 0.0 110.999 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -106.0 155.46 19.36 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.526 -0.734 . . . . 0.0 110.24 178.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -83.1 82.85 8.07 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.582 -0.699 . . . . 0.0 110.229 178.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.423 ' N ' ' CD ' ' A' ' 75' ' ' PRO . 3.1 mmtt -81.82 -50.42 0.87 Allowed Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.6 -0.687 . . . . 0.0 110.523 178.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.423 ' CD ' ' N ' ' A' ' 74' ' ' LYS . 50.3 Cg_exo -51.43 179.13 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.461 0 O-C-N 123.148 1.078 . . . . 0.0 111.089 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 11.1 tptm 52.88 45.64 28.36 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.383 -0.823 . . . . 0.0 110.859 178.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 9.7 ttmt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.222 178.721 . . . . . . . . 0 0 . 1 stop_ save_